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INTRODUCTION 
1.1 Definitions 
Intellectual disability (ID) is defined as a significant impairment of cognitive functions or intelligence 
and adaptive functions with onset before the age of 18 years (Maes, Fryns et al. 2000; Rauch, Hoyer et 
al. 2006; Tasse 2009).  Many terms have been proposed to designate this impairment of mental health. 
Of these, intellectual disability (ID) is currently widely accepted to replace the previous terms mental 
retardation (MR), learning disabilities or intellectual impairment (Salvador-Carulla and Bertelli 2008). 
Intelligence can be understood as the ability to reason, solve problems and to learn. Intelligence 
integrates functions such as perception, attention, memory, language or planning. As a potential, 
intelligence is reliably measured by standardized tests and expressed in a numeral score named 
Intelligence Quotient (IQ) (Berkenstadt, Ries-Levavi et al. 2007). Statistically, normal intelligence is 
defined by the mean ± 2SD, or an IQ of 100 ± 30. However, individuals with an IQ between 70 and 85 
are considered to have border-line intelligence, since they also experience impairments. IQ scores 
between 50 and 70 are defined as mild ID, between 50 and 35 as moderate ID, between 35 and 20 as 
severe ID and finally, below 20 as profound ID (http://www.who.int/whr/2001/en/whr01_en.pdf). It 
is estimated that about 3 % of world population have an IQ below 70 and 1/200 below 50 (Vissers, de 
Vries et al. 2010).  
Adaptive skills refer to basic skills needed for everyday life. They include communication, self-care, 
home living, social skills, leisure, health and safety, self-direction, functional academics (reading, 
writing, basic mathematics), and work (Hagerman, Amiri et al. 1991). 
Many instruments or standardized tests have been designed to assess IQ. These are known as 
psychometric tests. The majority of them include images or pictograms to evaluate the ability to cope 
with daily live. Surprisingly, most of the existing tools has been validated in Western countries and the 
pictograms typically refer to daily situations in these countries. Children from countries such as the DR 
Congo may perform poorly on such items when assessed using such culturally inappropriate tools and 
this may lead to an underestimation of their intelligence. Therefore, efforts are needed to produce 
assessment tools adapted to Congolese children.   
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1.2 Impact of ID  
ID has a major impact on the individual, his family and the communities. Once the ID is established, it 
will cause psychological and financial burden that will have a further negative effect on social 
development (Ropers 2010). At the individual and familial level, ID may psychologically impact 
relatives. Abasiubong et al., investigated psychological effects of ID on mothers in Nigeria and reported 
high levels of anxiety in 25.5 % and depression in 10.4 % (Abasiubong, Obembe et al. 2006).  In another 
study, they reported that 2.8 % thought about the physical elimination of their affected child 
(Abasiubong, Obembe et al. 2008). In addition to psychological damage, ID of a child may increase 
family expenses up to 8 % (Rauch, Hoyer et al. 2006). 
There is a vicious circle, particularly in developing countries, involving poverty and ID. Special cares to 
ID patients can be prohibitive as proven in developing countries (Wang 2012; Buescher, Cidav et al. 
2014; Genereaux, van Karnebeek et al. 2015). Therefore, the family can be quickly run out of finances 
in limited resources countries, were national responses are limited. This results in increased poverty 
which has as corollaries malnutrition, limited access to healthcare, infectious diseases. It is well known 
that these corollaries are among environmental factors causing ID.   
1.3 The aetiology of Intellectual disability  
ID refers to a characteristic observed in a heterogeneous group of disorders. Consequently, causes of 
ID are also heterogeneous. The search for the cause of ID is often a complex process, and involves 
detailed family and personal history, clinical examination with special attention for the presence of 
dysmorphic signs and complementary testing, such as brain imaging, metabolic and genetic tests 
(Moeschler and Shevell 2014).  
Various way of classifying the aetiology of ID have been proposed, depending on the point of view and 
purpose of the classification (Chelly, Khelfaoui et al. 2006; Rauch, Hoyer et al. 2006). Causes of ID may 
be classified according to the time of origin (pre-, peri-, and postnatal), or according to the type of 
defect (genetic, environmental, and multifactorial). A classification including both the timing and type 
of defect may also be considered (Moog 2005). In Western countries, genetic causes account for an 
estimated 4 to 41.1 % of cases (Battaglia, Bianchini et al. 1999; Moeschler 2008; Bernardini, Alesi et al. 
2010). 
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1.4 Approaches to identify genetic causes: targeted or genome-wide screening 
From a clinical point of view, ID can be isolated or associated with additional dysmorphic, neurological 
and behavioural features, defining specific syndromes such as Down syndrome, Partington syndrome 
or Smith-Magenis syndrome. These syndromes present a recognizable pattern of malformation with 
the presence of multiple minor anomalies (called dysmorphism) and/or major malformations. This is 
often associated with a behavioural phenotype (Harris 2010). When a syndrome is identified, targeted 
testing is possible meaning the analysis of a specific gene or performance of a metabolic test. Hence, 
the clinical recognition of specific disorders, especially when rare, is a critical step in the diagnostic 
process.  
1.4.1 Syndromology 
Syndromology is the medical discipline with expertise in the classification and diagnosis of specific 
syndromes. During the last decades, tremendous efforts have been made in clinically describing and 
defining a large number of syndromes in large cohorts of patients. Syndrome databases have been 
implemented such as the London Medical Dysmorphology Database and POSSUM to offer the 
possibility to match combinations of features to syndromes (van Steensel and Winter 1998). Tools for 
an accurate description of phenotypic features have been developed including an internationally 
accepted Human Phenotype Ontology (Robinson, Kohler et al. 2008) and a series of articles with the 
definition and illustration of a wide range of morphological anomalies (Allanson, Cunniff et al. 2009). 
Efforts to introduce objective morphometric analysis of digital images (2D or 3D) of patients are 
underway, and hold great promise. However, syndromology remains largely based on expert-opinion, 
especially for rare syndromes.    
1.4.2 Genetic testing 
Over the last 10 years, progress in the identification of genetic causes of ID in Western countries has 
been impressive. This is essentially driven by the technological revolutions such as microarray-
Comparative Genome Hybridisation (array-CGH) and more recently Next-Generation Sequencing 
(NGS) technology. These techniques allow a genome-wide screening for mutations of different sizes, 
copy number variations (larger than 1 kb), single nucleotide variants (SNV’s, 1 nucleotide) and indels 
(in between these two). This has accelerated the identification of genes causing previously well 
characterized genetic disorders as well as the recognition of many novel entities. This is illustrated by 
the identification of submicroscopic chromosomal imbalances causing common and well known 
syndromes such as Williams syndrome (del7q11.23), Velocardiofacial syndrome (del22q11.2), Smith-
Magenis syndrome (del17p11.2). Novel and now also clinically recognizable syndromes include 
del17q21.31, del1p36 and the 7q11.23 duplication (Nevado, Mergener et al. 2014).  
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For monogenic disorders, the progress has been even more impressive in terms of the number of genes 
identified. The causal gene can now often be identified through the analysis of only a few families with 
an (ultra)rare disorder, resulting in a spectacular increase in the number of novel entities and 
associated genes (Bamshad, Ng et al. 2011; Wright, Fitzgerald et al. 2015). Moreover, knowledge 
gained is rapidly translated into the clinic, thus revolutionizing genetic diagnosis.  
In particular, array-CGH allows a genome-wide screening for chromosomal imbalances at a resolution 
exceeding at least 10 fold that of traditional karyotyping. On average, the detection rate of a 
pathogenic copy number variation (CNV) in an individual with clinically unexplained ID is 15-20 %, 
compared to approximately 3 % by traditional karyotyping (Miller, Adam et al. 2010). The likelihood of 
detecting a causal chromosomal imbalance depends on the phenotype. The presence of a major 
malformation (e.g. of the heart, musculoskeletal system or central nervous system) is associated with 
a higher chance of detecting a pathogenic CNV (Shoukier, Klein et al. 2013; Preiksaitiene, Molyte et al. 
2014). In a study of children with syndromic congenital heart defects (CHD), the presence of 
dysmorphism (defined as three or more minor anomalies) increased the likelihood of detecting a 
pathogenic chromosomal imbalance (Breckpot, Thienpont et al. 2010). Battaglia also reported a higher 
diagnostic yield in ID when associated with dysmorphism (Battaglia, Doccini et al. 2013). Array-CGH 
has been applied for other indications besides ID, but in general, the yield of pathogenic CNV’s is lower. 
For instance, in individuals with an isolated CHD, the yield varied between 4 to 14 % (Andersen, 
Troelsen Kde et al. 2014). In autism spectrum disorders (ASD), two studies using a platform with a 
resolution of 20 kb or larger, detected de novo CNV’s in 8 % of cases, 6 % higher than in their unaffected 
siblings (Levy, Ronemus et al. 2011; Sanders, Ercan-Sencicek et al. 2011). Also in ASD, more de novo 
CNV’s were detected in individuals with ID compared to those with a normal IQ (Sanders, Ercan-
Sencicek et al. 2011). Array-CGH studies in epilepsy have a yield of clinically relevant CNV’s of 
approximately 12 % (Sisodiya 2015). Also in schizophrenia CNV’s appear to play a pathogenic role in a 
variable subset of patients (Basset et al., 2010).  
Over the past 10 years, many novel pathogenic CNV’s have been identified causing various 
developmental disorders. The clinical utility of Array-CGH is complicated by the fact that several of 
these CNV’s are in fact susceptibility loci, associated with an increased risk of a disorder. This is 
reflected by the fact that even though they may occur de novo, they are often inherited from an 
unaffected parent. Moreover, these CNV’s are associated with variable clinical manifestations. For 
instance, the deletion in chromosome 16p11.2 is a risk factor for ID, autism spectrum disorders and 
epilepsy, and is associated with obesity and macrocephaly (Miller, Nasir et al. 1993). In the genetic 
clinic, where risk prediction is one of the main tasks, the finding of such a CNV’s poses major challenges. 
This is especially true in a prenatal setting (Vanakker, Vilain et al. 2014). 
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Until recently, testing for monogenic conditions was limited to specific genes, guided by a clinical 
(suspected) diagnosis. Recently, NGS technology allows the massive parallel sequencing of a large 
number of candidate genes for a certain phenotype (gene panels), the exons of all genes associated to 
a Mendelian disorder (Mendeliome), the exons of all known genes (the exome) and even the entire 
genome (whole genome sequencing). Despite technical limitations, which explain the lower sensitivity 
to detect a mutation compared to traditional Sanger sequencing, this approach offers unprecedented 
opportunities for mutation screening in individuals with a heterogeneous condition such as ID. In large 
clinically preselected cohorts, the additional yield of exome analysis in a trio approach (both parents 
and child) ranged from 16 % to 45 % (Rauch, Wieczorek et al. 2012; Yang, Muzny et al. 2013; Wright, 
Fitzgerald et al. 2015). More recently, using whole genome sequencing, an etiological diagnosis could 
be reached in an additional 42 % of individuals (Gilissen, Hehir-Kwa et al. 2014). Taken together, in 
clinically undiagnosed patients, it is estimated that the cumulative chance of reaching an etiological 
diagnosis using the most advanced genetic testing (i.e. Array-CGH and whole genome sequencing in a 
trio approach) is approximately 62 % (Gilissen, Hehir-Kwa et al. 2014). The aetiology of the ID in the 
remaining unsolved cases is currently not known. Acquired, non-genetic causes may involve 
unidentified environmental insults disturbing brain development. One can also envisage the 
occurrence of different types of other genetic mutations that escape the detection of current tools, 
including mosaicism, non-coding mutations, certain structural variations and the possibility of 
epigenetic mutations. Most strategies are currently biased towards the identification of de novo 
mutations or those absent in a normal control population. The consequences of inherited mutations 
with variable expression due to imprinting or due to additional oligogenic modifiers (comparable to 
the susceptibility CNV’s) are only beginning to be investigated. 
Despite remarkable progress, many cases remain without a precise etiological diagnosis. Reasons 
include the enormous heterogeneity in causes of ID or in clinically defined conditions (such as epileptic 
encephalopathy), the lack of clinically recognizable phenotypes for many genetic mutations and the 
variability in expression. This frequently results in a long diagnostic process, involving many 
consecutive rounds of (genetic) testing, often without reaching a definite etiological diagnosis. This 
“diagnostic odyssey” causes much distress in the families and may result in a diagnostic fatigue, both 
for the parents and physicians (Carmichael, Tsipis et al. 2015). One consequence of this is that many 
older individuals with ID often have not been investigated recently with up-to-date knowledge and 
technology. This group often comes back to the attention of the clinical geneticist when siblings raise 
questions regarding recurrence risk for their own children. As a result, for many rare and more recently 
delineated conditions, the adult phenotype is not known, hampering adequate counselling in young 
children. 
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1.4.3 Data interpretation: normal, pathogenic or unclassified?  
A diagnostic test based on genome wide screening for CNV’s, indels or SNV’s is challenging regarding 
the interpretation of the data. Genomic studies have indeed revealed an unanticipated amount of 
variation in the normal population. Thus, one can only speak of a reference genome: the “normal 
genome” does not exist. As a result, extensive filtering of CNV and sequence data is required in order 
to interpret the data. Below, we describe the rationale behind the different filter steps. 
Since many variants are common in the normal population, a first step is the removal of known, 
common variants. There exist several databases collecting normal population variants (Richards, Aziz 
et al. 2015). Since many variants occur at an increased frequency in specific population, additional 
filtering against a local database of local common variants is an effective step (Brown, Lee et al. 2015). 
Under the hypothesis of a de novo cause of the ID (which is the most common situation), the causal 
variants are not expected to be observed in the normal population. Taken possible errors in the 
database into account (e.g. sequencing errors), one excludes variants that are observed in a significant 
percentage of the normal population. For X-linked and autosomal recessive conditions, one needs to 
consider that these variants may be present in normal carriers. In (rare) founder populations, where 
pathogenic variants may reach higher frequencies, one needs to adapt these limits. 
The databases of known polymorphic variants are complemented by disease specific mutation 
databases (Richards, Aziz et al. 2015). However, most databases are contaminated with a large amount 
of variants that are in fact non-functional variants. For instance, for cardiomyopathies and arrhythmias, 
in exome sequences from normal persons, the frequency of variants catalogued in disease specific 
mutation databases was at least 10 times higher than expected based on the population incidence of 
these disorders (Refsgaard, Holst et al. 2012; Andreasen, Nielsen et al. 2013; Risgaard, Jabbari et al. 
2013). One explanation is that these databases were created many years ago, when we lacked the 
recent insight in the vast amount of normal human genetic variation. At that time, only common 
variants were known. Variants representing over 1 % of alleles were considered to be non-functional 
and called polymorphism. Variants with a lower frequency were (falsely) assumed to be functional. 
Thus, when a novel variant was detected in a gene causing the disorder in a patient, it was considered 
to be a pathogenic mutation when it was not observed in 100 controls, and/or when it segregated with 
the disease in the (often small) family. It is now clear that there is an enormous amount of rare 
variation, mostly without functional consequences. Efforts to curate the existing databases are 
ongoing, complemented to the creation of novel databases such as ClinVar (Landrum, Lee et al. 2014). 
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One of the lacunae in our current knowledge is the capacity to predict functional consequences of 
variants. Variants that are likely to disrupt gene function include nonsense, frameshift and canonical 
splice site (+/- 1 or 2) variants, but one needs to be cautious (reviewed by Richards et al., 2015). The 
main interpretational challenge resides with non-synonymous SNVs. An increasing number of tools 
exist that predict deleteriousness for missense mutations. These are based on various sources of 
information, such as evolutionary conservation, the biochemical consequences of the change in amino 
acid, the domain in which they occur etc. The far from perfect concordance of the results of different 
tools, their low accuracy (65-80 %) and low specificity illustrate that they are not sufficiently reliable 
to be used in a routine clinical setting (Thusberg, Olatubosun et al. 2011). However, one can expect 
that the increased knowledge and the use of combinations of different tools will lead to more reliable 
results (Dong, Wei et al. 2015).  
In severe phenotypes, de novo mutations are the most common type of mutations (Gilissen, Hehir-
Kwa et al. 2014; Wright, Fitzgerald et al. 2015). Therefore, a trio approach, which compares genomic 
sequences of parents and their affected child is a very efficient strategy to identify causal mutations. 
However, de novo on its own is not a sufficient criteria anymore to establish causality when using a 
genome-wide screen: each individual carries on average about 50 de novo SNV’s in their genome, and 
this number increases with paternal age (Kong, Frigge et al. 2012). Of these, on average 1-2 are in the 
exome (coding or splicing regions (Wright, Fitzgerald et al. 2015). Also, a de novo CNV occurs in 
approximately 2-3 % of the normal population (Levy, Ronemus et al. 2011; Sanders, Ercan-Sencicek et 
al. 2011; Wright, Fitzgerald et al. 2015). This complicates the interpretation. For instance, in an exome 
sequencing study of individuals with autism, their parents and unaffected siblings, the same number 
of de novo SNV’s was observed in cases and their unaffected siblings. However, the functional effects 
of these variants differed, including more de novo loss-of-function mutations in cases, as reviewed by 
Ronemus et al., 2014 (Ronemus, Iossifov et al. 2014). A related question is how to establish a causal 
relationship between a (mutated) gene and a specific certain phenotype. Since large cohorts of 
children with ID are being sequenced, the same gene could repeatedly be mutated merely by chance. 
Stringent criteria therefore need to be applied, incorporating gene specific mutation rates such as gene 
length (Wright, Fitzgerald et al. 2015). The de novo hypothesis does not apply for autosomal recessive 
conditions and should be interpreted with caution for X-linked recessive since the mother may be an 
asymptomatic carrier. For less severe autosomal dominant phenotypes, one should take into account 
the possibility of variable expression and reduced penetrance. Phenotyping of the parents and 
constructing a detailed pedigree therefore remains important.  
8 
 
Another level of variant interpretation concerns the phenotypic effects of the found variant. For most 
genes with exception for haploinsufficient genes, loss-of-function will only result in a phenotype when 
both alleles are affected. On the X-chromosome loss of function of over 1 % of X-linked genes is 
compatible with normal life in males, a truly unexpected finding (Tarpey, Smith et al. 2009). Dominant 
effects may result from haploinsufficiency, whereas for other genes, a dominant phenotype may result 
only when the protein is altered in such a way that a novel dominant negative or gain-of-function effect 
results.  
Ultimately, existing knowledge on genotype-phenotype associations will be the final guide to decide 
which variants in which genes are disease causing. Building and curating databases containing both 
clinical and genotypic data requires continuous international efforts. DECIPHER, (Database of 
Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources) is the main example of 
a successful initiative, which has contributed significantly to the identification of novel causal CNV’s, 
and performs a key role as a reference for the clinical interpretation of array-CGH in diagnostic 
laboratories. Accurate phenotypic data remain however crucial.   
In many instances, a variant (be it CNV or SNV) cannot unambiguously be classified as pathogenic 
versus non-functional. For this reason, variants are classified according to their likelihood of being 
causal using a five-tier system (ranging from known pathogenic to known non-functional).  
Another complicating factor in the introduction of genome-wide screening is the potential of incidental 
findings, i.e. variants which have clinical significance, but are not related to the primary question. 
Whereas this might be perceived as a threat, many see this as an opportunity and therefore advocate 
to actively search for such so-called secondary variants in a limited set of genes, considered to be 
clinically actionable (Green, Berg et al. 2013; May 2015).   
1.5 Studies on the aetiology of ID in Central Africa.  
The prevalence of ID is higher in developing countries compared to the developed ones (Durkin 2002) 
and some ascribe this to various environmental and societal risk factors, many of which are 
interrelated. Examples include poverty, malnutrition, birth trauma, low parental education, high 
maternal age, high birth order, lack of stimulation, consanguinity and infectious diseases (Bashi 1977; 
Bergen 2008; Van Rie, Mupuala et al. 2008; Adnams 2010).  
To date, etiological studies of ID in Central Africa are almost non-existent. The situation in developing 
countries stands in sharp contrast to the tremendous progress in genetic knowledge and technology 
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in the developed world. These countries face not only an almost complete lack of access to diagnostic 
technologies, but also lack of up-to-date scientific knowledge and training in genetics. As a result, 
mystical and traditional beliefs on the causes of ID often prevail, further hampering scientific progress 
(Kromberg, Zwane et al. 2008; Njenga 2008). In a survey of mothers of disabled persons in a special 
institution in Nigeria, Abasiubong et al. (Abasiubong, Obembe et al. 2008) found that only 10 % of 
mothers linked the disability of their child to biological factors whereas the vast majority of mothers 
incriminated religious and mystical factors. The impact of raising a child with ID is very high for a 
mother, but cultural attitudes and beliefs surrounding disability - which are largely negative - 
contribute greatly to mothers’ disempowerment in the developing world (Abasiubong, Obembe et al. 
2006). There is a paucity of research publications on mental health in DR Congo. The traditional and 
most common belief is that a diseases in general are either curses or a punishments. Curses are 
imposed by evil spirits or witches whereas the punishments are inflected by “Nzambi ya Mpungu” 
(Almighty god) or unhappy ancestors in reaction to misconducts. Reporting about mental health in DRC 
Congo, the CDC (Centres for Disease Control, USA) stated that “Mental illness is often considered a 
curse (sometimes believed to be caused by supernatural elements or the result of witchcraft)”. 
(http://www.cdc.gov/immigrantrefugeehealth/profiles/congolese/background/index.html).  
In 2010, the UNICEF reported a conception that is getting more and more popular in some African 
countries, including the DRC, that children with a mental disability are themselves accused of being  
"child witches" (UN April 2010, 2, 40). 
As in majority of developing countries, the care for individuals with ID is poorly organized in the DR 
Congo. Recently, there has been an increased interest for mental health in the DR Congo. This was 
initiated by the implementation of a National Program for Mental Health, under the umbrella of Public 
Health Ministry. Following this initiative, the international NGO Handicap International implemented 
a network of institutions to provide care for people with special needs. However, these efforts are still 
insufficient. As an illustration, there are only 13 institutions specialized in mental health for more than 
8 million inhabitants in Kinshasa. In Katanga, the second largest province of DR Congo, there is only 
one specialized institution. Moreover, almost all these institutions are private and registration is 
subjected to payment of expensive tuition fees. Since most families have limited financial means, the 
overwhelming majority of children with ID do not attend a school and do not receive any remediation. 
In addition, many of the existing institutions are not engaging in research on ID.   
Research into the genetic causes of ID in a developing country can break the vicious circle. It will 
provide sound scientific data on genetic factors in the aetiology of ID and incidence of specific genetic 
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disorders. Reaching an etiological diagnosis in a person with intellectual disability is crucial for health 
care management in the society. The identification of preventable causes such as infections, congenital 
hypothyroidism or malnutrition is essential for accurate prevention programs. Also, on an individual 
level, an exact etiological diagnosis provides the parents and caregivers with a more accurate 
prognosis. It improves management and allows counselling on recurrence risks (Moeschler and Shevell 
2014). In addition, this also offers the opportunity to openly discuss false believes and feelings of guilt.  
However, the challenges for genetic studies of ID are huge. From a clinical point of view, knowledge 
on specific genetic disorders or syndromes is based on Caucasians. The reliability of these clinical 
criteria for specific syndromes established in Caucasians has not been investigated in central Africa. 
For instance, pictures of patients with African ancestry are almost completely lacking in the illustrated 
series of Terms in Morphology (Allanson, Cunniff et al. 2009). Environmental and societal risk factors 
for ID are more prevalent in developing countries. Thus, one can expect more complex causes of ID. 
State-of-the art genetic laboratory testing offers tremendous possibilities in reaching a diagnostic. 
However, the technical challenges in Central Africa are enormous, with a lack of laboratory 
infrastructure for molecular techniques. In addition, the lack of genetic studies in local populations 
results in the absence of reliable reference genetic data (e.g. CNV’s of SNV’s), which hampers the 
interpretation of genetic data, e.g. when deciding if a variant is causal. To illustrate this, the incidence 
of secondary variants detected in large scale exome studies in African-Americans is about half of that 
of Caucasians, indicating that the genetic databases are not representative for this part of the 
population (Dorschner, Amendola et al. 2013; Amendola, Dorschner et al. 2015). Finally, the mystical 
believes may also deter parents from participating in such studies.  
On the other hand, there are also unique opportunities for research. DR Congo is a “mosaic” country 
with more than 220 ethnicities, which are groups of clans or people sharing the same language, history 
and traditions. In addition, people within an ethnic group are characterized by close morphological 
appearance. These are organized in 4 main ethnic groups including Bantous, Sudanese, Nilotic and 
Pigmies. The Bantous ethnic group constitute about 80 % of the Congolese population. The province 
of Kinshasa, where the current study was conducted, is located in the West of DR Congo. The 
population of Kinshasa is a melting-pot of people from various groups. However, majority of the 
population is from the Bantous group and migrated from neighbouring west, north and centre 
provinces. There are more than 220 local dialects and 4 official national languages in DR Congo. Three 
of the 4 are of Bantous in origin. All genetic studies indicate a large genetic variation of the African 
population. Previous studies have shown that the Bantous group has undergone multiple interactions 
with surrounding groups at different locations, thus resulting also in a large genetic diversity within 
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the Bantous (Marks, Montinaro, et al., 2015). Noticeably, with exception of the pigmy population, 
Congolese have not been included in earlier genetic studies, and details about genetic diversity in the 
Congolese population groups are still lacking. 
However, based on the wide ethnic diversity, the presence of large families and frequent consanguinity 
in certain ethnicities, the DR Congo offers unique opportunities for genetic studies on the aetiology 
and mechanisms of ID (Gurdasani, Carstensen et al. 2015).  
Research in ID in the DR Congo has the additional perspective of building capacity in the disciplines of 
medical genetics, (paediatric) neurology and psychiatry. There is a need for medical doctors who are 
able to think and act scientifically when confronted with ID, i.e. able to recognize, categorize, and 
identify possible etiological factors, select adequate diagnostic steps, counsel the parents and to 
perform research in this field. The present research project is one step towards reaching this goal.  
Full references for articles cited in the general introduction can be found after the general discussion.   
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AIMS OF THE STUDY 
A first aim of this study is to contribute to the understanding of the genetic aetiology of ID in Central 
Africa.  We will therefore  
- identify the aetiology of ID in a cohort of Congolese individuals with unexplained ID, using state-
of-the art clinical and genetic studies. 
- define the incidence of Fragile-X syndrome in this cohort and evaluate the usefulness of three 
different checklists as a screening tool. 
- define clinical parameters associated with a higher chance of reaching an etiological diagnosis. 
A second aim is to gain insight into the variability in clinical expression of specific genetic disorders in 
Central Africa. This will be done by comparison of phenotypic manifestations in Congolese cases with 
those in the literature. 
The third aim is to gain insight into causes of and variability in genetic mutations observed in Congolese 
patients with a genetic disorder, through the study of cases we identify. 
 
 
 
 
 
 
14 
 
 
 
  
15 
 
A CLINICAL AND GENETIC STUDY IN 127 PATIENTS WITH ID IN KINSHASA, DR CONGO 
 
(Manuscript in preparation) 
Authors: Aimé Lumaka1,2,3,4, Hilde Peeters1, Prosper Lukusa1,2,3,4, Koenraad Devriendt1,5 
Affiliations: 
1. Centre for Human Genetics, University Hospital, University of Leuven, Belgium 
2. Centre for Human Genetics, Faculty of Medicine, University of Kinshasa, DR Congo 
3. Department of Paediatrics, Faculty of Medicine, University of Kinshasa, DR Congo 
4. Institut National de Recherche Biomédicale, Kinshasa, DR Congo 
5. Corresponding author 
 
 
 
 
 
Corresponding author: 
Professor Koenraad Devriendt, MD, PhD 
Centre for Human Genetics, University Hospitals, University of Leuven,  
Herestraat 49, Bus 602, 3000 Leuven, Belgium.  
Email: koenraad.devriendt@uzleuven.be 
Tel.: +32 16 34 59 03  
Fax: +32 16 34 60 60 
16 
 
1.6 Introduction. 
Reaching an etiological diagnosis often has a major impact on the management plan for a child with ID 
or a developmental disorder. Not only can this guide towards efficient care, but also it will make 
possible the implementation of preventive measures such as pre-conceptual counselling and prenatal 
testing. In the African context, were ID is mainly attributed to mystical causes (Abasiubong, Obembe 
et al. 2008; Njenga 2008), a study of genetic causes will provide strong arguments to campaign against 
false beliefs and help to improve actions of caregivers. Data on the genetic aetiology of ID in Central 
Africa are scarce. With exception for some case reports, only few studies have investigated a cohort of 
patients with ID using advanced technologies (Uwineza, Caberg et al. 2014). 
From a clinical point of view, clues towards a possible diagnosis can be retrieved from the family 
history, the personal medical history as well as from the development and behaviour. In the clinical 
examination, special attention is given to the presence of dysmorphism, biometry (especially head 
circumference) and neurological findings. When a clinical diagnosis is suspected, targeted (genetic) 
testing can be undertaken. For certain clinically recognizable conditions (e.g. VATER association), no 
cause is known and the diagnosis remains purely clinical. When no clinical diagnosis can be made, 
genetic screening can be performed. According to a consensus statement, genome-wide screening for 
chromosomal imbalances is considered to be a first-tier test, replacing the traditional karyotyping 
(Battaglia, Doccini et al. 2013; Moeschler and Shevell 2014). 
Genetic causes have been detected in 4 to 41 %, depending of the recruitment strategy, type and 
resolution of techniques (Battaglia, Bianchini et al. 1999; Moeschler 2008; Bernardini, Alesi et al. 2010). 
Reaching a genetic diagnosis in an individual with ID is based on different but complementary 
approaches. Chromosomal aberrations represent the major diagnostic category in the older studies 
(Devriendt, Holvoet et al. 2003; Rauch, Hoyer et al. 2006). Depending on the resolution of the applied 
platform, submicroscopic imbalances represent 6 to 20 % of causes (Rauch, Hoyer et al. 2006; Chong, 
Lo et al. 2014; Nicholl, Waters et al. 2014; Utine, Haliloglu et al. 2014). The most common monogenic 
cause of ID is the Fragile-X syndrome, that results from mutations in the FMR1 gene (MIM 309550). 
Since the vast majority of cases are caused by an expansion of a CGG repeat in the 5’-UTR of the gene, 
a straightforward genetic screening test exists assessing the number of CGG repeats. For this reason, 
all patients with ID are investigated for the CGG repeat size (Moeschler and Shevell 2014). Mutations 
in X-linked genes are a common cause of ID and explain an excess of males with ID (Mandel and Chelly 
2004; Ropers 2010). X-linked ID is observed in 6-12 % of males with ID (Hu, Haas et al. 2015; Tzschach, 
Grasshoff et al. 2015). However, XLID is heterogeneous with more than 100 genes identified to date 
(Hu, Haas et al. 2015). Thus NGS offers opportunity to screen for x-linked ID. X-linked inheritance is 
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suspected when a clinically recognizable X-linked syndrome is observed or when ID segregates in the 
pedigree in a clear X-linked way. In addition, unaffected mothers who are carrier of certain X-linked 
mutations have a skewed X-inactivation pattern, meaning that a preferential inactivation mostly occurs 
of the X-chromosome that carries the mutation. An example is the ATRX-syndrome. Thus, skewed X-
inactivation in a mother of a boy with unexplained ID may point to an X-linked cause. Plenge et al. 
(2002) studied X-linked ID families, and demonstrated a high incidence of skewed X-inactivation in 
carrier females (Plenge, Stevenson et al. 2002). Rauch et al. (2006) reported that 5.6 % of mothers of 
boys with unexplained ID have more skewed of X-inactivation (> 95 %) suggesting X-linked ID (Rauch, 
Hoyer et al. 2006). Also, females may present X-linked disorders, typically because the dominant effect 
of a mutation. This is seen in incontinentia pigmenti caused by mutations in the IKBKG or NEMO gene, 
and in females with a CASK mutation (Martinez-Pomar, Munoz-Saa et al. 2005). Also, skewed X-
inactivation, with preferential inactivation of the normal allele may result in an X-linked condition in a 
female (Esquilin, Takemoto et al. 2012) 
Whole Exome sequencing (WES) is an emerging technology and a powerful means to identify a causal 
SNV in autosomal genes. However, one of the limiting factors is the large number of unclassified SNV’s 
each individual carries. Therefore, additional filtering based on the phenotype, supposed inheritance 
pattern (e.g. X-linked ID or autosomal recessive ID) and population specific polymorphisms aids in 
further limiting the number of potential candidate causal SNV’s. In this study, we took two different 
approaches. First, we selected cases with a high probability of X-linked ID. In the absence of clearly X-
linked pedigrees, we took skewed X-inactivation in the mother of a boy with unexplained ID as an 
indication of possible XL-ID, as discussed above. Likewise, skewed X-inactivation in a girl with 
unexplained ID may also indicate that an underlying X-linked mutation explained her ID. Therefore, we 
undertook an X-inactivation screening of all available mothers of boys in our cohort, as well as all 
female patients. Next, in two sisters with syndromic ID, an autosomal recessive cause was thought to 
be the most likely inheritance pattern. We performed exome sequencing in both of them and filtered 
for shared variants. In addition, under the hypothesis of a de novo dominant mutation and germline 
mosaicism in one of the parents, we also filtered for potentially pathogenic variants shared by the two 
sisters in the genes causing AD ID (based on the DDD2G gene list).   
These general principles form the basis of the outline of our study, as illustrated in figure 1. 
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                                          Figure 1. Flow chart of the current study.  
Clinical examination was at the centre of the current study. Depending on the out-come, either a targeted testing or a wide genetic screening was decided 
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1.7 Materials and methods 
1.7.1 Description of the recruitment of the cohort 
In 2009 the International Non-Governmental Organization Handicap International identified 13 
institutions specialized for intellectual disability in Kinshasa. We contacted the directors of these 
institutions, explained our project and asked whether they were willing to collaborate and allow us to 
recruit patients from their institutions to participate in the study. Two hospitals and 4 specialized 
schools agreed to participate: University Hospitals of University of Kinshasa (CUK); Centre de Neuro-
PsychoPathologie de Kinshasa (CNPP); Village Bondeko Kabambare; Centre d’Etude, d’Intervention et 
d’Evaluation pour le Handicap Mental et l’Autisme (CEIEHMA); Centre Pour Enfant Bon Départ (CPEBD) 
and Ecole primaire Notre Dame d’Afrique. We included patients with intellectual disability (ID) after 
obtaining informed consent from their parent(s) or legal representative(s). 
In each of these 6 institutions we worked in close collaboration with the directors and applied a 
stepwise recruitment and consent process: 
1° Contact by mail. The institution provided the parents an envelope containing the leaflet explaining 
the study, a copy of the study questionnaire and an invitation to attend an information day at the 
institution. We wished to inform the parents of our study, prepare them to our questions and allow 
them to consider specific questions they may wish to ask us during the information day scheduled 1 
week later.  
2° Information day: during this meeting, we introduced ourselves and provided a short overview on 
ID, genetics and genetics of ID. We discussed in details the aims of the study, the methods and foreseen 
issues, what was expected from them and what they could expect from us. We took questions from 
the attendants during a plenary session. This was followed, when necessary, by a private conversation 
in a separate room. At the end of the meeting, we invited parents who wished to participate to sign 
and return the consent form, after an additional week of reflection. These children were then 
examined at a later date in the institution.  
3° The clinical examination was done at a later occasion, at the institution. We conducted a 
standardized clinical examination including body measurements and a dysmorphological evaluation. 
Personal and family history was obtained from the parents and tutors. Body measurements were 
converted into standard deviation scores using the Centres for Disease Control (CDC, USA) growth 
charts. We used the obtained information to score three fragile-X screening checklists (Hagerman, 
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Amiri et al. 1991; Maes, Fryns et al. 2000; Guruju, Lavanya et al. 2009). Familial ID was defined as a 
family history with another ID patient (up to 3rd degree relative). Otherwise, the patient was classified 
as sporadic ID. A patient was classified as dysmorphic when he had either 2 major malformations or ≥ 
3 minor anomalies (Hennekam 2011). We referred to the Elements of Morphology: Standard 
Terminology published in 2009 (Allanson, Cunniff et al. 2009; Biesecker, Aase et al. 2009; Carey, Cohen 
et al. 2009; Hall, Graham et al. 2009; Hennekam, Cormier-Daire et al. 2009; Hunter, Frias et al. 2009; 
Klinger and Merlob 2009). 
We finally included, collected clinical information and obtained DNA from 127 patients (33 females 
and 94 males), aged from 1.24 to 24.65 years and with a mean of 10.03 ± 4.68 years.  
1.7.2 Technology: 
1.7.2.1 DNA extraction 
Venous blood was obtain from a peripheral vein and genomic DNA was extracted by the salt saturation 
method as previously described (Miller, Dykes et al. 1988). Between 2010 and 2012, blood samples or 
leucocytes pellets were shipped to Belgium by airplane and DNA extraction was done in the Centre for 
Human Genetic in Leuven. In meantime we managed to establish a reliable DNA extraction facility at 
the Institut National de Recherche Biomédicale (INRB) in Kinshasa. From 2013 on, the DNA extraction 
facility at the INRB was fully operational and we were able to perform DNA extraction in Kinshasa and 
ship the extracted DNA to Belgium for further analyses. 
1.7.2.2 FMR1 testing 
To assess the fragment size of the CGG repeat in the promoter region of the FMR1 gene, the target 
region was amplified during a PRC reaction using the PRC-enhancer kit (Invitrogen) and the FRAXA-A 
and FRAXA-B primers. The reaction mix contained 5.6 µl of water, 2 ml of the 10X PCRx Amplification 
buffer, 0.6 µm of 50 mM MgSO4, 1 µl of dNTPs (4 mM), 8 µl of PCRx Enhancer Solution, 1.5 µl of Primer 
mix (10 pm/µl) and 0.25 µl of Taq DNA Polymerase from Roche. The cycling comprised an initial 
denaturation at 95°C for 3 minutes followed by 27 amplification cycles made of short denaturation at 
95°C for 15 seconds, annealing at 64°C for 1 minute and elongation at 75°C for 1 minute. The reaction 
was terminated with a final elongation at 75°C for 7 minutes and cooling at 15°C ∞. PCR control was 
done on 2 % agarose gel with 1 kb size marker. The PCR product was resuspended with a mixture of 
20 µl HiDi Formamide (Applied Biosystems) and Rox 500 (Applied Biosystems). Fragment were 
separated on the on ABI 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA 94404 USA) then 
analysed with GeneMapper Software. 
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1.7.2.3 Microarray-CGH using stripped slides 
We performed whole genome copy number screening using CytoSure™ ISCA v2 array 8x60k format 
(OGT, Oxford UK). To make this technology accessible in a resource poor setting, we adapted the 
existing protocol to recycle arrays used once before. Used arrays were provided by the Cytogenetic 
laboratory, UZ Leuven. We validated the protocol using 9 DNA samples with previously characterized 
CNV’s using high resolution Illumina SNP array v2.1 and CytoSure™ ISCA v2 array 4x180k format from 
OGT. These 8x60k slides have 8 slots and each slot contains 60.000 oligonucleotide probes. The 
backbone coverage is 1 probe every 60 kb but at each of the 480 targeted regions, the coverage is 
increased to 1 probe every 31 kb, corresponding on mean to 4 probes per gene in the targeted regions.  
The validation experiment was done as follows: 
a) We tested 3 slides that were used once within 7 days maximum. During their first use, these 
slides were labelled for 2 hours (at 37°C), hybridization for 16 hours, washed and scanned 
following the manufacturer’s protocol then kept in a dehumidified cabinet after scanning. 
b) We stripped the slides in the Little dipper robot, containing wash buffer 2 (350 ml) + MiliQ 
water (350 ml) in the dish 1 and 700 ml MiliQ water in the dish 2. The liquid in dish 1 was 
heated beforehand to 65°C at least 30 minutes beforehand and the stirring bar was set at 
speed 7. The liquid in dish 2 remained at room temperature. Used slides were washed for 30 
minutes and submerged 20 times/minute. Slides were immediately transferred to the dish 2 
were they were similarly submerged for 1 minute. Slides were dried at room temperature for 
2 minutes then stored in a lightproof box in the dehumidified cabinet until their use. 
c) For the re-hybridization, we used 9 samples (3 females and 6 males) from a previously studied 
autism cohort, fully characterized with CytoSure™ ISCA v2 array 4x180K and Illumina SNP 
arrays v.2. We run and analysed the female and male samples separately in groups of three 
patients, using the loop-design (Allemeersch et al., 2009.) The hybridization protocol was 
according to the manufacturer’s except the following change: labelling at 37°C for 22 hours.  
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The protocol for patients’ testing included: 
a) Labelling, hybridization and washing were done following manufacturer instructions, with 
the exception that we obtained optimal dye incorporation when we extended the labelling 
duration to 22 hours in a lightproof box placed in a 37°C oven. 
b) Arrays were scanned with Surescan High-Resolution Technology Microarray at 2 μm wave 
length, followed by feature extraction using Agilent Feature Extraction Software® v.10.10.11. 
Aberration detection was done by Circular Binary Segmentation (CBS) algorithm via CytoSure 
Interpret Software ® v.4.0. A CNV was reported as deletion when the Log2 ratio was < to -
0.36 and duplication when > to +0.36. Genomic coordinates were based on the UCSC 
February 2009 (hg19) (NCBI build 37). We used a loop strategy to compare sample to 
reference (Allemeersch, Van Vooren et al. 2009). 
c) Data interpretation. We uploaded our data to Cartagenia CNV bench (Horpaopan, Spier et al. 
2015). This allowed a more efficient classification of found copy number variations by 
comparison with databases of normal variation (Database of Genomic Variants) and 
pathogenic CNV’s (DECIPHER, ISCA consortium) and known local pathogenic or benign CNV’s.  
1.7.2.4 q-PCR 
To confirm microarray-CGH results, evaluate parental inheritance or confirm a clinical diagnosis of 
Down syndrome, we performed qPCR using the LightCycler480® (Roche). The Primer3web version 
4.0.0 tool (http://bioinfo.ut.ee/primer3/ (last accession on 08 February 2015) was used to design 
primers listed at the end of the chapter. We used the ddCt relative quantification method (Sequence 
Detection System bulletin 2, Applied Biosystems) with SYBR-green. For Down syndrome, we used 
NCAM2 (NM_004540) located on 21q21.1 as the target and the SCN2A (NM_021007) located on 
2q24.3 as reference gene. Since the 2 primer sets showed similar efficiency, we were able to use the 
ddCt relative quantification method. The standard curve experiments were done with fourfold 
dilutions of genomic DNA, starting with 10 ng in the first dilution. The 20 µl reaction mixtures consisted 
of 10 µl of LightCycler® 480 SYBR Green I Master (Roche Diagnostics GmbH, Mannheim, Germany), 3 
ml of PCR-grade water (Roche) 500 nM of each primer and 10 ng DNA. After an initial denaturation 
step for 10 min at 95°C, thermal cycling conditions were 10 s at 95°C and 30 s at 60°C for 45 cycles. 
When testing patients’ samples, we included No-DNA templates and 3 calibrators (1 from DR Congo 
and 2 from Flanders) and all samples were run in Duplo following the standard 20 µl qPCR protocol. 
  
23 
 
1.7.2.5 X-chromosome inactivation pattern 
The X-chromosome inactivation pattern was analysed through the polymorphic CAG-repeat in the 
androgen receptor gene using HpaII restriction enzyme as described. We included RsaI in the non-
digested samples as the control enzyme. The proportion of X-inactivation of the two X chromosomes 
was calculated as follows: the proportion of digested alleles (A) was obtained by dividing the Area 
Under the Curve (AUC) of allele 1 by AUC of allele 2 after HpaII digestion, whereas the proportion of 
non-digested alleles (B) was the ratio of AUC of allele 1 to AUC of allele 2 in the experiment using RsaI 
digestion. The X-inactivation pattern was calculated with the following formula:  
% =
𝑅𝑥100
𝑅+1
       R being equal to  
𝐴
𝐵
  
1.7.2.6 Whole Exome analysis 
Exome sequencing was done either in the Genomics core KULeuven (n=2) or in collaboration with the 
Medical Genetics Laboratories, Baylor College of Medicine (n = 10), using the SeqCap EZ Human Exome 
Library v3.0 (Roche, NimbleGen), and the Illumina HiSeq2000 platform. Data analysis was done using 
commercial and in-house developed software. Exome sequences were obtained from the patients 
only. 
The variant filtering was done as described in table 1. We first filtered the variants under the 
hypothesis of an X-linked condition, followed by a possible autosomal dominant (AD) or autosomal 
recessive (AR) cause. During initial variant filtering we retained only non-synonymous variants in 
coding regions, including exonic and splicing variants (including the first 5 intronic nt). Next, we 
removed common variants using a cut-off of > 1 % for X-linked and AD or >2 % for AR in the 1000 
Genomes Project and ESP databases. We further discarded variants observed in other Belgian and 
Congolese cases. We retained variant within genes on list of genes known to be implicated in 
developmental disorders and ID, obtained from the UK DDD2G project (Deciphering Developmental 
Delay), update of July 18th 2014. In addition, variants were further prioritized using three different in 
silico prediction tools (PolyPhen2, Mutation Taster or SIFT). Promising variants were validated with 
Sanger sequencing and inheritance was investigated when parental DNA samples were available. 
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Table 1. Variant filtering strategies 
Steps X-linked  Autosomal Dominant  Autosomal Recessive 
Compound heterozygote  Homozygous 
1 Retain coding variants  Retain coding variants  Retain coding variants  Retain coding variants  
2 Filter out synonymous variants  Filter out synonymous variants  Filter out synonymous variants  Filter out synonymous variants  
3 Filter out variants with frequency >1% in 1000 GP 
and ESP  
Filter out variants with frequency 
>1% in 1000 GP and ESP 
Filter out variants with frequency >2% in 
1000 GP and ESP 
Filter out variants with frequency >2% in 
1000 GP and ESP 
4 retain X-chromosome variants  retain heterozygous  variants  retain heterozygous  variants retain  only homozygous  variants   
5 Remove duplicates Remove duplicates Filter out variants reported as 
heterozygous in more than 5 or 
homozygous in one or more local controls 
(patients without ID) 
REMOVE duplicates 
6 Retain only SNVs heterozygous in female patient Filter out variants observed in local 
controls (patients without ID) 
Remove duplicates Filter out variants reported as 
heterozygous in more than 5 or 
homozygous in one or more local 
controls (patients without ID) 
7 Filter out variants observed in local controls 
(patients without ID)  
Keep variants in genes from the 
DDD2G list  
Filter out genes with only 1 SNV Keep variants in genes from the DDD2G 
list 
8 Keep variants in genes from the DDD2G list and 
look for concordance of phenotype 
Keep  deleterious SNVs s or missense 
SNVs predicted to be Disease 
Causing by at least 2 prediction tools 
Keep variants in genes from the DDD2G 
list  
Keep variants in genes involved in AR 
disorders and evaluate concordance of 
phenotype 
9 Select variants in all X-linked genes  
- deleterious  mutations (Splice, frameshift or 
stop)  
- missense variants predicted to be Disease 
Causing by at least 2 prediction tools 
(PolyPhen2, Mutation Taster or SIFT)  
and evaluate concordance of phenotype 
Keep variants in genes involved in AD 
disorders and evaluate concordance 
of phenotype 
Keep variants in genes involved in AR 
disorders and evaluate concordance of 
phenotype  
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1.7.2.7 Sanger sequencing for Exome validation 
Sequencing primers used for Sanger validation are listed at the end on the chapter. The 50 μl 
amplification reaction contained 5 μl of DNA (50 ng), 5 μl of PCR reaction buffer + Mg2+ (Roche), 5 μl 
of each Primer solution (2.5 pmol/μl), 5 μl of dNTP's (2 mM), 0.5 μl (2.5 U) of Taq DNA Polymerase 
(Roche) and 24.5 μl of Ultrapure water (Baxter). The PCR was run on a 2720 Thermal Cycler (Applied 
Biosystems, Foster City, CA 94404 USA) using the following program: initial denaturation stage at 95 
°C for 5 min; 35 cycles of denaturation at 95 °C for 30 s, annealing at 58 °C for 30 s and elongation at 
72 °C for 45 s; and a final extension stage at 72 °C for 5 min. PCR products were sequenced using Big 
Dye termination method and detected with ABI 3730xl DNA Analyzer instrument (Applied Biosystems, 
Foster City, CA 94404 USA). 
1.7.2.8 Fragment analysis for ARX CAG repeat 
We used 2 primer sets (Primer 4044 ARX-2F and JR2-FAM) to amplify the first 2 CAG stretches in the 
ARX. The reaction mix contained 1 µl of DNA, 5 µl of 10X amplification buffer, 5 µl of dNTP’s (2 mM), 
15 µl of 3X PCR enhancer, 1.5 µl of 50 mM MgSO4, 12 µl of water and 0.5 µl of Taq DNA Pol. (5U/µl). 
The 35 cycles had the following conditions: 95°C  for 30 sec, 58°C  for 30 sec and 68°C  for 60 sec. 0.1 
µl of PCR product was re-suspended in 20 µl HiDi Formamide/Rox500 and loaded onto a Genetic 
Analyzer for Fragment separation. The separated file was analyzed with GeneMapper® v.5. 
1.7.3 Ethics  
The participants were informed about the structure and aims of the study. They were informed 
concerning their right to withdraw from the study. For each participant, parents or legal 
representatives provided written consent for study participation. We applied an anonymous and non-
personal coding system to protect participants’ privacy. Our research protocol was approved under 
the number ESP/CE/008/2015 by the National Ethical Committee of the Public Health School of the 
University of Kinshasa, Kinshasa, and the DR Congo. 
1.7.4 Statistics 
In order to conclude on the QC-Metric from the striped slides, we used the statistic tool R to compute 
the Paired Wilcoxon Ranked Sum Test P-Value.  
We used WinPePi v.11 to build confidence Intervals for the proportions of XCI, at a 95 % confidence. 
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1.8 Results 
1.8.1 General clinical characterization of the cohort  
A total of 131 patients were initially recruited for the study from 6 institutions in Kinshasa in the 
Democratic Republic of Congo. Four were lost to follow-up, thus this study will report on 127 patients. 
Figure 2.A presents the origin of recruitment of the 127 remaining participants. There were 33 (25.98 
%) girls and 94 (74.02 %) boys (Figure 2.B), with an age 10.32 ± 4.68 years (ranges 1.24 - 24.65). Only 7 
patients were aged equal or above 18 years, 120 were below 18 years.   
 
Fig 2. Panel A. Distribution of patients based on Institution of origin. CPEBD= Centre Pour Enfants Bon 
Départ; CEEIHMA= Centre d’Etude, d’Intervention et d’Evaluation du Handicap Mental et l’Autisme; 
CUK=Cliniques Universitaires de Kinshasa; Vil. Bond= Village Bondeko; N. Dame= primary school Notre 
Dame; CNPP= Centre de NeuroPsycho-Pathologie of Kinshasa. Panel B. Gender distribution, note 
unequal distribution. 
The IQ levels were available for 72 (56.69 %) patients (figure 3) and had been determined by various 
intelligence tests, depending on the school or institution. 
 
Figure 3. IQ level of participants in this study.  
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Family history was negative with regard to ID in 113 patients, 14 had a positive family history of ID (up 
to the third degree). 
Personal history and clinical examination revealed neurological manifestations in 24 patients, including 
seizures in 15, deafness in 4, cerebral palsy in 3 and dystonia in 2. Nine patients had a major 
malformation at birth including congenital heart defect in 2, congenital inguinal hernia in 2 and one 
each of coloboma of eyelid, congenital cataract, cryptorchidism, limb reduction defect, micro-penis 
and a congenital testicular cyst. Microcephaly (OFC ≤ - 2 SD) was present in 38 patients and 
macrocephaly (OFC ≥ +2SD) in 10 (figure 4). The OFC was not available in 1 patient. 
 
Figure 4. Distribution of head circumference.  
The number of minor anomalies was recorded for each individual (Figure 5). Fifty (45.87 %) of the 108 
patients (after exclusion of the 19 Down syndrome patients) had three or more minor anomalies, and 
were considered to be dysmorphic. 
 
Figure 5. Distribution of the number of minor anomalies in patients (after exclusion of Down syndrome 
cases).  
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1.8.2 Clinically recognized syndromes. 
In 19 patients, the diagnosis of Down syndrome was made. In addition to this, we clinically diagnosed 
one patient with Williams-Beuren syndrome (WBS), Partington syndrome, Noonan syndrome, Oculo-
Auriculo-Vertebral Spectrum (OAVS) and Amniotic Bands Sequence. In 8 individuals, the most likely 
diagnosis was an acquired cause of their ID. Below, we describe and discuss the patients with a clinical 
diagnosis. 
1.8.2.1 Down syndrome.  
We identified features consistent with Down syndrome in 19 patients aged 1.86 to 17.08 years. 
Fourteen (73.68 %) were born to mothers aged above 35 years. Maternal age was not available for 
one. Microcephaly was present in 16 patients and was associated with respectively upslant of eyes and 
hypertelorism in 14, epicanthus and sandal gap in 13, respectively (Table 2). None of them had a 
diagnosed heart defect or another major congenital malformation.  
 
Figure 6. Faces of patients with Down syndrome. Patients sorted in accordance with table 2. 
The diagnosis of Down syndrome was confirmed in all cases, using different techniques depending on 
the time of recruitment. In the first 6 clinically diagnosed DS patients, a G-banded karyotype was done. 
In a second group of 6 patients, microarray-CGH confirmed a duplication of the entire chromosome 
21. Finally, in the remaining 7 patients, as well as the previous 12, the diagnosis was confirmed by 
means of q-PCR (see materials and methods section) (figure 7).  In one patient (DRC-0157), with a 
clinical diagnosis of Down syndrome (figure 6-K, figure 7 and table 2), we observed a relative ratio of 
1.2, consistent with mosaicism for trisomy 21.  
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Table 2. Description of patients with Down syndrome 
 
ID Gender Age 
(Y) 
Maternal 
age 
OFC 
(z sc) 
weigh
t 
(Z-sc) 
Heigh
t 
(Z-sc) 
Upslant 
of eyes 
(14/19) 
Hyper- 
telorism 
(14/19) 
Epicanthus 
(13/19) 
Sandal gap 
(13/19) 
Flat face 
(11/19) 
Brachy- 
cephaly 
(10/19) 
Transv
erse 
palmar 
crease 
(10/19) 
Small/ 
flat 
nose 
(7/19) 
Bra- 
chydactyly  
of toes 
(7/19) 
Tongue 
protrusion 
(6/19) 
Low 
posterior 
hairline/ 
webbing 
(4/19) 
Low 
set 
ears 
(3/19
) 
Karyotype 
(6/19) 
aCG
H 
(6/1
9
) 
qPCR 
(rel. 
qant) 
(1 /19) 
DRC-0100 M 4,21 37,97 -2,06 0,70 -0,72 + +  + + 
 
+   +  + NA T21 1,587401 
DRC-0015 M 4,52 36,66 -3,6 NA NA + + +  + 
 
 +    
 
NA T21 1,52274 
437634 M 5,08 NA -2,74 -1,80 -0,91 +   +  + +   +  
 
T21 NA 1,543993 
437587 M 6,88 40,25 -1,43 NA NA  +  +  
 
+     + T21 NA 1,470867 
447754 M 7,00 39,62 -0,42 NA -2,77 + +  + + + + +    
 
T21 NA 1,491399 
437573 M 7,70 39,41 -2,21 -1,64 -1,82 + + +  + 
 
 +  +  
 
T21 NA 1,450617 
DRC-0051 M 12,52 35,62 -2,2 0,11 -1,6 + + + + + + +  +  + 
 
NA NA 1,501773 
437632 M 13,38 31,76 -3,07 NA NA  + + +  
 
 +    
 
T21 NA 1,570982 
DRC-0161 M 13,98 36,79 -3,21 -2,39 -3,14   + + + +   + + + 
 
NA NA 1,538652 
437590 M 14,65 36,49 -2,7 NA NA + +    + +    + + T21 NA 1,522737 
DRC-0157 M 17,03 26,15 -2,57 -1,89 -4,24 + + +   + Deep 
creases 
 +   
 
NA T21 1,203025 
DRC-0041 M 17,08 42,02 -2,58 <-3 -3,69  + +  + 
 
+  +   
 
NA NA 1,470867 
DRC-0013 F 1,86 24,32 NA NA NA + + + + + 
 
 + + +  
 
NA NA 1,506987 
DRC-0177 F 8,32 37,71 -3,69 -1,73 -3,33  + +  + 
 
+ +    
 
NA T21 1,881218 
DRC-0058 F 9,51 26,43 -3,95 -2,84 -3,58 +  + +  + +     
 
NA NA 1,538652 
DRC-0152 F 9,93 40,47 -2,56 -2,88 -2,41 + + + + + +  + + + + 
 
NA T21 1,707241 
DRC-0174 F 11,03 40,79 -2,8 -2,34 -2,4 +   +  
 
     
 
NA T21 1,649086 
DRC-0062 F 12,73 42,92 -2,28 -1,89 -3,09 + + + +  + +     
 
NA NA 1,517469 
DRC-0171 F 13,73 43,27 -2,6 0,93 -1,47 +  + + + +   +   
 
NA NA 1,396356 
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Figure 7. qPCR analysis confirming the diagnosis of trisomy 21 in all patients with the clinical diagnosis 
of Down syndrome. 
1.8.2.2  Williams-Beuren syndrome. 
The clinical features in the patient with WBS are described in detail in chapter 5.3 (Challenges for 
genetic studies in Africa). First, FISH testing was performed to confirm the suspected clinical diagnosis 
of Williams syndrome. Only one ELN signal was detected in all of the hundred cells analysed, whereas 
all cells had 2 signals for the control probe. Next, to define the exact size of the deletion, microarray-
CGH was done using a stripped 8x60k slide. This revealed the recurrent 1.57 Mb deletion arr [hg19] 
7q11.23(72,634,874-74,203,685)x1. 
1.8.2.3 Partington syndrome.  
This patient was 16.53-year-old born to unrelated parents and had normal functioning,. He was the 
second of 5 children including one older and 1 younger brother and 2 younger sisters (pedigree figure 
8-A). Pregnancy and delivery were uneventful. He had mild ID and speech problems and went to a 
specialized primary school. He had a normal biometry (OFC 57.2 cm, 0.93SD; weight 61 cm, -0.19SD 
and height 172.5 cm, -0.28SD). He had a long and triangular face with large and protruding ears. He 
had marked dystonic movements of his hands and arms. Speech was dysarthric. He had mild ID. His 
older brother was equally affected and attended the same specialized school as the index. Clinically, 
he had a long and triangular face, large and protruding ears, scoliosis and the same dystonic 
movements and dysarthric speech as his brother (figure 8-B). The clinical diagnosis of Partington 
syndrome was made and subsequently confirmed by molecular testing of the Aristaless Related 
homeoboX (ARX) gene. Both brothers carry the recurrent duplication of 24 bp in exon 2 
(c.429_452dup24), which results in an increase of a polyalanine tract in the ARX protein from 12 to 20 
alanines (Curie et al., 2014).  
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Figure 8. Pedigree and phenotype in Partington siblings. Long, triangular face in the index (B-1) and his 
brother (B-4), large and protruding ears in the index (B-1 and B-2) and in his brother (B-4 and B-5); 
dystonic position of hands less in the index (B-3) and, more pronounced in his older brother (B-6). 
1.8.2.4 Noonan syndrome 
This 6.15-year-old boy was born after a normal pregnancy as the second of four children from 
unrelated parents. He was the only male child. Family history was negative for ID. His father was 
diagnosed with a cardiac valvular problem at older age. The maternal grandfather had a heart disorder 
and a maternal uncle has a pacemaker. The patient was born with pulmonary valve stenosis, surgically 
corrected. He had speech problems, autistic like behaviour and mild ID with an IQ of 66. On clinical 
examination we noted a normal head circumference (52 cm, 0.2SD), relatively short stature (height 
111 cm, -1.39SD) and normal weight (19.8 kg, 0.41SD). He was hypotonic, with drooling and a high 
arched palate (figure 9). He had ptosis, a high forehead, mild facial asymmetry, a high arched palate 
and special ears (over folded helices and upturned lobes). The toes were short and hands were slightly 
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swollen. Targeted resequencing of a panel of genes implicated in Noonan syndrome did not identify 
pathogenic mutation. This panel included the following genes: SOS1 (NM_005633.3) all the coding 
region; RAF1 (NM_002880.3) exons 7, 14 and 17; RIT1 (NM_006912.5) all the coding region; KRAS 
(NM_004985.3) all the coding region; BRAF (NM_004333.4) exons 4, 6, 11-16; MEK1/MAP2K1 
(NM_002755.3) exons 2 and 3; MEK2/MAP2K2 (NM_030662.3) exons 2, 3 and 7; HRAS (NM_005343.2) 
exon 2. Fragile X testing, maternal X-chromosome inactivation profile and microarray-CGH were also 
normal. 
 
Figure 9. Clinical features of the child with Noonan syndrome. Facial features (1-4) with ptosis, ears 
with upturned lobe and overfolded helices, high forehead. (5) Short toes, (6) oedematous aspects of 
the dorsal sides of the hands, (7) High arched palate. 
1.8.2.5 Oculo-auriculo-vertebral spectrum.  
This patient was a 7.85-year-old girl, the oldest of 3 children from healthy, unrelated parents. 
Pregnancy and delivery were uneventful. She functions at the level of moderate ID. On clinical 
examination, biometry was normal with OFC 53.5 cm (1.35 SD), weight 22 kg (-0.86 SD) and height 124 
cm (-0.47 cm). We noted an asymmetry of the face with right-sided plagiocephaly, a prominent 
forehead, hypertelorism, epibulbar dermoid and coloboma of upper eyelid on the left eye, hypoplasia 
of the left malar bone and a small cheek on the left, bilateral pre-auricular tags, flat nasal tip, long 
philtrum, high arched palate, micro-retrognathia, short fingers and sandal gap (figure 10). There were 
no limitations in the mobility of her neck. Neurological examination was normal. All these features 
were consistent for the oculo-auriculo-vertebral spectrum (OAVS). Microarray-CGH was normal. ID is 
not a consistent feature of OAVS, but has been observed before (Beleza-Meireles, Clayton-Smith et al. 
2014).  
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Figure 10. Facial features of the girl with oculo-auriculo-vertebral spectrum. Note the facial asymmetry, 
hypertelorism, hypoplastic malar bone and small left cheek (A), retrognathia, bilateral preauricular 
tags (B,C), epibulbar dermoid (D), coloboma of left eyelid (D), high arched palate (F).  
1.8.2.6 Amniotic band syndrome. 
This girl was 7.06-year-old and the only child of unrelated, healthy parents. Pregnancy and delivery 
were normal. At birth, limb reduction defects were observed for which a surgical intervention occurred 
at age 2. Details of this intervention are not available. Later, learning difficulties were noticed. Her OFC 
was 50 cm (-1.08 SD), weight 19 kg  (-1.31 SD) and height 111 cm (-2.06 SD). We noted mild facial 
asymmetry with ptosis of the left eye and a high frontal hairline. On the hands, there were terminal 
reduction defects and partial syndactyly of the fingers. On the 5th finger on the left hand we noted a 
constriction ring. On the right foot, there was a severe reduction defect of the toes with syndactyly of 
the remaining parts of all toes. Neurological examination was normal (Figure 11). These features are 
consistent with amniotic band sequence (Moerman, Fryns et al. 1992). Intellectual disability has 
occasionally been observed in this condition. However, we were not able to perform brain imaging to 
exclude an underlying brain anomaly, as was described (Ruggieri, Spalice et al. 2007). 
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Figure 11. Clinical features of the patient with amniotic band syndrome. High frontal hairline (A and C), 
facial asymmetry with ptosis of the left eye (B), reduction defects of the toes and syndactyly (D), 
terminal reduction of the fingers, partial syndactyly and constriction crease (indicated with arrow) (E).  
1.8.2.7 Acquired causes of ID. 
In 8 patients, a tentative diagnosis of an acquired cause of their ID was made, based on a combination 
of findings, i.e. a clear history of an exceptionally severe central nervous system insult (meningitis, 
coma, severe birth injury), and at least two out of three of the following features: otherwise 
unexplained macrocephaly or microcephaly, epilepsy or severe neurological signs (spasticity, 
hypotonia or dystonia). In none of them, brain imaging could be performed. 
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1.8.3 Genome-wide screening with microarray-CGH  
In 105 patients chromosomal microarray-CGH was performed, including 2 patients without a clinical 
diagnosis, the Noonan syndrome patient and the patient with OAVS. Also the patients with a suspected 
acquired cause were included, given the possibility of an underlying genetic cause (see chapter 4.3 for 
an illustration of this in the case with Williams syndrome). For economic reasons, we applied a protocol 
that permits the use of stripped slides. We re-used CytoSure™ ISCA v2 array 8x60k format (OGT, Oxford 
UK) slides, used once before.  
1.8.3.1 Validation aCGH using CytoSure™ ISCA v2 array 8x60k stripped slides.  
First, we compared the QCMetric in our experiment to those recorded when 3 slides were used for the 
first time and calculated the Paired Wilcoxon Ranked Sum Test P-Value. Recorded values for all 
QCmetrics were within normal ranges. There was no significant difference between the first and the 
second hybridization for DLRSpread (p= 0.1232), Signal Intensity (Red signal p= 0.9102 and Green signal 
p = 0.9102) and Non-Uniform Features (p = 0.1755) whereas the difference was significant for 
Background Noise (Red signal p = 0.003906 and Green signal p = 0.05469), Signal to Noise Ratio (Red 
signal p = 0.003906 and Green signal p = 0.05469) and Signal Reproducibility (Red signal p = 0.003906 
and Green signal p = 0.05469). We concluded that the stripping process increased background but still 
within acceptable limits after one stripping cycle. Therefore we considered that our protocol for 
stripping the slides passed the quality criteria. 
Next, we investigated the ability for stripped slides to detect known aberrations in tested patients. Our 
stripped slides did not miss any of the known aberrations greater than or equal to 400 kb (sensitivity 
100 % at 400 kb). For CNVs with known clinical significance, the sensitivity was 100 % at 300 kb size. 
We concluded that stripped slides could reliably detect aberration greater than or equal to 400 kb.  
1.8.3.2 Overview and discussion of microarray-CGH results in the patient cohort.  
In 19 cases, the DNA samples did not pass the quality criteria. For these samples, the initial preparation 
of the mononuclear cells was done in Kinshasa, after which the cell pellets were transported to Leuven 
for further DNA preparation.  
We considered CNV’s to be causal when (a) they contain the critical region of known disease-related 
CNV’s, or (b) when they comprise a dosage-sensitive gene known to cause ID when mutated (Breckpot, 
Thienpont et al. 2010). Thus, 10 CNV’s were considered to be causal of the ID in 86 patients (11.6 %). 
All causal variants were confirmed using an independent technique, qPCR (in 9/10) or SNP-array (in 1 
patient with a mosaic deletion). 
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      Table 3. Causal CNVs identified in 10 patients 
Num Patient ISCA nomenclature Type Size (bp) Validation  
(tested gene) 
inheritance 
1 DRC-0033 arr 2p16.1(59,886,015-61,213,851)x1 Del 1,327,837  qPCR [BCL11A] Mother normal, father NA 
2 437575 arr [hg19] 2q24.3(165,828,304-166,616,001)x1 Del 787,698 qPCR [SCN3A] Parents NA 
3 DRC-0018 arr [hg19] 8p23.3-p23.1(61,749-11,985,357)x1 Del 11,923,609 qPCR [GATA4] Mother normal, father NA 
4 DRC-0136 arr [hg19] 13q14.2-q32.1(49,189,356-97,091,014)x1 Mos Del 47,901,659 SNP Array Parents NA 
5 DRC-0114 arr [hg19] 15q24.1-q24.2(72,963,962-75,535,357)x1 Del 2,571,396 qPCR [PCSK2] Absent in both parents  
6 437633 arr [hg19] 17p11.2(16,782,547-20,294,010)x1 Del 3,511,464  qPCR [RAI1] Parents NA 
7 437582 arr [hg19] 20q11.22-q11.23(33,186,305-34,775,792)x1 Del 1,589,488  qPCR [GDF5] Parents NA 
8 DRC-0040 arr [hg19] 20p13-q11.22(60,734-33,254,059)x3 Dup 33,193,326 qPCR [PCSK2] Father normal, mother NA 
9 416840 arr [hg19] 22q13.31q13.33(44,985,665-51,220,923)x1 Del 6,235,259 qPCR [SHANK3] Parents NA 
10 447761_4 arr [hg19] 15q11.2(22,698,520-23,217,513)x1 Del 518,994 qPCR [CYFIP1] Paternal 
      NA: Not Available 
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1.8.3.3 Clinical and genetic description of the causal chromosomal imbalances  
In the following sections, we describe patients with submicroscopic aberrations and provide a short 
discussion based on the literature.  
Deletion chromosome 2p16.1 
Patient DRC-0033 was a 14.89 years-old girl from unrelated, healthy parents. Pregnancy and delivery 
were uneventful. Her development was characterized by hypotonia, feeding difficulties and motor 
delay. She had seizures until the age of 3. Learning difficulties became apparent and she functions at 
a level of severe ID. On clinical examination the OFC was 51.5 cm (-1.73 SD), weight 45.9 kg (-0.73 SD) 
and height 154 cm (-1.2 SD). We noticed a narrow forehead, upslant of the eyes, ptosis, protruding lips 
and small mouth and chin, a remnant of post axial polydactyly (right hand), a left single palmar crease, 
pes planus and short toes (figure 12). FMR1 testing showed 31/31 CGG repeats and XCI a 72.97 % 
pattern. She carried a 1,327,837 bp deletion on chromosome 2p16.1, arr [hg19] 2p16.1(59,886,015-
61,213,851)x1. This deletion was not detected in the mother and the father was not available. This 
region contains the refseq genes BCL11A, PAPOLG, REL and 3’ end of RUS10.   
Several microdeletions in this region have been described associated with ID (Balci, Sawyer et al. 2015). 
The critical region for ID encompasses BCL11A and this was confirmed by the finding of a small deletion 
limited to BCL11A in a boy with ID (Peter et al., 2014). The deletion in the present case closely matches 
those reported by Hancarova et al. (2013) and case 1 of Piccione et al. (2012) (Piccione, Piro et al. 2012; 
Hancarova, Simandlova et al. 2013). They share severe ID and all three have a (relative) microcephaly 
and absence of major malformations. There is no obvious common facial dysmorphism. The child with 
only a deletion of the BCL11A gene had only mild ID and no microcephaly, suggesting that other genes 
in the deleted region contribute to these phenotypes.   
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Figure 12. Clinical features of the patient with cryptic 2p16.1 deletion. Note: narrow forehead, upslant 
of the palpebral fissures, ptosis (A), protruding lips and small mouth and chin (A-B), a remnant of post 
axial polydactyly on right hand (D), a left single palmar crease(D), short toes (E). 
Deletion chromosome 2q24.3 
Patient 437575 was a 10.40 years old boy, the eldest of two sons, and born to unrelated healthy 
parents. There was no record of pregnancy or birth complications, ID in the family or seizures in the 
patient. He had speech and learning disability. He was not assessed for IQ. He presents hand biting. On 
clinical examination, head circumference (54 cm, 0.36 SD), weight (41 kg, 1.01 SD) and height (143 cm, 
0.38 SD) were normal. He had a truncal obesity, mildly hypoplastic thumbs, clinodactyly of the 5th toes 
and short toenails (figure 13). Conventional karyotyping was normal and FMR1 assay detected 27 CGG 
repeats. Microarray-CGH detected a 787,698 bp deletion, arr [hg19] 2q24.3(165,828,304-
166,616,001)x1, encompassing 3 RefSeq genes (SCN3A, SCN2A, CSRNP3) and few exons of GALNT3. 
The parents were not available for analysis. Other patients have been reported with ID who carried a 
deletion of SCN2A and SCN3A (Chen, Lin et al. 2010; Bartnik, Chun-Hui Tsai et al. 2011; Celle, Cuoco et 
al. 2013). This was variably associated with autism and seizures. Therefore, this deletion explains the 
phenotype of the patient.  
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Figure 13. Phenotype in patient with del2q24.3. Note truncal obesity (A), normal facial appearance (B) 
mildly hypoplastic thumbs (C), clinodactyly of the 5th toes and short toenails (D). 
Deletion chromosome 8p23.3-p23.1 
DRC-0018 was an 8.31 years-old girl and only child. Medical history of the father was not available. The 
mother had hearing problems. Pregnancy was uncomplicated but at birth she presented with neonatal 
distress and was treated in a neonatal intensive care unit. At age 2 months, a congenital heart defect, 
not otherwise described, was diagnosed, but follow-up was discontinued after age 4 years. She started 
crawling at 12 months and walking at 2 years after physical therapy. Later, she exhibited difficulties for 
grasping things such as a pen. Her speech was delayed and a hearing problem was notice by the family 
but she did not receive appropriate medical assessment. A psychiatrist followed her for behavioural 
problems. She functions at a level of mild ID. Her OFC was 50 cm (-1.42 SD) relatively small compared 
to her weight (29.5 kg, 0.55 SD) and height (131 cm, 0.27 SD). We observed mild strabismus, prominent 
nasolabial folds, flat philtrum, thin upper lip vermillion with absent cupid’s bow, mild retrognathia and 
long fingers and toes (figure 14). Genetic assessment was normal for FMR1 (31/32 repeats) but a highly 
skewed XCI  profile was observed (8.97 %). Microarray-CHG revealed an 11.92 Mb deletion on the short 
arm of chromosome 8, arr [hg19] 8p23.3-p23.1(61.749-11.985.357)x1. The deletion was not present 
in the mother, the father was not available.  The phenotype of deletions in the short arm of 
chromosome 8p, encompassing 8p23.1 has been extensively reported before (Claeys, Holvoet et al. 
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1997; Devriendt, Matthijs et al. 1999; Ballarati, Cereda et al. 2011). The phenotype in the present 
patient is consistent with this, including ID, behavioural difficulties, a relative microcephaly and a 
congenital heart defect, related to haploinsufficiency of the transcription factor GATA4.  
 
Figure 14. Phenotype in patient with a del8p23.3-p23.1. Note mild strabismus (A), prominent 
nasolabial folds (A), flat philtrum (A&B), thin upper lip vermillion with absent cupid’s bow (A&B),  mild 
retrognathia (B) and long fingers and toes (C&D). 
Mosaic deletion chromosome 13q14.2-q32.1 
Patient DRC-0136 was 14.66 years-old when she was examined. She was born to healthy unrelated 
parents following an uncomplicated pregnancy and delivery. She had delayed development and her IQ 
was estimated at 63 (Bonhomme test). On clinical examination we noted a relative macrocephaly with 
OFC 56.6 cm (1.92 SD) for weight 40 kg (-1.58 SD) and a short stature with height 138 cm (-3.63 SD). 
There was a mild lower limb asymmetry. She had coarse facial features with a prominent forehead, 
depressed glabella, hypertelorism, strabismus, broad nose, flat philtrum, bilateral preauricular pits, 
short thumbs, deep palmar creases, dry palmar skin, bilateral clino-and brachydactyly of 5th fingers, 
swan neck deformity of fingers, swollen feet, a haemangioma on the anterior right upper leg and on 
the posterior left lower leg (figure 15). FMR1 analysis was normal and she had a moderately skewed 
XCI (16.85 %). Microarray-CGH revealed a 47.9 Mb mosaic deletion, arr [hg19] 13q14.2-
q32.1(49,189,356-97,091,014)x1. This was confirmed using a SNP array with Illumina v2.1 which 
revealed the deletion in about 53 % of cells (figure 16). We did not find another case with the same 
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mosaic deletion in the literature. However, several patients are known with constitutive deletions in 
this region, but none of the same size as in the present patient. Nevertheless, the large size of the 
deletion and presence in over 50 % of white blood cells is a strong argument in favor of causality. 
 
Figure 15. Phenotype in patient with mosaic del13q14.2-q32.1. Relative macrocephaly and asymmetric 
lower limbs (A), coarse face, strabismus, hypertelorism, broad nose (B), prominent forehead (C), 
preauricular pits (C-D) and peculiar shape of the ears (D), hypoplastic thumbs, brachydactyly of the 5th 
fingers and swan neck deformity of fingers (E-F), dry palm skin (F), swollen feet with short toes, limb 
hemangioma (H).  
 
Figure 16. Views of the mosaic deletion with 8x60K ISCA Array (A) and Illumina v2.1 (B). The B-Allele 
Frequency is about 0.76. 
42 
 
Deletion chromosome 15q24.1-q24.2. 
DRC-0114 was a 10.6 years boy, born to unrelated healthy parents. History of pregnancy and delivery 
were uneventful. He presented with speech regression from age 2 and psychological evaluation 
revealed moderate ID with autistic behaviour. On our clinical examination, OFC was 52.9 cm (-0.44 SD), 
weight 26 kg (-1.73 SD) and height 146 cm (0.65 SD). He had prominent nasolabial folds, a pointed 
small chin, small and protruding ears, multiple skin creases on the neck, long and slender fingers, 
brachydactyly of toes 4-5, a high sandal gap and phalangeal joint hyperlaxity (figure 17). FMR1 analysis 
was normal and maternal XCI profile was 44.99 %. Microarray-CGH identified a 2.57 Mb deletion arr 
[hg19] 15q24.1-q24.2(72,963,962-75,535,357)x1, de novo. This deletion corresponds to the recurrent 
15q14 deletion syndrome, with breakpoints in LCR A and C (Mefford, Shur et al. 1993; Mefford, 
Rosenfeld et al. 2012). This is a known cause of ID, variably associated with major malformations and 
multiple minor anomalies. The reported facial features in other cases are not sufficiently distinct to 
allow a meaningful comparison with the present patient.  
 
Figure 17. Phenotype in patient with Del15q24.1-q24.2. Prominent nasolabial folds, pointed chin, small 
and protruding ears (A), multiple skin creases on the neck (B), long and slender fingers (C), 
brachydactyly of toes 4-5, high sandal gap and phalangeal joint hyperlaxity (D). 
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Deletion of chromosome 17p11.2 (Smith-Magenis syndrome).  
Patient 437633 was a 5.14 years old boy. He was the oldest of three sons born to unrelated parents. 
Pregnancy and birth were normal. He developed mood and behaviour problems characterized with 
self-injuries. His speech was limited, and he functions at a level of severe ID. On clinical examination, 
OFC was 50.2 cm (-0.78 SD), weight 17 kg (-0.74 SD) and height 104 cm (-1.19 SD). The face was 
triangular and hypotonic. There was a short bulbous nose with tented upper lip, upslant of the 
palpebral fissures, a short philtrum, and ears were dysplastic. He had scars from self-injuries on the 
front and on both hands (figure 18). Conventional karyotype and FMR1 analysis were normal. 
Microarray-CGH identified the recurrent 3.5 Mb Smith-Magenis deletion, arr 
[hg19]17p11.2(16,782,547-20,294,010)x1. The clinical phenotype of the present patient are in 
agreement with those observed in this well-known microdeletion syndrome.  
 
Figure 18. Phenotype in patient with Smith-Magenis syndrome. (A): the facial hypotonia, short, 
bulbous nose, tented upper lip with short philtrum and upslant of the palpebral fissures; (B&C) short 
toes; (D&E) Scars on the hands due to self-injury (hand biting).  
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Deletion chromosome 20q11.22q11.23 
Patient 437582, a 15.62 years-old boy was the oldest of 6 children from unrelated healthy parents. His 
development was characterized by pervasive behaviour and learning problems. He has an IQ of 51 
(Bonhomme). Clinical examination revealed an OFC of 56.2 cm (0.49 SD), weight 46 kg (-1.56 SD) and 
height 152 cm (-2.48). He had hypertrichosis, a square chin, hypertelorism with downslant of the eyes, 
camptodactyly of the 5th fingers, brachydactyly of toes 4-5 and metatarsus adductus (figure 19). 
Karyotype and FMR1 testing were normal. Microarray-CGH showed a 1.58 Mb deletion on 
chromosome 20q11.22q11.23: arr [hg19] 20q11.22-q11.23(33,186,305-34,775,792)x1. 
Deletions in this region have been reported before. The deletion encompasses GDF5, and 
haploinsufficiency is known to cause brachydactyly type C.  
 
Figure 19. Panel A shows the deleted region and genes, including GDF5. Panel B displays the phenotype 
in the patient with del20q11.22q11.23. (B1) Hypertelorism, dowsnlant of eyes and square chin; (B2) 
brachydactyly of toes 4-5 and metatarsus adductus); (B3) camptodactyly of the 5th fingers. 
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Duplication 20p13-q11.22 
DRC-0040, a 17.7 years-old boy is the youngest of 7 children, born to unrelated, normal parents. After 
a normal pregnancy, he presented with neonatal distress at birth. The development was delayed, and 
he presented speech regression at the age of 2 years. He has severe ID and autistic behaviour. On 
clinical examination, OFC was 57 cm (0.53 SD), weight 54 kg (-1.44 SD) and height 184 cm (1.13 SD). 
There was marked facial dysmorphism with a low set anterior and posterior hairline, thick and arched 
eyebrows, ptosis, a broad nose with broad nasal ridge, flat nasal tip, broad and everted nostril, short 
philtrum, thick and everted vermilion of the lips. There was camptodactyly and calluses on the 5th 
fingers and foetal fingertip pads (figure 20). FMR1 testing was normal. Microarray-CGH detected a 
33.19 Mb interstitial duplication of chromosome 20p13q11.22: arr [hg19]20p13-q11.22(60,734-
33,254,059)x3. Our patient presented features such as microcephaly, macrostomia, large ears similar 
to mosaic trisomy 20 patients 1 and 2 reported by Willis et al., 2008 (Willis, Bird et al. 2008).  
 
Figure 20. Phenotype in patient with dup20p13-q11.22. (A) low anterior hairline, thick and arched 
eyebrows, ptosis, broad nose with broad nasal ridge, flat nasal tip and broad and everted nostrils, short 
philtrum, thick and everted lip vermilion, (B) low set posterior hairline, (C&E) camptodactyly and callus 
on 5th finger, (D) foetal pads. 
46 
 
Deletion 22q13.31q13.33 
Patient 416840, aged 5.14 years, was the oldest boy of 3 children born to unrelated healthy parents. 
Family history was negative for ID. His development was delayed with regard to speech and motor 
milestones. He exhibit drooling, autistic behaviour and severe ID. On clinical examination, we noticed 
a relatively small head with OFC of 49 cm (-1.63 SD) with weight 20 kg (0.51) and height 118 cm (1.79 
SD). He had a global hypotonia. He had dysmorphic features with arched eyebrows, long palpebral 
fissures, a short and bulbous nose, tented upper lip, and large ears. The fingers and toes were long and 
slender (figure 21). Karyotype and FMR1 analysis was normal. Microarray-CGH showed a 6.23 Mb 
deletion on terminal chromosome 22, arr [hg19] 22q13.31q13.33(44,985,665-51,220,923)x1. The 
terminal 22q deletion is a well-known entity. The presentation in our patient matches the phenotype 
of the syndrome which encompasses neonatal hypotonia, global developmental delay, normal to 
accelerated growth, absent to severely delayed speech and minor dysmorphic features a principal 
manifestations (Phelan, Rogers et al. 2001; Havens, Visootsak et al. 2004; Manning, Cassidy et al. 2004; 
Phelan 2008; Sarasua, Dwivedi et al. 2011; Phelan and McDermid 2012). SHANK3, one of the genes 
deleted in our patient, is thought to be the critical gene implicated in the neurodevelopmental 
phenotype (Wilson, Wong et al. 2003).  
   
Figure 21. Phenotype in patient with a terminal 22q deletion. Note the global hypotonic habitus (A-B), 
long hands and feet (A), arched eyebrows, long palpebral fissures, short and bulbous nose, tented 
upper lip (B), large peculiar ears (C).  
  
47 
 
Deletion 15q11.2 
Patient, 447761, was 17.65 years old, the third of 7 children born to unrelated healthy parents. 
Pregnancy and delivery were normal and there was no record of ID in the family. His development was 
reportedly normal until the age 13. Then parent noticed school problems, pervasive behaviour and 
increased mood instability. At the time of examination, he received treatment with multiple drugs 
including Haloperidol, Valproic acid, Clomipramine, Trihexyphenidyl and Promazine. On examination 
he was macrocephalic, with OFC 62 cm (3.8 SD) weight was 75.3 kg (0.72 SD) and height 182.5 cm (0.92 
SD). Apart from thick eyebrows and a sandal gap, his appearance was normal (figure 22). FMR1 analysis 
was normal. Microarray-CGH revealed the presence of a 518.99 kb deletion on chromosome 15q11.2, 
arr [hg19] 15q11.2(22,698,520-23,217,513)x1. This corresponds to the recurrence BP1-BP2 deletion, 
including the gene CYFIP1. This microdeletion is a known risk factor for developmental disorders, 
including ID, autism spectrum disorders, schizophrenia and epilepsy (De Wolf, Brison et al. 2013). The 
deletion was also present in his father. This is in line with the observation that the vast majority of 
del15q11.2 are inherited, mostly from a normal parent. For this reason, and because of a high 
incidence in the normal population, this deletion is considered to be a susceptibility locus for ID, with 
an estimated penetrance of 10 %.  
 
Figure 22. Phenotype in patient with the del15q11.2. Macrocephaly. Thick and straight eyebrows (A), 
normal hands (B) and sandal gap (C). 
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1.8.4 Fragile-X syndrome. 
In the 105 patients tested with microarray-CGH, 25 girls and 80 boys, the size of the FMR1 CGG repeat 
was determined. Among the 130 alleles, not a single premutation or full mutation was detected (figure 
23). Allele sizes ranged from 18 to 48 and the mean was 28.55 ± 2.84. Two patients presented with 
intermediate size alleles (47 and 48 repeats). Please refer to chapter 4 for a more detailed discussion 
of the FMR1 analysis.  
 
Figure 23. Distribution of CGG repeat alleles 
1.8.5 X-chromosome inactivation analysis to identify X-linked ID. 
From our cohort of individuals with ID we investigated X chromosome inactivation (XCI) profile in all 
27 females indexes, as well as 41 mothers of male indexes from whom DNA was available. Of 41 
mothers of boys with ID tested, 3 (7.32 %, CI: 1.89 - 18.63) had a highly skewed XCI (i.e. ≥90%) (figure 
24). Three mothers (7.32 %) had moderate skewed XCI (i.e. 80%≤XCI<90%), 8 (19.51 %) had mild 
skewed XCI (70%≤XCI<80%) whereas 27 (65.85 %) showed random X-inactivation (i.e. <70). Among the 
27 female indexes with ID, we detected 3 (11.11 %) with a highly skewed X-inactivation. Five (18.52 %) 
had moderate and mild skewing, respectively; and 14 (51.85 %) had random X-inactivation.  
The proportion of mothers with highly skewed XCI is not significantly different from the normal 
population of adult females, where highly skewed X-inactivation was observed in 3.6 % (22 out of 415 
females) (Amos-Landgraf, Cottle et al. 2006). This is probably due to the small size of our sample. 
However, when we consider both mothers and girls, 6 cases of highly skewed XCI were detected out 
of 68 individuals tested (8.82 %, CI: 3.65 - 17.45). Our prevalence is statistically higher compared to 1.8 
% general proportion reported by Amos-Landgraf (Amos-Landgraf, Cottle et al. 2006). Both the small 
size of the population and the selective character of the sample may explain the apparent enrichment 
of skewed XCI in this cohort. 
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Figure 24. Distribution of X-inactivation patterns among girls with ID and mothers of boys with ID. 
Case descriptions 
We identified 3 boys with highly skewed X-inactivation in their mother (n = 3) and 3 females with ID 
and highly skewed X-inactivation. The clinical data are described below.  
Case 1.  
This boy was clinically examined at age 6.97 years. He is the only child of healthy, unrelated parents, 
and born after a normal pregnancy and delivery. Family history was negative with regard to ID. He 
presented with autistic behaviour and severe ID. On clinical examination his OFC was 51.7 cm (-0.06 
SD), height 120 cm (-0.29 SD) and weight 19 kg (-1.46 SD). He was mildly dysmorphic, with 
underdeveloped ear lobes, long fingers and bilateral extra palmar skin creases on fingers 2-4.  
Neurological examination was normal. Microarray-CGH was normal. His mother had a highly skewed 
XCI pattern (91.76 %). Exome sequencing was performed.  
Case 2.  
This boy, aged 6.78 years, was the 5th child of healthy, unrelated parents. He has five healthy sisters. 
Family history was negative regarding ID. Pregnancy and delivery were normal. He presented delayed 
speech with first words pronounced at age 4 years. From the age of 2 years he had seizures, under 
control with medication. He was shy and friendly but had episodes of self-biting and uncontrolled 
appetite. He was reported to be difficult to assess for IQ. On clinical examination we noted 
microcephaly (head circumference 49 cm, -2.11 SD), normal height (110 cm, -1.89 SD) and weight (19.9 
kg, -0.86 SD). He had a long face, high forehead, ptosis, downslant of the eyes, large ears, small and 
bulbous nose, everted lower lip, bilateral clinodactyly of the fifth fingers and toes, as well as scars 
resulting from hand biting. Microarray-CGH was normal.  The mother had an XCI pattern of 92.75 %. 
Exome sequencing was performed.  
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 Case 3. 
This 6.51-year-old boy was born after an uneventful pregnancy and birth as the second of 3 children. 
His parents were healthy and unrelated, and family history was negative regarding ID. He had a normal 
motor development. Since the age of 3 years he presented seizures and under control with Sodium 
Valproate, Lamictal and Clonazepam. Language development was delayed, and when examined at the 
age of 6.51 years, he was unable to make sentences. He had learning difficulties with an estimated IQ 
of 57 (Borel-Maisonny test). He was hyperactive with attention deficit and presented gaze avoidance. 
He was diagnosed with autism based on the F84.0 [299.00] instrument from DSM IV. On clinical 
examination head circumference was 51 cm (-0.63 SD), height (114 cm, -0.83 SD) and weight (30.1 kg, 
+1.90 SD). His body mass index was 23.2 (+2.58 SD). He had a high frontal hairline, low set ears and a 
depressed nasal tip. His mother presented skewed X-inactivation (91 %). We did not have sufficient 
good quality DNA to proceed with exome sequencing. 
 
Figure 25. Clinical feature in patients DRC-0042 (case 1, Figure 25-A), DRC-0108 (case 2, Figure 25-B) 
and DRC- DRC-0118 5 (Case 3, Figure 25-C).  
Case 4.  
This girl with highly skewed XCI (5.18 %) was born from a mother with ID. Pregnancy and delivery were 
normal. She presented delayed speech development and seizures from the age of 2. She has a friendly 
behaviour. Intelligence was not assessed. On clinical examination at age 11.65, we noted severe 
microcephaly (OFC 48.5 cm -3.29 SD), weight 30 kg (-1.61 SD) and height 150 cm (0.18 SD). She had 
long fingers with extra skin creases on fingers 2-4, bilaterally. Microarray-CGH was normal. Her mother 
had moderate ID with speech problems but normal biometry, head circumference of 56cm (0.96 SD), 
height 159.5 cm (-0.59 SD) and weight 51 kg. She had long fingers, but clinical examination was 
otherwise unremarkable. X-inactivation patterns in her mother was not assessed. Exome sequencing 
was done in the index. 
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Figure 26. A=Clinical presentation in patients DRC-0032 (case 4), B=DRC-0154 (case 5) and C=DRC-0018 
(case 6). Detailed dysmorphic description is made above. 
Case 5.  
This girl was born from a mother who also had ID. Pregnancy was uneventful and delivery was normal. 
She walked at age 12 months, first words came at age 4-5 years. When she started school, learning 
difficulties were apparent and her IQ was estimated at 53. She had attention deficit and limited social 
interactions. Clinical examination at age 11.68 revealed a global growth delay: microcephaly (OFC 50 
cm, -2.21 SD), weight 22 kg (-3.76 SD) and height 129 cm (-3.39 SD). She had long fingers and toes with 
shortening of the 5th toes. She had a small chin. Microarray-CGH was normal. She has a skewed XCI 
(94.49 %). No sufficient good quality DNA was available for exome sequencing.  
Case 6.  
This girl carries a deletion 8p23.3-p23.1, and was already described above (DRC-0018).  
1.8.6 Whole Exome Sequencing  
We selected three cases (two boys and the girl without a causal CNV) from whom sufficient and good 
quality DNA was available, to perform whole exome sequencing (case 1, case 2 and case 4 described 
above).   
In table 4, we show, for each of the three patients, the Sanger validated candidate variants that were 
retained after filtering, as outlined in the materials and methods section.  
In Patient DRC-0042 (case 1) we did not identify any pathogenic X-linked variant. He was compound 
heterozygous for 2 variants in the AMINOACYLASE 1, ACY1 gene (MIM 104620). Each of his parent was 
carrier of one of the 2 variants. Mutations in ACY1 are responsible for Aminoacylase 1 deficiency 
(609924) an autosomal recessive metabolic disease characterized by ID, seizures, hypotonia, motor 
delay and, in one family, sensorineural hearing loss (Van Coster, Gerlo et al. 2005; Ferri, Funghini et al. 
2014). Interestingly, one of the 2 mutations (p.R386C) was previously reported and proven to down-
regulate the activity of the Aminoacylase-1 (Sommer, Christensen et al. 2011). Confirmation of this 
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disorder can be done by metabolic testing on urine. However, this is not available locally for the 
moment. 
Patient DRC-0108 (case 2) carried 2 variants in the SZT2 gene (MIM 615463), inherited from both 
parents. Mutations in this gene cause autosomal recessive epileptic encephalopathy, early infantile 
(MIM 615476), characterized by early-onset refractory epilepsy, with absent developmental 
milestones. Our patient has a history of early-onset seizures, which are now under control. The facial 
features are similar to those reported before, including downslant of the palpebral fissures, high 
forehead and ptosis (Basel-Vanagaite, Hershkovitz et al. 2013). Falcone et al., reported three brothers 
homozygous for a loss-of-function mutation in this gene, with a milder phenotype of non-syndromic 
mild to moderate ID, but without seizures, indicating large variability in expression of this condition. In 
our case, two missense variants were detected. The prediction tools do not support a pathogenic 
effect. Thus, it is not certain whether the found variants explain the phenotype in this patient.  
In addition, we identified in case 2 a missense mutation in the X-linked gene 
TAF1:NM_004606:exon28:c.A4442G:p.N1481S, inherited from the mother. In a large screen of 405 
families with XLID, 2 families were found to carry a mutation in this gene (Hu, Haas et al. 2015). 
However, no details about the phenotype were given. Because of its interactions with autism and ID 
genes such as CHD8 and MLL1, it appears a good candidate for XLID. However, better genotype-
phenotype correlations are needed as well as functional studies of the found mutations before one 
can draw definite conclusions. Reduced expression of this gene has been found in X-linked Dystonia-
Parkinsonism (MIM 314250).  
  
53 
 
Table 4. Report of WES in the 3 patients from XCI study 
Patients Phenotype Mode of inheritance Gene Type NCBI 
RefSeq. 
Exon base 
change 
AA change Prediction*  Phenotypic 
concordance 
Previously  reported 
mutation 
Segregation Conclusion 
Boy,  
Case 1 
DRC-0042 
 
 
 
 
 
 
 
autistic 
behaviour and 
severe ID, with 
underdevelope
d ear lobes, 
long fingers and 
bilateral extra 
palmar skin 
creases on 
fingers 2-4 
X-Linked None 
       
    
 
Autosomal 
Dominant 
COL4A2 Missense NM_001
846 
42 c.C3920G p.P1307R 3 Possible rs201627758  Maternally 
inherited 
Excluded: inherited 
from normal mother 
Aut. Recessive 
Homozygous 
None 
       
    
 
Aut. Recessive 
Compound  
Heterozygous 
ACY1 Missense NM_000
666 
2 c.C49T p.R17C 3 Yes None Not Maternal  Good candidate 
ACY1 Missense NM_000
666 
15 c.C1156T p.R386C 3 Yes Reported as pathogenic: 
mutation PMID: 21414403  
Maternally 
inherited 
Good candidate 
Case 2 Boy,  
DRC-0108 
 
 
 
 
 
 
 
Severe ID, 
seizures, facial 
dysmorphism 
(high forehead 
& ptosis 
  
  
  
  
X-Linked TAF1 Missense NM_004
606 
28 c.A4442G p.N1481S 3 Yes – ID 
PMID: 
25644381:  
Not reported Maternally 
inherited 
Good candidate 
A. dominant GRIN2B Missense NM_000
834 
13 c.G3389A p.R1130Q 2 Possible 
Autism gene 
rs148625092 Maternally 
inherited 
Excluded: 
inherited from 
normal mother 
 A. Recessive 
Homozygous 
None 
       
    
 
A. Recessive 
Compound 
Heterozygous 
SZT2 Missense NM_015
284 
27 c.T3880C p.W1294R 0 Yes.  infantile 
epilepsy, 
similar facial 
features 
Yes 
rs72883814 Maternally 
inherited 
Good candidate 
SZT2 Missense NM_015
284 
53 c.G7402A p.V2468I 0 rs139486476 Paternally 
inherited 
Good candidate 
Girl, Case 4 
DRC-0032 
Microcephaly, 
long fingers, 
bilateral extra 
skinfolds of 
fingers 2-4 
bilaterally 
X-Linked AMER1 Missense NM_152
424 
2 c.G1721A p.R574Q 0 Yes ClinVar: RCV000119998.1 inherited 
form affected 
mother 
Excluded: No 
concordance 
 
Autosomal 
Dominant 
TUBB2B Missense NM_178
012 
4 c.G553A p.A185T 2 Yes SNV present in a normal 
male and female control 
ClinVar: RCV000147838.1 
absent in 
mother 
Excluded: present in 
a normal controls 
 *Number of tools predicting the mutation as pathogenic or disease causing among the following: Mutation Taster, Polyphen2 and SIFT. 
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Patient DRC-0032 (Case 4), has highly skewed XCI and had a mother with ID. We filtered the exome 
data for X-linked and autosomal dominant inheritance. We identified a missense mutation in the 
AMER1 gene, inherited from her mother. This gene causes osteopathia striata with cranial sclerosis 
(MIM 300373) characterized by macrocephaly, cleft palate, mild learning disabilities, sclerosis of the 
long bones and skull. This phenotype did not match with our patient nor her mother. She carried a 
variant in the TUBB2B gene, which was previously reported in Clinvar as RCV000147838.1. This variant 
was not inherited from the mother, and we also found this in a normal control. Therefore, we believe 
this is not a pathogenic mutation. 
In addition to the 3 patients from XCI assessment, two affected sisters also underwent WES. We 
hypothesized the presence of an autosomal recessive inheritance. They were born to unrelated 
parents. Pregnancies and births were uneventful. There was no family history of ID or psychiatric 
problems.  
The index was 20.1 years. She had a delayed development: she sat alone at age 12 months and walked 
after 2 years of age. Speech consisted of unintelligible sounds only. She had fine motor difficulties, and 
was not able to dress or undress herself. At the age of 2 years she had episodes of seizures, under 
control with antiepileptic medication. She had aggressive behaviour with multiple lesions from self-
injury. She had a normal biometry (OFC: 55 cm, 0.26 SD; height 165 cm, weight: 60 kg). We note a 
diplegic gait, coarse facial features, hypertelorism, ptosis, strabismus, a pointed chin, rigidity of the 
limbs and scars on the hands from hand biting. 
 
Figure 27. Phenotype in sisters with ID and psychiatric behaviour. Index in A, B and C; her sister in D, E 
and F. Coarse face (A, B, D&E), hypertelorism (B&E), ptosis (B&E), strabismus (B&E), pointed chin (B&E), 
diplegic upper limbs (A&D), scars from self injury (B, C, E & F). 
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Her sister was 25.11 years. She had a history of neonatal distress. Likewise, she had a delayed motor 
development, impaired fine motor skills and unintelligible speech. Behaviour is as impaired as in the 
index. She did not present seizures. She is under psychiatric care for behavioural problems. Her 
biometry was normal (OFC: 57 cm, 1.64 SD; height: 160 cm and weight: 83.4 kg). Similar to her sister, 
she had a diplegic gait, coarse face, ptosis, strabismus, an everted lower lip, pointed chin, rigidity of 
the limbs and scars resulting from hand biting. 
FMR1 testing and microarray-CGH were normal. XCI was not informative. Both of them underwent 
WES. We did not identify a causal mutation after filtering for autosomal recessive or dominant 
inheritance. We identified 2 compound heterozygous mutations in the LINS gene (implicated in 
autosomal recessive Mental Retardation 27): NM_001040616:exon6:c.G1373A:p.G458D and 
NM_001040616:exon5:c.A1000G:p.M334V. However, Sanger validation shows that both were 
inherited from the normal mother, thus excluding a causal role for this gene.  
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1.9 Discussion 
We report the results of an etiological diagnostic study in 127 individuals with ID, recruited in Kinshasa, 
capital of DR Congo in Central Africa. Figure 28 (flow chart) gives an overview of the different steps in 
the study and results, according to different diagnostic categories. The results for individual patients 
were already discussed in the results section, and here, we discuss the general aspects of our results.  
 
Figure 28. Overview of screening results. Detailed steps taken and number of cases at each step. 
We used different strategies to identify the aetiology for the ID in this study. Clinically, we established 
a diagnosis in 24 out of the 127 patients (19 %). There were two disorders without a known genetic 
cause, amniotic band syndrome and oculo-auriculo-vertebral syndrome. Of the 22 cases clinically 
diagnosed, 21 (95 %) were confirmed by targeted genetic testing.  In the child with clinically convincing 
Noonan syndrome, no mutation was detected in the panel of genes currently associated with this 
condition. To date, in approximately 15 % of Noonan syndrome cases, no genetic cause is identified 
(http://www.ncbi.nlm.nih.gov/books/NBK1124/).   
In 8 patients, we suspected a probable acquired cause based on the birth history of trauma or severe 
neonatal distress, a history of brain cerebral infection at a young age, neurological sequel such as 
cerebral palsy, seizures and microcephaly. One of the limitations of our study is that in this setting, 
brain imaging is not routinely available. Therefore, brain imaging to support a suspected acquired 
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cause by demonstrating brain lesions is missing. Since an acquired cause may coexist with a genetic 
defect, the 8 patients were further studied by genetic screening tests, with normal results.  
The high yield of clinical diagnoses demonstrates that a clinical genetic approach is still the basis of 
genetic diagnosis (Rauch, Hoyer et al. 2006). 
According to the current guidelines genetic screening tests in unexplained ID include FMR1 testing and 
microarray-CGH (Moeschler and Shevell 2014). We did not identify a single case with Fragile X 
syndrome. This is discussed in more detail in chapter 4. By means of microarray-CGH, a pathogenic 
CNV was identified in 10/86 patients with good quality data (11.6 %). Of these, 9 were true causal 
CNV’s, i.e. sufficient to cause the ID. In one individual, a del15q1.2 was identified, which is a low risk 
factor for developmental delay and ID. 
Next, we performed a preselection of cases for further study by means of exome sequencing. In two 
siblings with syndromic ID, no causal variant was identified. Of the 68 female patients and mothers of 
affected boys, tested for XCI, 6 (13.6 %) presented with highly skewed X-inactivation. This proportion 
is close to 9.8 % previously reported (Amos-Landgraf, Cottle et al. 2006). We selected three cases for 
exome sequencing. In two of them, a possible genetic cause was identified. One boy was compound 
heterozygous for two variants in the ACY1, causing Aminoacylase 1 deficiency. Confirmation of this 
diagnosis is pending on metabolic studies. In the other boy, a likely causal mutation was identified in 
the TAF1-gene, a recently identified candidate gene for XL-ID. However, more clinical evidence and 
functional studies of the found variant are needed in order to confirm that this is a causal mutation.  
Taken together, a genetic diagnosis was reached in 34/127 patients (26.8 %). When we include the 8 
probably acquired causes and the results of the exome analysis, a diagnosis was obtained in 44 (34.7 
%). 
  
Figure 29. Distribution of different categories of etiological diagnoses  
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Altogether, genetic causes were identified in 34/127 patients, the majority of them chromosomal 
aberrations, including submicroscopic aberration in 11 patients. In addition, monogenic causes were 
identified in 3 patients (1 Partington syndrome patient and probably also in 2 patients by means of 
WES).  
With 19 cases out of 127 (14.8 %; CI: 9.531 % - 21.97 %), Down syndrome is the most prevalent genetic 
cause in our cohort. In most series, Down syndrome is the most prevalent cause of ID (Devriendt, 
Holvoet et al. 2003; Rauch, Hoyer et al. 2006). However, our finding is higher than 9.2 % reported by 
Rauch et al. in Switzerland, and 7.1 % reported by Devriendt et al in Flanders. This could be due to the 
absence of prenatal screening program in DR Congo. Among the 19 Down syndrome patients, 1 of 
them presented with a less pronounced facial characteristics, and genetic testing was consistent with 
a mosaicism. Advanced maternal age is a well-known risk factor for the classical type of free trisomy 
21 (Snijders, Sebire et al. 1995; Snijders, Sebire et al. 1995; Csermely, Czeizel et al. 2015). Also in our 
cohort, an advanced maternal age equal or above 35 years was observed in the majority of mothers of 
children with Down syndrome.  
For the purpose of this study, we implemented a rapid and easy-to-handle qPCR which correlated with 
the karyotype and microarray-CGH results. We therefore suggest that qPCR assay is the method of 
choice for the initial genetic confirmation of a clinically diagnosis of Down syndrome in the DR Congo.  
Eleven submicroscopic chromosomal imbalances were identified. Of interest, four of these are known, 
recurrent CNV’s, mediated by flanking low copy repeats: Williams syndrome, Smith-Magenis 
syndrome, the del15q11.2 and the del 15q24.  The phenotypes, even though only recognized clinically 
in the Williams syndrome patient, correspond to the descriptions in Caucasian patients, taking in to 
account the large variability often observed for these syndromes.  
To identify monogenic causal defects, we applied different strategies including targeted testing for 
diagnoses suspected by clinical examination (Partington syndrome), screening for the fragile syndrome 
and an XCI assay to identify potential carriers of X-linked disorders, followed by whole exome 
sequencing.  
The index with Partington syndrome as well as his older brother had the typical clinical presentation 
as described in Caucasian patients in the literature (Partington, Mulley et al. 1988; Gedeon, Partington 
et al. 1994; Cossee, Faivre et al. 2011). We could not find records of similar cases from Central Africa.   
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Although we did not detect a patient with fragile pre- or full mutation, we identified 2 carriers for the 
intermediate size allele. Since these represent susceptibility alleles, this suggests that the Fragile X 
syndrome does exist in Congolese patients, but that larger studies are needed to identify them.  
In two sisters with a same phenotype of severe ID, behavioural problems and similar facial and 
neurological phenotype, we failed to identify a genetic cause by means a of exome sequencing. 
The data we present concern children attending special schools or institutions in Kinshasa. For this 
reason, this is a biased study. In the local cultural and economic context, children with more severe ID 
and those with major malformations rarely attend school. In total, only 9 patients had a major 
malformation. In a similar study in Flanders, the likelihood of having a major malformation when there 
are 5 or more minor anomalies was 44 % (Devriendt, Holvoet et al. 2003). We compared the 
distribution of minor anomalies in our cohort to that of the Flemish study. Overall, the distribution was 
similar, except for a clear underrepresentation of the ones with multiple minor anomalies (Figure 30). 
In addition to economic and cultural selection, another reason for the smaller number of cases with 
major malformation in our series could be the limited chance to survive from life-threatening 
malformations in limited resource setting sub-Saharan Africa. 
  
Figure 30. Comparison of proportion of minor anomalies in this study versus Flanders. 
This is one of the first studies on genetic aspects of ID in a central African country. The results clearly 
show that the same range of genetic and environmental causes are identified compared to other 
societies. This is an important message for families of children with ID and caregivers, to refute 
commonly held ideas and traditional mystical believes on the causes of ID. 
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Sequencing primer with M13 Tag (Red sequences) 
AUTS2_Ex19_F: tgtaaaacgacggccagtTTGAGGGATCCTTACCGAGA 
AUTS2_Ex19_R :   caggaaacagctatgaccGATAGTGCATGCTGGGGAGT 
COL4A2_Ex42_F :  tgtaaaacgacggccagtCCAGAGACTGTCGCCTGA 
COL4A2_Ex42_R: caggaaacagctatgaccGGGAGACCAAACACACCAG 
ACY1_Ex2_F:  tgtaaaacgacggccagtGTGCAGGAGCTCACCATTTC 
ACY1_Ex2_R : caggaaacagctatgaccACCTTGGTCAGCAGCAGAGT 
ACY1_Ex15_F:  tgtaaaacgacggccagtCCCATTCATCAGGCTCTTTC 
 ACY1_Ex15_R :  caggaaacagctatgaccAGGGGCAAAGGTTTAGGAGT 
RELN_Ex_22_R: tgtaaaacgacggccagtTTCACTTACAGTGGGTGAGTAGACA 
RELN_Ex22_F:  caggaaacagctatgaccCATGCTATTGTGCTTAACTTGC 
SHANK2_Ex2_F:  tgtaaaacgacggccagtAGACCATTGGGAGCTACGTG 
SHANK2_Ex2_R :  caggaaacagctatgaccGCAGGGACAGTGAGCAAAAC 
TUBB2B_Ex4_F:  tgtaaaacgacggccagtGTCATACAGGGCCTCGTTGT 
TUBB2B_Ex4_R :  caggaaacagctatgaccCTTCCAGCTGACCCACTCTC 
AMER1_Ex2_F :   tgtaaaacgacggccagtGCCTTGAGAACTCTCCACCT 
AMER1_Ex2_R: caggaaacagctatgaccCTGGGTCTCTCGGACTTGAG 
TAF1_Ex28_F:  tgtaaaacgacggccagtTCCAGTCAATGCAAAGGTTG 
TAF1_Ex28_R : caggaaacagctatgaccGTCCAATCTAGTCTGAATTTAGGG 
GRIN2B_Ex13_F :  tgtaaaacgacggccagtGGCGTAAGCAGCAATATAAGG 
GRIN2B_Ex13_R :  caggaaacagctatgaccGTCGGTCAGGTCTACGTGCT 
SZT2_Ex27_F :  tgtaaaacgacggccagtTTTGCTGACAGCGGTAGATG 
SZT2_Ex27_R :  caggaaacagctatgaccCCCCCTTATCCATCATTCAA 
SZT2_Ex53_F :  tgtaaaacgacggccagtCTGGAGCCCAGAGACAAAAG 
SZT2_Ex53_R :  caggaaacagctatgaccTCTGGACACTGAGGCACAAC 
LINS_Ex_R :  tgtaaaacgacggccagtTGACCTTCTTAAAGCCTCATCT 
LINS_Ex6_F :  caggaaacagctatgaccTTTCCCCCAAATGATGAAAG 
LINS_Ex5_F:  tgtaaaacgacggccagtGCTTGCTGCTCTAAGGATCAC 
LINS_Ex5_R :  caggaaacagctatgaccTTCTCATCGCCTCCAGAATC 
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qPCR primers : 
qPCR_CYFIP1_F_: GCTAGACACGGACAGACAGGA 
qPCR_CYFIP1_R : GGGTGTGTGTGTCGAGTGA   
qPCR_MEF2C_F :  CCAGGCTTAAGTCCCACTGA 
qPCR_MEF2C_R :  GTGACAGCATTCCAGAAGCA 
qPCR_NCAM2_Ex16_v2_F : TCGAAGAAGGAAAAGCTGCA 
qPCR_NCAM2_Ex16_v2_R : CCCTCAGGTAAAGCACTCGA 
qPCR_SCN2A_F: TGTAGGCCTGAAGACCATTGT 
qPCR_SCN2A_R:TTGCCCATGAACAACTGCAA 
qPCR_SHANK3_R: TCAGGTTGATATCGCTGGCT 
qPCR_SHANK3_F : CCCCTTACCCCAGTACCATT 
qPCR_GATA4_Ex7_F: CCTCCTCTGCCTGGTAATGA 
qPCR_GATA4_Ex7_R: AAAATCCAACACCCGCTTCC 
qPCR_MIP_Ex3_F : AGTTGTGGATGGGGACTCAC 
qPCR_MIP_Ex3_R: GTGAGATGCGGTTGTCAAGG 
qPCR_RAI1_Ex3_v2_F : AACATCTCCAACACCGTCCA 
qPCR_RAI1_Ex3_v2_R : TGGACACGAGGTTCTTGACA 
qPCR_PCSK2_Ex12_v2_F : AAGTCCATTTTGCTGAGCCG 
qPCR_PCSK2_ex12_v2_R : TGAGTGGTCATGAAAGGCCA 
qPRC_BCL11A_Ex2_F :  CCTTCCCCTTCACCAATCGA 
qPRC_BCL11A_Ex2_R : AACAATCGTCATCCTCTGGC 
qPCR_GDF5_v1_F : CCAAGAAACGGGACCTGTTC 
qPCR_GDF5_v1_R : GTCTTATCGTCCTGGCCAGA 
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1.11 Introduction 
The Fragile X Syndrome (FXS) (OMIM 300624) is one of the most common monogenic causes of 
Intellectual Disability (ID).  Its prevalence varies between 1/6,000 and 1/4,000 males in the general 
population (Turner, Webb et al. 1996; de Vries, Mohkamsing et al. 1999). Because of this high 
incidence, screening for Fragile X syndrome is considered essential in any child with developmental 
delay or intellectual disability (ID) (Moeschler and Shevell 2014).  A variable prevalence is observed in 
different geographical parts of the world, but prevalence also depends on the clinical characteristics 
of the tested group, gender and sampling strategy (Crawford, Acuna et al. 2001). Only few studies have 
investigated FXS in Africa. In children attending schools for special education, Goldman reported a 
prevalence of 6.1 %  of FXS among black Africans in South Africa (Goldman, Jenkins et al. 1998). Later, 
Crawford et al., reported a prevalence of 1/2,545 among African Americans in special education in the 
public school system of metropolitan Atlanta, USA (Crawford, Meadows et al. 2002). To date, there are 
no reports on FXS in schools for special education or clinics for children in Central Africa. 
In at least 99 % of FXS cases, the genetic mutation is an expansion above normal ranges of the CGG 
repeats in the 5'-UTR in the promoter region of the FMR1 (Fragile X Mental Retardation 1; OMIM: 
309550). The remaining cases are explained either by chromosomal imbalances (e.g. deletions) or rare 
intragenic mutations (Tarleton, Richie et al. 1993; Albright, Lachiewicz et al. 1994; D'Hulst and Kooy 
2009; Okray, de Esch et al. 2015). Normal alleles range from ~5 to ~44 repeats, intermediate alleles 
from ~45 to ~54 repeats, premutation alleles from ~55 to ~200 repeats and full mutations over 200-
230 repeats (Maddalena, Richards et al. 2001; Monaghan, Lyon et al. 2013). Comparatives studies 
between African Americans and Caucasian Americans reported a significant difference in the 
distribution of common alleles with shorter alleles (20-23 repeats) as well as larger alleles (41-60 
repeats) being less frequent in African Americans (Eichler, Hammond et al. 1995; Crawford, Zhang et 
al. 2000). Although the  29 and 30 CGG repeats are the most prevalent alleles in Africans, African 
Americans and Caucasians, the 29  repeats allele has a significantly higher frequency in black Africans 
whereas the 30 repeats allele is significantly more frequent in white Africans  (Chiurazzi, Destro-Bisol 
et al. 1996; Crawford, Meadows et al. 2002; Essop and Krause 2013).  
The FMR1 repeat is not a perfect tandem repeat, but interrupted by AGG trinucleotides at regular 
intervals. These appear to stabilize the repeat within normal ranges. Inversely, the instability increases 
with longer perfect repeats (Eichler, Macpherson et al. 1996). In Caucasians, the FMR1 expansion 
mutation is in linkage disequilibrium with specific alleles of flanking microsatellites (Chiurazzi, Destro-
Bisol et al. 1996; Larsen, Vuust et al. 2001). African and African Americans exhibit greater variability of 
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polymorphisms around the FRAXA locus, in line with evolutionary origin of Homo Sapiens which 
initiated in Central Africa (Chiurazzi, Destro-Bisol et al. 1996; Crawford, Zhang et al. 2000; Peprah, Allen 
et al. 2010). 
The FXS is associated with various clinical presentations depending on the number of repeats, sex and 
age (Oostra and Willemsen 2009). Hence, concepts such as "Fragile X Spectrum Disorder" (FXSD) or 
FMR1 related disorders have been proposed in order to include all FMR1-related phenotypes (Lozano, 
Rosero et al. 2014). The full mutation in young children manifests often with Attention Deficit 
Hyperactivity Disorder (ADHD) and/or Autism spectrum disorders (ASD) (Hagerman 2006; Sullivan, 
Hatton et al. 2006; Gabis and Kesner 2007). In older children, adolescents and adults the classic 
presentation consists of intellectual disability with an IQ < 50, associated to more characteristic 
behavioural and dysmorphic features  (Hagerman, Amiri et al. 1991; Tuncbilek, Alikasifoglu et al. 1999; 
Lachiewicz, Dawson et al. 2000; Mirkin 2007; D'Hulst and Kooy 2009; Lozano, Rosero et al. 2014). 
Although none of the listed features is pathognomonic for FXS, their association has been used to 
efficiently screen for the FXS using clinical checklists (Butler, Mangrum et al. 1991; Laing, Partington et 
al. 1991; Lachiewicz, Dawson et al. 2000). These checklists are not intended to substitute molecular 
testing. Instead, they allow a fast and efficient selection of patients with a higher probability for having 
FXS (Hagerman, Amiri et al. 1991; de Vries, Mohkamsing et al. 1999; Behery 2008).  
So far, no checklist has specifically been designed or adapted for the black African population. Indeed, 
craniofacial features in a population of African origin may show critical differences compared to those 
in Caucasian for certain genetic conditions, as was reported for the 22q11.2 deletion syndrome 
(McDonald-McGinn, Minugh-Purvis et al. 2005) and for FXS (Schwartz, Phelan et al. 1988). Such clinical 
variability points to the necessity to design population specific checklists or adapt existing tools to the 
population of interest. Examples of population specific checklists for FXS have been proposed for the 
Indian and Turkish population (Tuncbilek, Alikasifoglu et al. 1999; Guruju, Lavanya et al. 2009).  
The present study aimed to gain insight into the prevalence of FXS and the distribution of CGG alleles, 
and to evaluate the usefulness of three selected checklists as a screening tool for FXS in patients with 
ID followed in specialised clinics and schools in Kinshasa, DR Congo. 
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1.12 Material and Methods 
1.12.1 Patients  
We recruited 127 index patients from 2 hospitals and 4 schools specialised for ID across Kinshasa in 
the Democratic Republic of Congo (DRC). Informed consent was obtained from parents or legal 
representatives. We conducted a standard clinical genetic examination which allowed the 
identification of 22 patients with a clinically recognizable syndrome including Down syndrome (n = 19), 
and respectively one patient for Williams syndrome, Partington syndrome, amniotic band syndrome 
and Oculo-Auriculo-Vertebral Spectrum. One patient had a clinical diagnosis of Noonan syndrome, 
which was not confirmed by molecular testing. The remaining 105 patients, 81 males, 24 females, were 
included in the FXS study.  
All 105 patients underwent standardized clinical examination including measurements and evaluation 
of dysmorphism. Personal and family history were obtained from the parents or legal representative. 
A positive familial history of ID was defined as the presence of another relative with ID up to the 3rd 
degree.  
During the consultation, we asked the parents to complete a predesigned questionnaire compiling 
items from the 3 selected screening checklists for FXS, i.e. from Hagerman (Hagerman, Amiri et al. 
1991), Maes (Maes, Fryns et al. 2000) and Guruju (Guruju, Lavanya et al. 2009). We used the checklist 
from Hagerman because it is the most widely used and also because it was the basis for most other, 
adapted screening lists (Tuncbilek, Alikasifoglu et al. 1999; Guruju, Lavanya et al. 2009). The Maes’ 
checklist takes into account the fact that not all items have the same prediction power. They attributed 
coefficients to the most predictive items, thus increasing the chance for a fragile X patient to rank at 
the top. Because of this improvement we also selected this checklist for our study. We also included 
the checklist from Guruju who included additional physical features and adjusted the threshold 
compared to the reference checklist from Hagerman.  
All items from the 3 checklists were merged into one questionnaire. Each item was accompanied with 
an additional short description (Addendum 1). One week before the interview, the research 
questionnaire was sent to parents to make them familiar with the questions and help them prepare 
their answers. On the day of the clinical examination, we personally administered questions from the 
questionnaire and scored items. Parents or legal representatives were asked to respond with YES when 
they were certain that the item described in the questionnaire was currently present or had been 
present in the patient, NO when they were convinced that the item had never been observed or NOT 
SURE when they were uncertain. These responses were then translated into scores according to the 
scoring rules for each of the 3 checklists. Hagerman’s checklist has 3 scales, and thus YES was scored 
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as 2, NOT SURE as 1 and NO as 0. Guruju and Maes were 2 scales scoring systems in which YES received 
the score 1 whereas NOT SURE and NO received the score 0. When a score is equal or above to the 
referral scores, referral for molecular genetic testing is indicated. Referral scores are ≥ 10 for 
Hagerman, ≥ 17 for Maes and ≥ 5 Guruju. We used item frequencies to determine the most prevalent 
features in our patient cohort and the cumulative scores to assess the sensitivity and specificity of each 
checklist.  
1.12.2 DNA extraction 
Venous blood was sampled from a peripheral vein and genomic DNA was extracted by the salt 
saturation method as previously described (Miller, Dykes et al. 1988). Between 2010 and 2012 DNA 
extraction was done in the Centre for Human Genetic at Leuven. From 2013 onwards, a DNA extraction 
facility was implemented at the Institut National de Recherche Biomédicale (INRB) in Kinshasa so that 
white blood cell pellets or DNA were henceforth prepared at the INRB and then shipped to the Centre 
for Human Genetics, Leuven, Belgium, for further analysis. 
1.12.3 FMR1 CGG repeats testing 
To assess the fragment length of the CGG repeats in the promoter region of the FMR1 gene, the target 
region was amplified during a PCR reaction using the PRC-enhancer kit (Invitrogen) and the FRAXA-A 
and FRAXA-B primers.  
Primer sequences: 
FRAXA-A: GAC GGA GGC GCC GCT GCC AGG6FAM 
FRAXA-B: GTG GGC TGC GGG CGC TCG AGG 
The reaction mix contained 5.6 µl of water, 2 µl of the 10X PCRx Amplification buffer, 0.6 µl of 50 mM 
MgSO4, 1 µl of dNTPs (4 mM), 8 µl of PCRx Enhancer Solution, 1.5 µl of Primer mix (10 pm/µl) and 0.25 
µl of Taq DNA Polymerase from Roche. The cycling comprised an initial denaturation at 95°C for 3 
minutes followed by 27 amplification cycles made of short denaturation at 95°C for 15 seconds, 
annealing at 64°C for 1 minute and elongation at 75°C for 1 minute. The reaction was terminated with 
a final elongation at 75°C for 7 minutes and cooling at 15°C ∞. PCR product was controlled on 2 % 
agarose gel with 1 kb size marker. Then, 2 µl of the remaining PCR product was resuspended with an 
admixture of 20 µl HiDi Formamide (Applied Biosystems) and Rox 500 (Applied Biosystems). Fragment 
were separated on the on ABI 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA 94404 USA) 
then analysed with GeneMapper® Software 5 (Life Technologies Ltd, Paisley, UK). 
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1.12.4 Ethics 
The participants were duly informed about the structure and aims of the study. They were informed 
concerning their right to withdraw from the study. For each participant, parents or legal 
representatives provided written consent for study participation. We applied an anonymous and non-
personal coding system to protect participants’ privacy. Our research protocol was approved under 
the number ESP/CE/008/2015 by the National Ethical Committee of the Public Health School of the 
University of Kinshasa, Kinshasa, the DR Congo.  
1.13 Results 
1.13.1 FXS clinical checklists 
Using the Hagerman checklist our patients obtained cumulative scores ranging from 2 to 16 with an 
average of 8.13 ± 3.07. Thirty-nine patients (37.14 %) showed a total score in the referral range (fig. 1).  
  
Figure 1. Frequency of cumulative scores with the Hagerman checklist 
In addition to the ID present in all patients, behavioural features of attention deficit (62.86 %), 
hyperactivity (62.86 %) and gaze avoidance (46.67) were especially frequent, compared to dysmorphic 
features of large and prominent ears (18.09 %) or simian crease (0.95 %) (figure 2). 
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Figure 2. Frequencies for items from Hagerman’s checklist 
For the Maes’ checklist, the cumulative scores ranged between 2 and 27 with an average of 14.30 ± 
5.92 (figure 3).  A total of 37 patients (35.24 %) had a score within the referral range.  
 
Figure 3. Frequency of the cumulative scores from Maes’ checklist  
Also in this checklist, behavioural items including autistic-like components such as hypersensitivity to 
change, limited language, gaze avoidance and stereotypic hand movements, were more frequent 
compared to dysmorphic features (figure 4). 
74 
 
  
Figure 4. Frequency of items from the Maes’ checklist. 
On the Guruju’s checklist, the cumulative scores ranged from 1 to 10 with an average of 4.24 ±1.75. 46 
patients (43.80 %) had a total score ≥5, which means a high probability of FXS (figure 5).  
  
Figure 5. Frequency of the cumulative scores from Guruju’s checklist 
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Also in this checklist, behavioural features were more frequently observed than dysmorphism (fig. 6.). 
 
 Figure 6. Frequency of items from Guruju’s checklist 
1.13.2 CGG alleles sizes 
We analysed a total of 130 chromosomes including 80 from males and 50 from 25 females. Twenty 
one different alleles were observed. The average repeat size was 28.55 ± 2.83 (ranges: 17-48) (figure 
7). The most frequent allele size was 29 (24.61 %) and 73.84 % of alleles have sizes between 28 and 31 
repeats. There was a second and small peak at 21 repeats. No full mutations nor premutations were 
detected. In 2 male patients an intermediate allele size with 47 and 48 repeats was detected. The 47 
repeats allele was inherited from the normal mother who had highly skewed X-chromosome 
inactivation (92.75 %/7.25 %). DNA of the mother of the patient with 49 repeats was not available.  
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Figure 7. Distribution different CGG alleles 
1.13.3 Proportion of behaviour features and sensitivity of checklists 
The total score ranged between 2-16 for Hagerman, 2 to 27 for Maes and 1-9 for Guruju.  The average 
number of behavioural items scored positively per patient was 2.55 with Hagerman’s and Guruju’s 
tools and 7.79 items with Maes’ tool. Conversely, the average number for positive physical features 
was 0.29 for, 0.295 for Hagerman, 0.57 for Guruju and 0.62 for Maes.  
Given the absence of molecularly confirmed Fragile X patients in our cohort, sensitivity could not be 
calculated for the 3 checklists. However, we calculated the specificity, using the referral thresholds and 
found 62.86 %, 64.76 % and 56.5 % respectively for Hagerman, Maes and Guruju (table 2).  
1.14 Discussion 
The Fragile X syndrome is considered to be one of the most common causes of ID worldwide. However, 
no data exist on the incidence of FXS in Central Africa. This is the first study to evaluate this question 
in a systematic way in a high risk population of individuals attending schools for special education or 
specialized clinics for persons with ID.  
Among 105 individuals, 80 males and 25 females, not a single case of FXS was diagnosed with molecular 
testing. This may seem in contradiction with the observations made in South Africa were Goldman et 
al. reported a prevalence of 6.1 % among black patients in specialised schools and the results of Essop 
and Krause who identified FXS in 5.2 % in black patients with ID who underwent FMR1 testing in a 
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period of 25 years in Johannesburg (Goldman, Jenkins et al. 1998; Essop and Krause 2013). However, 
given the presence of intermediate alleles in our population (2/130 chromosomes), and since 
intermediate alleles may be unstable, we can anticipate that FXS is very likely to be present in the 
Congolese population. The absence of positive cases in our study in specialised institutions and 
hospitals may be explained by certain limitations of this study. One of the limitations is the relatively 
small size of studied sample. Also, given the limited resources in this country, not all parents can afford 
paying the specialized institutions and the majority of families are forced to keep their children at 
home, especially when they have severe behavioural manifestations or disabilities. Consequently, only 
patients from families with high revenues as well as those with less severe manifestations are 
encountered in these institutions. This may have resulted in an underrepresentation of FXS cases in 
this study. Also, FXS patients in DR Congo may present differently and thus be oriented to different 
specialties such as psychiatry or speech therapist.  
In order to increase the chance to identify FXS in Congolese patients, future studies should include a 
larger cohort of individuals, from different environments (schools, hospitals and a neighbourhood 
survey), and in collaboration with various medical specialties (psychiatry, neurology, paediatrics, etc).  
In addition, the recruitment of familial cases, with a pedigree compatible with X-linked inheritance 
may increase the likelihood of identifying FXS cases.  
 
Figure 8. Comparison of CGG distribution to 4 other African groups 
We have observed only 21 different alleles among the 129 studied chromosomes (Fig.7). Crawford et 
al. reported a larger number of alleles in Caucasians (42 alleles) compared to African Americans (37 
alleles) (Crawford, Zhang et al. 2000). The number of distinct alleles in the Congolese is similar to those 
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reported in other African groups (figure 8): 17 for Senegalese Mandeka (Kunst, Zerylnick et al. 1996), 
14 in Senegalese Wolof,  13 in Cameroonians Bamileke (Chiurazzi, Destro-Bisol et al. 1996) and 10 for 
Mbuti Pygmies from DR Congo (Eichler and Nelson 1996).      
Alleles in our cohort ranged from 17 to 48 repeats (mean: 28.55 ± 2.83). Interestingly, about 74 % were 
between 28 and 31 repeats and we detected only 2 alleles shorter than 20 repeats and 2 larger than 
45 (Figure 7). This observation is consistent with the prior observation that shorter and larger alleles 
are rare in African Americans and Africans (Crawford, Zhang et al. 2000; Peprah, Allen et al. 2010). The 
mean repeat size of 28.55 we observed is similar to the literature reports (Tuncbilek, Alikasifoglu et al. 
1999; Tzeng, Cho et al. 1999; Maddalena, Richards et al. 2001; Van Esch 2006; Yim, Jeon et al. 2008; 
Peprah, Allen et al. 2010). Alleles in our cohort form 2 clusters. A major cluster around the mean, and 
a minor cluster at 21 repeats. A similar 2 peaks pattern has been previously reported in African and 
non-African populations (Chiurazzi, Destro-Bisol et al. 1996; Kunst, Zerylnick et al. 1996; Crawford, 
Zhang et al. 2000; Peprah, Allen et al. 2010). In the majority of populations studied worldwide, the 
most common allele is either 29 CGG or 30 CGG or an equal frequency of both. Our results tend to 
corroborate the previously made assumption that 29 was the most common allele in African whereas 
the 30 was the most frequent in Caucasians (Essop and Krause 2013).  In addition, isolated populations 
such as Japanese, Pygmies (DR Congo) or Mayan (Mexico) are enriched for alleles 27 or 28 repeats 
(Eichler and Nelson 1996; Otsuka, Sakamoto et al. 2010) associated to a reduced frequency of the 29 
and 30 CGG alleles. Although originating from the same country, patients in our study, all from the 
Bantou population, have different CGG distribution from Mbuti pigmies. Possible founder effects in 
pigmy group is thought to be at the origin of the altered allele distribution in pigmies (Eichler and 
Nelson 1996; Otsuka, Sakamoto et al. 2010).  
After the results from molecular testing of FMR1 were available, we evaluated the 3 selected checklists 
knowing that there was no true positive patient in our cohort. The clinical scoring tools indicate a 
higher frequency for behavioural characteristics compared to physical features. This may be ascribed 
to the younger age of patients or to the absence of true fragile X in the cohort. Attention deficit and 
hyperactivity are the most common items. It may be that parents or tutors tend to overrate these 
features. It may also represent a natural characteristic of Congolese children consistent with the 
observation that Congolese children have and advance of about 6 months for motor development but 
have 6 months delay for adaptive development compared to Caucasians (Tady 2002). Importantly, our 
study suggests that these behavioural characteristics are so common in non-FXS children with ID, and 
therefore, incorporating these behavioural features in FXS screening lists will result in low specificities, 
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at least at thresholds used in the original screening tools. However, the predictive power of each 
feature can only be determined after identification of fragile X positive cases. 
Mean scores recorded in the present study are close to those reported from non-fragile X individuals 
in original studies (Table 1). 
Table 1. Scores from our study compared to the original studies 
  
  
 
Categories 
This study Original study 
Range Mean SD Range Mean SD 
 
Hagerman 
FX (-) 2 - 16 8.13 3.07 2 - 23 10.2 NA 
FX (+) NA NA NA 10 - 22 17.3 NA 
 
Maes 
FX (-) 2 - 27 14.30 5.92 0 - 24 NA NA 
FX (+) NA NA NA 16 - 49 NA NA 
 
Guruju 
FX (-) 1 - 9 4.25 1.75 2 - 9 5.44 1.29 
FX (+) NA NA NA 4 - 15 7.05 1.09 
Interestingly, if we consider the referral scores, a higher proportion of patients would have been 
referred for genetic testing in our study, indicating a higher rate of false positives. This is reflected in 
the much lower specificities of the 3 checklists in our cohort compared to original studies (Table 2). 
Based on the specificity only, we can anticipate that the 3 checklist have poor performances on 
Congolese population. An adaptation would be necessary to improve the performance in Congo. 
Nevertheless, final conclusion can only be drawn in comparison to the specificity when a positive 
patient will be identified. 
Table 2. Specificities in this study versus the original studies 
Checklists Referral threshold This study Original studies 
Hagerman ≥ 10 62.86 % 87 % 
Maes ≥ 17 64.76 % 92.3 % 
Guruju > 5 56.5 % 73.18 % 
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CHALLENGES FOR GENETIC STUDIES OF ID IN DR CONGO 
1.16 Introduction 
Genetic studies of intellectual disability (ID) are almost inexistent in Central Africa, despite the fact that 
they offer many opportunities to gain insight into the genetics of human disease.  
The African population is evolutionary the most ancient and has a unique genetic structure. There is 
evidence that the mechanisms leading to mutations may differ in Africans compared to other 
populations (Veltman and Brunner 2012). For instance, the recurrent microdeletion in chromosome 
17q21.31 mediated by low copy repeats only occurs in the germline of a parent carrying a 900-kb 
inversion polymorphism of this region (Koolen, Sharp et al. 2008). This inversion is common in 
individuals of European ancestry, but rare in Africans (Stefansson, Helgason et al. 2005). The 
evolutionary history may also explain why certain disorders have a different incidence in the Central 
African population. The classical example is the high incidence of sickle cell disease in Africans, due to 
an increased resistance of carriers against malaria infection. Another example is the increased 
incidence of a 2.7 kb deletion in the P-gene, causing oculocutaneous albinism type 2. Recently, the 
incidence and/or spectrum of mutations causing common, mostly autosomal dominant monogenetic 
disorders was found to differ. This was revealed by an approximately 50 % lower incidence of known 
mutations in a list of actionable genes in African Americans (Dorschner, Amendola et al. 2013; 
Amendola, Dorschner et al. 2015). Also, the incidence of many autosomal recessive conditions varies 
wildly, and some conditions are unique to certain populations. This is attributed to evolutionary factors 
such as consanguinity with founder effects and sometimes natural selection. In certain regions of DR 
Congo, consanguinity is part of the culture. Examples include Manianga in the province of Bas-Congo 
and Nande in North-Kivu. Genetic studies in Central Africa offer thus a unique opportunity to identify 
novel genes or mutations or mutational mechanisms, besides being relevant for the local population. 
However, the challenges are enormous.  
First, the laboratory infrastructure for genetic testing is almost entirely lacking. Since the onset of this 
project, I contributed in establishing a DNA extraction facility in the genetic centre in Kinshasa. The 
first genetic tests are being introduced (karyotyping and diagnosis of sickle cell disease). However, 
there remains a long way to go before one can envisage routine genetic testing such as microarray-
CGH, MLPA or sequencing. In the near future, gene panel analysis or even whole genome sequencing 
will become a first choice test for the detection of both SNV’s and CNV’s at an affordable price. 
Whereas this may seem to overcome the technical challenges, the bioinformatics infrastructure with 
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fast internet access needed to variant interpretation may be an even larger hurdle to overcome in a 
country where electricity supply is unpredictable. 
Also, clinical genetics faces many challenges. The societal aspects have been discussed in the general 
introduction. Knowledge of most genetic syndromes is based on Caucasian patients. Knowledge on 
African patients is mostly limited to African American cases. Since people with a different ethnicity 
have distinct facial features, it is not unexpected that the dysmorphic features in specific syndromes 
also differ. Only few studies exist that have explored this issues, none for central African patients. Also, 
environmental factors may influence the manifestations and clinical course of specific genetic 
disorders or syndromes. In Central Africa, the high burden of serious infectious diseases, birth trauma 
and nutritional deficiencies are factors that have to be taken into account during a clinical genetics 
evaluation.  
In this chapter, we explore these different opportunities and challenges, using examples from our 
study on ID, but equally on other families with other genetic conditions, we observed during our clinical 
work in Kinshasa.  
First, we study differences in facial dysmorphism in African and Caucasian patients. We compare 
differences in clinical evaluation of facial dysmorphism by African and European clinicians. We also 
assess differences in facial morphology in African and European Down syndrome patients, using 
Face2Gene, a recently introduced tool that permits an objective evaluation of facial features.    
Next, we describe two instances where the manifestations of a well-known genetic disorder have been 
modified due to intervening environmental influences. This resulted in an atypical picture and thus 
delayed diagnosis.  
Finally, we describe a familial case of Apert syndrome carrying a unique mutation thus far never 
described. The overwhelming majority of Apert cases carry the same mutation and we detect, in the 
first African case ever sequenced a novel mutation. This leaves us wondering whether this is 
coincidence or related to his central African origin. 
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1.17.1 Introduction 
Facial dysmorphism means that the facial aspect significantly deviates from what is expected. Since 
many syndromes (genetic or acquired) have a characteristic craniofacial appearance, the recognition 
of such atypical facial features may contribute to reaching an etiological diagnosis. Facial dysmorphism 
consists of the presence of multiple minor morphologic (physical) anomalies. Minor physical anomalies 
in turn may be defined as variant morphological features, are found in less than 4 % of the general 
population and have no serious medical or cosmetic significance to the individual (Jones 1988; 
Ambrosio-Gallardo, Cruz-Fuentes et al. 2015). Some of these are qualitative such as the presence of a 
transverse palmar crease or postaxial polydactyly. Others, like an increased distance between the eyes 
can be measured and are thus quantitative. For the latter, abnormal is defined as ±2 standard 
deviations” (SD) from the mean. However, some quantitative features such as anteversion of the 
nostrils cannot be measured in a routine clinical setting; therefore, their evaluation is usually 
subjective. Efforts have been undertaken to allow an uniform description of dysmorphism. In 2009, a 
standardized terminology was proposed to describe various dysmorphic features in different parts of 
the body (Allanson, Cunniff et al. 2009). Several studies have established a relationship between the 
number of minor anomalies and the chance of having an additional major malformation (Hennekam 
2011). This suggests that minor anomalies may be regarded as the result of a more generalized 
disturbance of the developmental process and can be used in clinics to suspect a developmental 
problem. The presence of three or more minor anomalies in a patient can be used as an operational 
definition of ‘dysmorphism’.  In practice however, a dysmorphological examination involves a more 
global or facial gestalt evaluation. Experienced dysmorphologists often recognize a child with a specific 
syndrome at first sight, based on similarities to other patients with a known syndrome. Subsequently, 
they search  for the specific signs or features associated to this syndrome, to substantiate the supposed 
diagnosis. 
However, the recognition of facial dysmorphism is not easy and is hampered by several factors. The 
expected, normal facial features depend on the age, sex and ethnic background. It may be influenced 
by the position during examination (static as in clinical pictures or dynamic when examining the 
individual ’life’) and confounding factors such as strabismus, neurological manifestations or 
deformations. A further limiting factor in the evaluation of dysmorphism is that this remains largely a 
subjective evaluation and requires significant experience. Therefore, efforts are ongoing to facilitate a 
more objective clinical evaluation of dysmorphism.  Recent advances in morphometric analysis have 
explored the possibility to perform an objective evaluation of the facial gestalt from 2D or 3D facial 
images and reach a reliable syndrome diagnosis. This requires matching the face of a patient with 
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similar patients in a database of individuals with known syndromes (Hammond, Hutton et al. 2005; 
Ferry, Steinberg et al. 2014). The primary goal of these computed phenotyping tools is to narrow down 
the search space by excluding inconsistent diagnosis with great certainty and facilitate further 
confirmatory testing. One such tool, Face2Gene (http://www.fdna.com/face2gene/)  is available 
online both as a web-based tool and as an application for smart-phones and tablets. Such a user-
friendly tool holds great promise of reaching a rapid diagnosis for common genetic syndromes, without 
the need for expert dysmorphological examination. Especially in low resource countries, where access 
to laboratory testing is limited, the potential of such a tool is great. 
Studying dysmorphism in Central Africa is challenging, because the facial morphology presents obvious 
differences between African and other populations. First, the incidence of certain minor anomalies 
differs between populations. For instance, postaxial polydactyly, thick lips vermilions and broad nasal 
tip are common in African males (Ofodile, Bokhari et al. 1993; Talbert, Kau et al. 2014). Second, the 
craniofacial presentation of a known syndrome in a patient of African origin may differ from a 
Caucasian with the same syndrome. This was reported for the Velocardiofacial syndrome (McDonald-
McGinn, Minugh-Purvis et al. 2005; Veerapandiyan, Abdul-Rahman et al. 2011), Fragile-X syndrome 
(Schwartz, Phelan et al. 1988) and fetal alcohol syndrome (Moore, Ward et al. 2007). These variations 
are thought to hinder the timely diagnosis of manageable diseases and may explain the apparently 
lower frequency of some disorders in non-Caucasian populations (Veerapandiyan, Abdul-Rahman et 
al. 2011). Unfortunately, existing reference values for most quantitative traits as well as subjective 
description of many minor anomalies are largely based on Caucasians but are not available for Africans.  
This is illustrated by the fact that in the series articles describing the terminology for minor anomalies, 
pictures from Africans are almost completely lacking. 
The aim of the present study is to evaluate the ability to interpret facial morphology in children from 
Central Africa with ID. First, we evaluated differences in the interpretation of facial gestalt in African 
children between experienced European and African dysmorphologists. Next, we assessed the 
performance of the existing computed phenotyping tool Face2Gene, at the current stage of its 
development, to recognize Down syndrome in Congolese versus Caucasian patients.   
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1.17.2 Material and Methods  
The study is part of an etiological diagnostic study in 127 patients with intellectual disability, recruited 
in 6 specialized clinics and schools in Kinshasa in the DR Congo. This cohort has been described before 
(chapter 3). 
Part 1. Comparison of scoring of facial (dys)morphology by African and European clinicians 
Pictures of all 127 cases (frontal view, and in most cases also a profile) taken during the clinical 
examination were evaluated by 10 clinicians including 5 from Africa (DR Congo and South Africa), and 
5 from Europe (Belgium and United Kingdom). Participants were asked to score the face of each 
patient, based on the facial gestalt, i.e. without formal and detailed analysis. They could score the face 
as either normal (score 0), clearly dysmorphic (score 2) or uncertain (score 1).  
We hypothesized that African and European physicians would score in the same way (Ho) and used 
SPSS to calculate kappa coefficient for inter-rater agreement (Tang, Hu et al. 2015). The interpretation 
of the kappa coefficient was made as follows: less than chance agreement when < 0, slight agreement 
when 0.01–0.20, fair agreement if 0.21–0.40, moderate agreement if 0.41–0.60, substantial 
agreement when 0.61–0.80 and almost perfect agreement when 0.81–0.99 (Viera and Garrett 2005). 
We were also interested in potential correlation between the group-score a patient received and the 
objective number of minor anomalies on the face. We used the Pearson correlation coefficient (r) to 
calculate the correlation and used the  t-test to measure the significance. Interpretation of the Pearson 
Correlation Coefficient in terms of magnitude of effect sizes was done according to Cohen J (Cohen 
1988) as following: “small” if r 0.10-0.30,  “medium” when 0.30-0.50 and “large” for r of 0.50 and 
above.   
Part 2. Assessment of FACE2GENE  
During the clinical examination, we identified 19 patients with a phenotype suggestive of Down 
syndrome (DS) among the 127 Congolese patients. This diagnosis was confirmed in all cases by means 
of standard karyotyping, qPCR or microarray-CGH.  
We also obtained facial photographs of 20 Down syndrome patients from Flanders in Belgium (K.D. 
and M.H.). They matched the 19 DS patients from the DRC for sex and age. In the Congolese Down 
syndrome cohort, there were 10 boys and 7 girls, and age ranged from 1.86-17 years, mean age was 
10.09 ± 4.45 yrs. In the Flemish Down syndrome cohort of 20 cases,  there were 10 boys and 10 girls, 
and age ranged from 2.4 years-14 years, mean age 8 ± 3.23 yrs.  
  
93 
 
Two of the Congolese DS patients were excluded because their facial photographs did not meet the 
quality criteria of the Face2Gene program. Thus, facial photographs from 17 Congolese and 20 Flemish 
were uploaded as ‘unknowns’ to Face2Gene application without adding any phenotypic description or 
diagnosis. Following its algorithm, Face2Gene extracts facial gestalt signatures from our patient and 
compares them to patients with known diagnostics in its database. Then, the top ranking 10 matches 
are reported, from the most likely to the less likely (Figure 1). Each patient received a score, from 1-
10, corresponding to the ranking of a match “Down syndrome” among the 10 matches suggested for 
that patient by the application. A conservative score of 11 was assigned when “Down syndrome” was 
not listed within the first 10 matches. The Face2Gene ranks for DS in Congolese and Belgian patients 
were compared using Wilcoxon test statistics and permutation tests. The Wilcoxon test statistic was 
calculated using R (version 3.1.1) and compared to 10,000 permutation tests 𝐻𝑎: µ𝐶 > µ𝐵). This was 
repeated 1,000 times to create a p-value interval for decision making. We also calculated the specificity 
and sensitivity of Face2Gene for Down Syndrome in Congolese and Belgians. We calculated the 
Accuracy and Precision of Face2Gene. The Accuracy of a measurement system is the degree of 
closeness of measurements obtained with that measurement system to that quantity's actual (true) 
value. Conversely, the Precision of a measurement system is the degree to which repeated 
measurements show the same results under unchanged conditions          
(http://simple.wikipedia.org/wiki/Accuracy_and_precision). 
 
Figure 1. Illustration of the Face2Gene report. Top panel displays the patient’s photographs uploaded to 
Face2Gene, the green lock indicates that images fulfil quality criteria for the tool. The middle and bottom panel 
show the 10 matches. For each match, the heating cloud indicates similarities between facial marks identified 
from the known diagnosis (left) and the patient (right).  
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1.17.2.1 Ethics issues 
The participants were duly informed about the structure and aims of the study. They were informed 
concerning their right to withdraw from the study. For each participant, parents or legal 
representatives provided written consent for study participation. We applied an anonymous and non-
personal coding system to protect participants’ privacy. Our research protocol was approved under 
the number ESP/CE/008/2015 by the National Ethical Committee of the Public Health School of the 
University of Kinshasa, Kinshasa, the DR Congo.  
1.17.3 Results. 
1.17.3.1 Comparison of the scoring by African and European clinicians 
African physicians attributed more frequently score 2 (290 times) than Europeans (222 times) and 
conversely scored less 0 (185 times) than the European colleagues (296 times) (Table 1). We defined 
the rater’s Cumulative Score as the sum of the 127 individual scores given by each rater. Mean 
cumulative score from the African raters was higher, 148 ± 27.78 (range 110 to 176) compared to 
Europeans 112.20 ± 27.48 (range 84 to 142). 
To assess whether the two groups of physicians had the same perception of dysmorphism in African 
patients we calculated the inter-rater coefficient of agreement. The kappa-coefficient was 0.29, 
corresponding to a fair agreement between the 2 groups.  
Table 1. Count of times each individual score has been used by each physician and group. 
  African Physicians European physicians 
Raters 1 2 3 4 5 Total A B C D E Total 
Score 0 58 26 20 42 39 185 80 54 75 48 39 296 
Score 1 28 26 49 9 48 160 10 22 17 34 34 117 
Score 2 41 75 58 76 40 290 37 51 35 45 54 222 
Total 127 127 127 127 127 635 127 127 127 127 127 635 
Legend: Columns 1 to 5 correspond to African raters and A to E to Europeans; Rows contain number of times the 
score in the first column has been use by the rater. For instance the African rater 1 attributed the score 0 to 58 
photos and all 5 African physicians used the score 0 a total of 185 times out of 635.  
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1.17.3.2 Correlation between score and number of minor anomalies on the face 
Besides the evaluation of the facial gestalt, a detailed dysmorphic examination was done during the 
physical examination (A.L, K.D., P.L.), during which all minor facial anomalies were recorded. We 
counted the number of minor facial features for each individual. We wanted to see whether the 
gestalt-based scoring for a patient correlated with number of minor anomalies he carried. To derive 
the correlation for scores from African raters, we tailed the scores from the 5 raters and did the same 
for the number of minor anomalies. The Pearson correlation coefficient was 0.409 (p=0.000) for African 
raters and 0.417 (p=0.000) for Europeans, consistent with medium correlation effects in both groups. 
 
Figure 2. Relation between mean score and number of minor dysmorphism. The mean score shows an 
increase almost proportionate to number of minor anomalies. 
 
1.17.3.3 Assessment of FACE2GENE for Down syndrome matches 
Among the 17 Congolese DS patients, Face2Gene reported matches with DS (i.e. within the first 10 
matches) only in 7 (35.29 %). For the 20 Belgian DS patients, a match was found in 16 (80 %). In depth 
analysis showed that for the 17 Congolese cases, Down syndrome was the first suggested match in 2, 
ranked within the first 5 matches in 5 and within the first 10 in 6 of them (table 2, figure 2). In the 20 
Flemish cases,  Down syndrome was the first suggested match in 8, ranked within the first 5 matches 
in 13 and within the first 10 in 17 of them (table 2, figure 3).  
Table 2. Ranking of DS match 
  Congolese  (n = 17) Flemish (n = 20) 
Within first 10 6 16 
Within first 5 5 13 
Ranks first 2 8 
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Figure 3. Ranks for DS match. 3A. shows the frequency of DS match in each ethnic group and for each 
rank. Note the high frequency of Congolese individuals without DS match (rank 11); 3B. Shows the 
proportion of DS matches at cumulated ranks. 
 
The mean rank in the Congolese patients was 8.29 (Figure 4), which is significantly lower than the mean 
4.65 recorded from Europeans (p = 0.004446 ± 0.000674). 
 
Figure 4. Mean ranking of a match “Down syndrome” in Congolese and European Down syndrome patients 
When we considered that DS ranking within the first 10 suggested diagnosis as a positive result, 
Face2Gene showed an Accuracy of 0.35 in Congolese against 0.8 in Belgians and a Precision of 1 in 
both groups.  
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1.17.4 Discussion.  
In a first part of this study, we have compared the way African and European clinicians with experience 
in dysmorphology evaluate facial dysmorphism. In a series of 127 individuals with ID, there was a good 
correlation between the number of minor facial anomalies, assessed independently during the clinical 
examination and a “gestalt” evaluation of the facial dysmorphism. This indicates that a “gestalt” 
evaluation by an experienced clinician is a valuable alternative for a detailed evaluation and counting 
the number of minor anomalies. The higher the number of minor facial anomalies, the more likely a 
person was regarded as dysmorphic, which is not unexpected. Of interest, on average, European 
clinicians were less likely to score an individual as dysmorphic compared to the African clinicians, 
regardless of the number of minor facial anomalies. We have no clear explanation for this observation, 
but this variable may need to be taken into account in dysmorphology studies in different ethnicities. 
It would be of interest to perform the inverse experiment, i.e. scoring faces of Caucasian children with 
ID by both groups, to see whether the same differences in scoring are made.  
These results also indicate that there is an important subjective aspect in the evaluation of (facial) 
dysmorphism. For this reason, there is interest in tools to obtain an objective evaluation or even a 
possible syndrome diagnosis. Online applications that can establish a syndrome diagnosis based on a 
facial picture of a person are becoming a reality. Such systems offer the potential  for a universal, rapid 
and cheap syndrome diagnosis. The performance of such systems is obviously a critical factor. We 
tested the Face2Gene tool, because we wished to compare its performance in Europeans and Africans.  
Our data indicate that the system has a high precision in both groups. However, the accuracy in the 
Caucasian cohort was much higher compared to the African cohort. This is interesting, since it confirms 
that there are differences in facial appearance of Caucasian versus African Down syndrome patients. 
The most likely explanation why Face2gene is underperforming in Congolese Down syndrome is that 
the tool is trained mostly with Caucasian cases. We therefore anticipate that the performance will 
improve when the system is trained with more Down syndrome cases from Central Africa. A 
collaborative effort to test this hypothesis is ongoing. Likewise, we expect that the efficiency of 
Face2Gene might improve if an increasing number of cases with a known diagnosis are uploaded.  
The current experiment suffers from a number of limitations. First, the number of cases included was 
limited. Also the Face2Gene application is an emerging tool and the number of training cases included 
might still be insufficient to permit an optimal performance. Most importantly, from a clinical point of 
view, the cases we tested were young children and adolescents, but no neonates. An early, neonatal 
diagnosis of Down syndrome is important for correct counselling and adequate follow-up. Given the 
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changing facial phenotype with ageing, more studies are needed to evaluate the performance of 
Face2Gene with neonates with Down syndrome.  
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Figure 6. Syndrome matches by Face2Gene in Flemish Down syndrome cases  
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KEY CLINICAL MESSAGE 
Patients with Williams-Beuren Syndrome can be recognized clinically, given the characteristic 
dysmorphism, intellectual disability and behaviour. We present a Congolese boy who was diagnosed 
only when he was 8.2 years old despite the typical WBS facial characteristics. His intelligence and 
behaviour profile were influenced by a meningitis and coma at the age of 2 years, resulting in a 
profound intellectual disability and atypical behaviour. The present report supports the notion that 
infections constitute a major pitfall for genetic diagnosis and should warn clinicians that a genetic 
disease may be masked by superimposed infectious diseases and brain damage. 
Keywords: Williams Syndrome, phenotype, Central Africa, Democratic Republic of Congo. 
1.18.1 Introduction 
Williams-Beuren Syndrome (WBS) is one of the most common recurrent microdeletion syndromes, 
with an estimated incidence varying from 1 in 7500 to 1 in 20.000 births (Morris and Mervis 2000; 
Stromme, Bjornstad et al. 2002). Patients can be recognized clinically, given their characteristic 
features, encompassing congenital heart defect, typically supravalvular aortic stenosis (SVAS) and/or 
peripheral pulmonary stenosis, short stature/growth retardation, recognizable facial dysmorphism, 
developmental delay and intellectual disability, distinct behavioural phenotype, and, in some 
instances, hypercalcemia. Facial dysmorphism includes a wide mouth, short nose with bulbous or 
upturned nasal tip, long philtrum, thick everted vermillion of the lips, bitemporal narrowing, periorbital 
fullness, full cheeks and a small jaw and the characteristic stellate pattern of the iris (Merla, Brunetti-
Pierri et al. 2010; Patil, Madhusudhan et al. 2012). The cognitive profile in WBS ranges from mild to 
severe ID (Martens, Wilson et al. 2008; Merla, Brunetti-Pierri et al. 2010; Mervis and John 2010). 
Although acquisition of language is often delayed in WBS, they later develop good language skills and 
become talkative (Pegoraro, Steiner et al. 2014; Tekendo-Ngongang, Dahoun et al. 2014). Behavioural 
issues in WBS comprise anxiety, hyperacousis, attention problems, hypersociability or friendly 
behaviour, and strong affinity and interest to music (Doyle, Bellugi et al. 2004; Ng, Lai et al. 2013; 
Pegoraro, Steiner et al. 2014). Recognition of the typical dysmorphism and characteristic behaviour 
lead to a clinical diagnosis. 
Some cases are more difficult to diagnose, since they present with atypical features (Sakhuja, Whyte 
et al. 2015), or because they have a different ethnicity where the features may be different from those 
observed in Caucasians. For instance, African patients with WBS from Cameroon have been reported 
with incomplete WBS facial dysmorphism (Tekendo-Ngongang, Dahoun et al. 2014). Finally, cases with 
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a deletion smaller or larger than the recurrent 1.5 Mb 7q11.23 microdeletion may also present with a 
milder or more severe phenotype (Fusco, Micale et al. 2014). 
We here report a WBS patient from Central Africa carrying the recurrent WBS microdeletion who 
presented with a typical facial dysmorphism but more severe intellectual disability and atypical 
behavioural phenotype due to a confounding factor, i.e. meningitis with coma supposedly resulting in 
brain damage. 
1.18.2 Case description 
An 8.2-year-old Congolese boy was referred by his paediatrician to the genetic clinic at the University 
Hospitals of the University of Kinshasa, DR Congo, for evaluation of intellectual disability, allegedly 
resulting from an episode of meningitis and coma. He was born from unrelated, healthy parents after 
an uneventful pregnancy and delivery. At the age of 2 years, he wasn’t able to stand-up without 
support or build simple sentences although he could call names of his relatives. Four months later, he 
suffered from meningitis and remained in coma for 2 days. After recovery, he presented severe 
intellectual disability and complete loss of intelligible speech. His behaviour had changed, including 
hyperactivity, irritability, hypersensitivity to noise and episodes of aggressiveness against strangers. In 
contrast, he was friendly towards familiar persons and demonstrated a strong attraction to music and 
musical sounds. He was diagnosed with sequel from meningitis and was followed by a neurologist until 
the age of 8 years, when he was referred for a genetic evaluation.  
At that time, he had severe global growth delay with microcephaly (OFC 47 cm; -3.82 SD), short stature 
(length 109 cm; -3.43 SD) and low weight (17 kg; <-3 SD). Family history revealed that two siblings of 
the patient (Figure 1, panel A) died from infectious diseases. There were two other males with ID in 
the pedigree, related through their mothers. Unfortunately, these were not available for evaluation. 
Patient’s phenotype consisted of a triangular face with low set ears, long philtrum, flat nasal bridge, 
bulbous nasal tip, anteverted nostrils, pronounced nasolabial folds, large mouth, thick and everted 
vermillion of the upper and lower lips and a small jaw (Figure 1, panel B). He also had widely spaced 
nipples, a small penis, bilateral cryptorchidism and deep palmar creases. Cardiac ultrasound revealed 
bicuspid aorta with aortic insufficiency. 
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FIG 1. Pedigree and dysmorphic features 
Legend: 1A. Pedigree showing 3 males with ID, consistent with the X-linked inheritance; 1B. Clinical 
features. Note triangular face with low set ears, long philtrum, flat nasal bridge, bulbous nasal tip, 
anteverted nostrils, pronounced nasolabial folds, large mouth, thick and everted vermillion of the 
upper and lower lips and a small jaw, widely spaced nipples and deep palmar creases.    
 
Although the pedigree was consistent with X-linked ID, a clinical diagnosis of WBS was retained.  
Fluorescent in situ hybridization (FISH) was performed on nuclei from peripheral white blood cells 
using the commercially available Vysis LSI ELN Kit (Vysis, Abbott Laboratories. Abbott Park, Illinois, 
U.S.A.). A total of 100 nuclei were examined and a single ELN was observed in all of them, whereas the 
control probe always showed 2 signals. This confirmed the diagnosis of WBS (Figure 2A). Microarray-
CGH was performed using a stripped CytoSure™ ISCA v2 array 8x60k format (OGT, Oxford UK) slide, 
the CytoSure™ Genomic DNA Labelling Kits (Oxford, UK) and the Oligo aCGH & ChIP-on-Chip 
Hybridization Kits (Agilent, Santa Clara, CA, 95051 United States) following manufacturers’ procedures.  
This revealed the presence of a recurrent 1.57 Mb deletion arr [hg19]7q11.23 (72,634,874-
74,203,685)x1 (Figure 2B).  
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FIG 2. FISH and Array CGH ideograms 
Legend: 2A.Two interphase nuclei showing a single signal for the Elastin probe (red) and 2 signals  for 
the control probe (green); 2B. Chromosome icon and the zoom-in on the deleted region. 
1.18.3 Discussion 
We report on a central African patient with WBS, diagnosed at age 7 years. Mean age of diagnosis for 
WBS in Western countries is 3.5 years (Huang, Sadler et al. 2002; Ferrero, Biamino et al. 2007). The 
facial appearance in our patient was typical for WBS. When we uploaded his facial photograph to 
Fage2Gene tool without adding any further description, the WBS match ranked 5th based only on the 
gestalt.  
Several factors may have contributed to a delayed diagnosis. First, the facial dysmorphism in WBS 
evolves over age and may be discrete in infancy and early childhood (Huang, Sadler et al. 2002; Ferrero, 
Biamino et al. 2007; Patil, Madhusudhan et al. 2012). Second, in patients of African origin, the 
phenotype for several known genetic disorders shows differences from the typical “gestalt” as defined 
mostly in Caucasian patients (Tekendo-Ngongang et al., 2014).  
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Examples include the Fragile X syndrome (Schwartz, Phelan et al. 1988; McDonald-McGinn, Minugh-
Purvis et al. 2005; Tekendo-Ngongang, Dahoun et al. 2014). Also, our patient had no SVAS, one of the 
most characteristic features often leading to the diagnosis (Eronen, Peippo et al. 2002; Ferrero, 
Biamino et al. 2007). Finally, the clinical course of the patient was complicated by a superimposed 
meningitis at the age of 2 years. As the deletion in our patient corresponds to the classical WBS 
microdeletion, we assume that the severe speech deficit and profound intellectual disability in the 
patient are more likely a complication of the meningitis and coma. It is thus likely that an acquired 
condition modified the clinical course of the patient toward the more severe and atypical phenotype 
for WBS causing the delay in diagnosis. Such overlapping of genetic disease with an infectious disease 
is expected to be frequent in the developing world, where infections represent the major medical 
problem. As previously reported, infections are major cause for misdiagnosis of genetic diseases in 
developing countries (Lumaka, Mubungu et al. 2012). The present report supports the assumption that 
infection constitutes a major pitfall for genetic diagnosis and should warn clinicians working in 
developing world setting that a genetic disease may be masked by a intercurrent infectious disease. 
To date, only one report exists concerning  WBS in Central Africa (Tekendo-Ngongang, Dahoun et al. 
2014). Given the incidence of 1/7500 for WBS (Stromme, Bjornstad et al. 2002), this suggests that most 
cases remain undiagnosed. This is most likely due to a lack of knowledge and training in the field of 
dysmorphology and lack of access to genetic facilities in that part of the world.  
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1.19.1 Introduction 
Adrenal Hypoplasia Congenita (AHC) is a failure in development of the definitive adult adrenal cortex 
(Phelan and McCabe 2001). This rare disease affects about 1 in 12,500 live births (Laverty, Fortune et 
al. 1973) and can be inherited as an autosomal recessive or X-linked disease (Ostermann, Salvi et al. 
2006; Shaikh, Boyes et al. 2008). 
The X-linked AHC has variable clinical presentations (Merke, Tajima et al. 1999; Achermann, Meeks et 
al. 2001; Pelissier, Merlin et al. 2005) and associates a primary adrenal insufficiency with 
hypogonadotrophic hypogonadism (Wheeler, George et al. 2008). Symptoms of primary adrenal 
insufficiency may appear within 5 to 7 days after birth (Pelissier, Merlin et al. 2005). The disease usually 
evolves as a salt wasting syndrome. The newborn or infant presents with failure to thrive, feeding 
difficulties, including regurgitation and vomiting, diarrhea, dehydration, lethargy, hyperkalemia, 
metabolic acidosis and hypoglycaemia (Pelissier, Merlin et al. 2005; Limal, Bouhours-Nouet et al. 2006; 
Wheeler, George et al. 2008). The patient may present with an acute adrenal crisis comprising 
dehydration, lethargy, seizures or neurological distress, shock or sudden death, either occurring 
spontaneously or during stress provoking conditions like infections, gastro-intestinal disorders or 
surgery (Limal, Bouhours-Nouet et al. 2006). The adrenal insufficiency also results in a progressive 
hyperpigmentation of the skin secondary to the rise of the ACTH hormone (Pelissier, Merlin et al. 
2005). Some newborns also present with persistent physiologic jaundice and hepatomegaly (Limal, 
Bouhours-Nouet et al. 2006; Lin, Gu et al. 2006). Without early appropriate steroid replacement, the 
AHC is lethal (Wheeler, George et al. 2008; Li, Liu et al. 2010). The typical adolescent presentation of 
AHC is a hypogonadotrophic hypogonadism (HH), characterized by puberty delay, sometimes preceded 
by cryptorchidism. 
X-linked AHC is caused by deletions or mutations in DAX1 gene (which stands for Dosage-sensitive sex 
reversal, Adrenal Hypoplasia Congenita critical region on the X chromosome, gene 1; also called 
NROB1) (Lin, Gu et al. 2006; Shaikh, Boyes et al. 2008). The DAX1 gene consists of two exons of 1,168 
and 245 bp, respectively, separated by a 3,385-kb intron, and codes for an atypical, 470-amino acid 
member of the orphan nuclear receptor superfamily (Zanaria, Muscatelli et al. 1994; Guo, Mason et 
al. 1995).  DAX1 expression has been detected in the anterior pituitary, hypothalamic ventromedial 
nucleus, developing adrenal cortex, adult adrenal cortex, Sertoli and Leydig cells in the testis, and theca 
and granulosa cells in the ovary (Zanaria, Muscatelli et al. 1994; Guo, Burris et al. 1995; Ostermann, 
Salvi et al. 2006). More than 100 causal mutations in the DAX1 gene have been reported so far (Phelan 
and McCabe 2001; Lin, Gu et al. 2006; Li, Liu et al. 2010). 
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To date, no data on the clinical presentation of AHC caused by DAX1 mutations in central Africa are 
reported. Here we report a Congolese pedigree with many cases of unexplained male deaths and the 
detection of a novel DAX1 missense mutation in an obligate female carrier. 
1.19.2 Case report 
The proband and her husband are young, unrelated and of Congolese origin (III:10 and III:11 figure 2).  
She was referred for unexplained recurrent early death in her offspring. The first pregnancy ended as 
a miscarriage at 16 weeks during a malaria episode. The first child, a boy, was delivered at 38 weeks 
by C-section for maternal-fetal disproportion (figure 1A; IV:11 figure 2). After birth resuscitation was 
not needed. The male newborn had a birth weight of 3800 g (>P90), height of 48 cm (P25-P50), a head 
circumference (OFC) of 33 cm (P25-P50). No hyperpigmentation was noticed at birth neither were 
there dysmorphic features. At day 2, he presented with isolated jaundice. Because of a suspected 
neonatal infection, antibiotic treatment was installed for seven days and he received phototherapy 
during 4 days. Hormones and electrolytes levels were not tested. The jaundice disappeared after 5 
days, and he was discharged at day 9. He presented a progressive generalized hyperpigmentation and 
loss of weight even though he was regularly breast fed. There were no complications after his 
immunizations. On day 74, he presented an acute episode with lethargy and seizures, and resuscitation 
at an emergency department failed. Weight at that time was 3000 g (P3=4300g). No post-mortem 
examination was performed. The third pregnancy evolved normally. A male infant was delivered at 
gestational age of 39 weeks (IV:12, figure 2).  Birth weight was 3600 g (P75-P90), height 48 cm (P25-
P50) and OFC 34 cm (P50-P75). He was regularly breast fed. He presented a progressive 
hyperpigmentation of the skin (Figure 1B). At birth, he received BCG and first oral dose of poliomyelitis 
vaccines without complications. At 45 days of age, he received the second dose of poliomyelitis 
vaccine, the first dose of DPT (Diphtheria, Pertussis, and Tetanus) and hepatitis. The immunization was 
followed by an episode of fever and excessive urine production.  He initially received paracetamol and 
oral water supply at home. However, about six hours later he presented anuria, lethargy and inability 
to drink.  He died on the way to the hospital. No autopsy was performed. 
The family history revealed eleven other cases of early, unexplained deaths of male infants (Figure 2). 
In retrospect, it became clear that they all had presented progressive hyperpigmentation. No 
additional dysmorphism or malformations were noted. No biochemical tests were performed. 
However, the family history, which was compatible with an X-linked condition and the clinical features 
of hyperpigmentation and sudden deaths, raised the possibility of X-linked Adrenal Hypoplasia 
Congenita. This was confirmed by the detection of a DAX1 mutation in the proband. She carried a 
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heterozygous missense mutation c.1274G>T, (p.Arg425Ile). The substitution occurs in a highly 
conserved domain in the second exon of gene. This substitution leads to the replacement of Arginine 
by Isoleucine in the putative Ligand Binding Domain (LBD) of the protein with subsequent loss of 
function.  
Figure 1.  Proband’s children 
 
Legend Fig 1: 1A: first infant on day 4. Note jaundice on the face and hyperpigmentation elsewhere. 
1B: second infant on day 34. Note diffuse hyperpigmentation and failure to thrive. 
Figure 2. Pedigree of the family. 
 
Note the presence of 13 unexplained deaths in males, related through females, evoking the X-linked 
pattern of inheritance 
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1.19.3 Discussion 
We present a Congolese family with genetically confirmed X-linked Adrenal Hypoplasia Congenita. The 
proband is a heterozygous carrier of a novel missense mutation,   but two other different missense 
mutations in that position were previously reported: R425G and R425T (Lin, Gu et al. 2006). In 
retrospect, the first child in the family probably presented a progressive salt wasting syndrome, with 
failure to thrive, jaundice, and complicated by an acute adrenal crisis with sudden onset lethargy and 
seizures. The second child had normal initial evolution except for progressive skin hyperpigmentation. 
The triggering event was probably post-immunization fever. Two patients with acute adrenal crisis 
after DPT immunization were previously reported (Yang, Sujan et al. 2006). 
Corticoid replacement is the key treatment for this condition, with intravenous hydrocortisone as well 
as saline and glucose solutions during an acute adrenal crisis (Wheeler, George et al. 2008). The 
outcome depends on the time of diagnosis and initiation of treatment. Altogether, 13 unexplained 
hyperpigmented male infants were retrospectively identified in this pedigree.  
The real incidence of the CAH is not known. For the X-linked form, the incidence is estimated between 
1:140,000 and 1:1,200,000 children (Lin, Gu et al. 2006). However, currently, no reports exist on the 
occurrence of CAH in Sub-Saharan Africa. The most likely explanation is that this condition remains 
undiagnosed in the majority of cases in developing countries. A number of reasons exist for this 
misdiagnosis, including the high prevalence of neonatal infections and the similarity in clinical 
presentation of  adrenal insufficiency and neonatal infections, the lack of laboratories that provide 
routine hormone testing, the difficulty to recognize skin hyperpigmentation in a black person  and the 
poor medical genetic knowledge. In comparison with other developing countries, the Democratic 
Republic of Congo has the highest Neonatal Mortality Rate. About 29 % of neonatal deaths worldwide 
are due to neonatal infections (Lawn, Kerber et al. 2010). Therefore, many practitioners focus their 
attention on infectious diseases. Also, the AHC symptoms observed in the present cases such as sudden 
lethargy, seizures, fever, jaundice and hypoglycaemia mimic infections or cerebral malaria in infancy. 
The differential diagnosis of AHC includes Congenital Adrenal Hyperplasia (CAH), 
Adrenoleucodystrophy and exceptionally congenital defects of hypothalamus and pituitary (Ozer, Kaya 
et al. 2009). To resolve this, hormone measurements are required. However, in developing countries, 
such testing is mostly unavailable in primary, secondary and even in some tertiary care hospitals. 
Another major challenge is the assessment of the skin hyperpigmentation in the black population (Fig 
1). Clinicians have to rely on their experience in assessing skin colour, but more important is the 
description of the evolution of the intensity of the skin colour as reported by the parents. Finally, the 
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diagnosis was suggested by a careful analysis of the pedigree of this family, which leads to the 
recognition of an X-linked inheritance pattern. This illustrates the necessity for medical and clinical 
genetics to be part of the curriculum of medical school in developing countries.  
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1.20.1 Introduction 
Apert syndrome (OMIM 101200) is a rare genetic condition with an estimated prevalence of ~1 in 
70,000 live births and presenting craniosynostosis (premature and antenatal fusion of skull sutures) 
associated with  syndactyly of hands and feet (Ibrahimi, Eliseenkova et al. 2001; Bochukova, Roscioli 
et al. 2009). The phenotype can be variable, both regarding to the severity of the 
acrocephalosyndactyly or to the presence of additional manifestations (such as cleft palate or 
intellectual disability) (Park, Theda et al. 1995; Oldridge, Lunt et al. 1997; Lajeunie, Cameron et al. 
1999; Mundhofir, Sistermans et al. 2013). However, this variability cannot readily be explained by the 
underlying causal mutations. Indeed, majority of patients present with single nucleotide substitution 
in the linker  region between the immunoglobulin-like domains II and IIIa (IgII and IgIIIa) of the 
ectodomain of the Fibroblast Growth Factor Receptor 2 (FGFR2, OMIM 176943) (Wilkie, Slaney et al. 
1995; Oldridge, Lunt et al. 1997; Lajeunie, Cameron et al. 1999; Sakai, Tokunaga et al. 2001). Consistent 
with other paternal age effect mutations, those causing AS exclusively originate during 
spermatogenesis, have a gain-of-function (GOF) effect and exhibit a remarkable  enrichment in 
spermatogonia with ageing due to a protein-driven selective advantage from the mutant protein 
(Risch, Reich et al. 1987; Ibrahimi, Eliseenkova et al. 2001; Goriely, McVean et al. 2005; Bochukova, 
Roscioli et al. 2009; Goriely and Wilkie 2012).  As expected for any GOF mutation, the repertoire of 
mutations causing AS is limited. Two single nucleotide substitutions in the FGFR2 gene, c.755C>G; 
p.Ser252Trp (65 %) and c.758C>G; p.Pro253Arg (34 %), are recurrent in Apert Syndrome (Lajeunie, 
Cameron et al. 1999).  
Besides the two canonical single nucleotide mutations, rare consecutive double nucleotide 
substitutions involving the CpG dinucleotide at position 755_756 and changing Ser252 into 
Phenylalanine (c.755_756delCGinsTT; p.Ser252Phe and c.755_756delCGinsTC; p.Ser252Phe) have 
been reported in Apert syndrome (Oldridge, Lunt et al. 1997; Lajeunie, Cameron et al. 1999; Goriely, 
McVean et al. 2005). The rarity of p.Ser252Phe mutation is ascribed to the requirement that two 
consecutive nucleotides of the Serine at codon 252 need to be mutated (Goriely, McVean et al. 2005). 
Oldridge et al. reported the only patient carrying consecutive triple nucleotide substitutions in the 
linker region (c.755_757delCGCinsTCT) resulting in the change in two consecutive amino acids 
(Ser252Phe and Pro253Ser). Although Ser252Phe substitution is known to cause Apert syndrome, the 
patient carrying both Ser252Phe and Pro253Ser substitutions presented with the less severe Pfeiffer 
syndrome (Oldridge, Lunt et al. 1997; Kan, Elanko et al. 2002).      
Here we report a male patient and his mother, both affected with Apert syndrome, carrying a new 
heterozygous mutation and showing variable expression.  
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1.20.2 Clinical report 
1.20.2.1 Case descriptions 
A 42-day-old Congolese male infant was referred to genetic consultation at the University Hospitals, 
University of Kinshasa because of congenital malformations. He was the only child of unrelated parents 
and was born after an uneventful pregnancy and delivery. At birth, he presented with craniofacial and 
limb anomalies (Figure 1). At the time of consultation, his weight was 7.7 kg (P90), length 68 cm 
(P97=67.5 cm) and OFC 41 cm (P75-90). Craniofacial anomalies included craniosynostosis, midfacial 
retrusion, mild proptosis, hypertelorism, strabismus and tented upper lip (Figure 1A&B). The ears were 
mildly low set with overfolded helices. There was a bilateral symmetric type 2 hand syndactyly, 
according to the classification by Cohen and Kreiborg (Cohen and Kreiborg 1995), and bilateral post-
axial polydactyly. His feet showed bilateral and symmetrical type 1feet syndactyly (Cohen and Kreiborg 
1995). The palate was normal.  
The 44-year-old father, unavailable for clinical examination, was reported to have normal development 
and to be free of obvious malformations. The index’s mother was born from a 49 years old father and 
was 33 years old when she gave birth to the index. She had mild intellectual disability, OFC of 53 cm 
(P10), length of 176 cm (P90-P97), no major craniofacial malformations but exhibited mild 
exophthalmos, externally rotated ears with unfolded helix (Figure 1H&I). There was symmetrical and 
bilateral type 1 hand syndactyly, bilateral medial deviation of toes, more pronounced on the first toe, 
and type 1 feet syndactyly  of (Cohen and Kreiborg 1995).  
The maternal grandfather had died by the time of consultation as well as 3 maternal uncles of the 
index. None of them reportedly had facial or limb malformations. 
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Figure 1. Photographs of patients 
Legend: A-G: index. A & B: Frontal and lateral view of the index: note prominent front, depressed midface, 
exophthalmos, hypertelorism, strabismus, overfolded helix, anteriorly rotated lobule and low set ears, tented 
upper lip, oxycephalic skull ; C, D & E: Index’s hands. Note abnormal position of the thumb and syndactyly of 
fingers II-IV; F&G: index, bilateral syndactyly of toes H-L: index’s mother. H&I: frontal and lateral view of the 
mother’s head. No major skull malformations observed. Note exophthalmos, protruding ears with unfolded helix; 
J: bilateral syndactyly of fingers II-V; K&L: toe syndactyly on right and left foot. 
Radiographic investigations (Figure 2) confirmed syndactyly in the mother (type 1) and in the index 
(type 2 in hands and type 1 in feet), showed deviation of thumbs and duplication of terminal fifth 
phalange, classical type 1first metatarsal pattern, described by Cohen et al. (Cohen and Kreiborg 1995) 
as deviated  first metatarsal of halluces with proximal phalanx located on its fibular side, in the index; 
bilateral carpal-metacarpal coalition made up with proximal fusion of fourth-fifth metacarpal and 
fusion of carpal bones made, and small extra bone between first and second metacarpal of thumbs in 
his mother.  
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Figure 2. Radiographs of hands and feet 
Legend: index’s hands showing deviation of thumbs and duplication of terminal fifth phalange (A&B); Mother’s 
hands presenting with bilateral carpal-metacarpal coalition made up by proximal syndactyly of fourth-fifth 
metacarpal and fusion of carpal bones, and small extra bone between first and second phalanx of thumbs (C&D); 
Index’s feet with classical type 1 first metatarsal pattern (E&F); mother’s feet with fibular deviation of first 
metatarsal of great toe and coalition tarsal bones (G&H). 
1.20.2.2 Molecular testing 
Genomic DNA were extracted locally in the Genetics laboratory, Kinshasa from venous blood by the 
salt saturation method as previously described (Miller, Dykes et al. 1988). The exon seven of the 
Isoform 1 of the FGFR2 (RefSeq NM_000141.4) was amplified using the following M13-tagged primer 
pairs: 
Forward primer 5’-TGTAAAACGACGGCCAGTGAGGTCACTGACAGCCCTCT-3’ and Reverse primer 5’-
CAGGAAACAGCTATGACCCCCCTACTCCATAGTTCCCTTC-3’.  
The 50 µl amplification reaction contained 5 µl of DNA (50 ng), 5 µl of PCR reaction buffer+Mg2+ 
(Roche), 5 µl of each Primer solution (2.5 pmol/µl), 5 µl of dNTP’s (2 mM), 0.5 µl (2.5 U) of Taq DNA 
Polymerase (Roche) and 24.5 µl of Ultrapure water (Baxter). The PCR was run on a 2720 Thermal Cycler 
(Applied Biosystems, Foster City, CA 94404 USA) using the following program: initial denaturation stage 
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at 95 °C for 5 minutes; 35 cycles of denaturation at 95 °C for 30 s, annealing at 58 °C for 30 s and 
elongation at 72 °C for 45 s; and a final extension stage at 72 °C for 5 minutes. PCR products were 
sequenced on ABI 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA 94404 USA) using Big Dye 
termination method.  
Both the mother and her son carry a substitution of three consecutive nucleotides in the linker region: 
RefSeq NM_000141.4:c.756_758delGCCinsCTT (NC_000010.10:g.123279674_123279676delinsAAG). 
The mutation overlaps two adjacent amino acids and results in a synonymous mutation for  Serine at 
position 252 and in a missense mutation for neighbouring Proline (p. Pro253Phe) (Figure 3). There was 
no evidence for mosaicism in the mother.  
 
Figure 3. Structure of FGFR2, previous and current mutations 
Legend: The top panel shows the FGFR2 structure. Amino acid Ser252 and Pro253 are marked by filed black ovals. 
L, Leader sequence; IgI, IgII and IgIII for Immunoglobulin-like domains 1, 2 and 3 respectively; A, Acidic box; C; 
CAM homology domain;  BHS, heparin-binding site in the IgII; TM, Transmembrane helix; TK1 and TK2 represents 
spit-Tyrosine Kinase domain. Middle panel shows the normal amino acids sequence at positions 252 and 253 in 
the IgII-IgIIIa linker region, their nucleotide counterpart, and previous and current mutations in the region 
responsible for Apert Syndrome. The bottom panel consists of electropherograms showing mutation in the index 
and his mother for the current report. Nucleotides affected by the mutation are surrounded by the red box. 
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We analysed 210 chromosomes from 105 unrelated Congolese screening for population specific 
polymorphisms in the linker region by sequencing (data not shown). None of them had variations in 
this region.  
This new mutation was submitted to ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar/intro/) 
and received the accession number (rs387907372: delGCCinsCTT). 
1.20.3 Discussion 
We present a Congolese infant with the classical phenotype of Apert syndrome, i.e. severe 
craniosynostosis and syndactyly of hands and feet. His mother was less severely affected, presenting 
mainly limb malformations. Such an intrafamilial variability was previously reported in monozygotic 
twins (Breugem, Fitzpatrick et al. 2008) and remains unexplained. 
FGFR2 mutations causing Apert syndrome mostly occur during spermatogenesis and exhibit a very 
strong paternal age effect (Goriely, McVean et al. 2003; Goriely and Wilkie 2012). The fact that the 
maternal grand-father was 49 years at the moment the index’s mother was born is likely a risk factor 
in this family. 
Interestingly, we observed a novel, previously undescribed FGFR2 mutation causing Apert syndrome: 
p.Pro253Phe. Consistent with the previously reported AS causing mutations, this new mutation 
substitutes the Proline by a more bulky side-chain amino acid (Grantham 1974; Dufton 1997; 
Bochukova, Roscioli et al. 2009). This is the second alternative amino acid mutation ever reported 
affecting the proline at position 253 after the p.Pro253Arg (Lajeunie, Cameron et al. 1999). 
Genotype-phenotype correlations in Apert syndrome suggested that mutations of residue Ser252 were 
correlated with more severe craniofacial defects whereas mutations of residue p.Pro253 were 
associated with more severe limb anomalies (Lajeunie, Cameron et al. 1999; Ibrahimi, Eliseenkova et 
al. 2001; Agochukwu, Solomon et al. 2013). The absence of obvious skull defect in the mother together 
with carpal coalition would be consistent with this observation.  
A second intriguing observation is the presence of a mutation in three consecutive nucleotides: 
c.756_758delGCCinsCTT. Such variants, multiple nucleotide substitutions are not frequently observed 
in the human genome (Smith, Webster et al. 2003) and are rare in human genetic diseases (Kondrashov 
2003). Three Apert syndrome patients have been reported carrying consecutive double nucleotide 
substitutions in the linker region (c.755_756delCGinsTC and c.755_756delCGinsTT) leading to 
p.Ser252Phe substitution and to Apert syndrome (Oldridge, Lunt et al. 1997; Lajeunie, Cameron et al. 
1999; Goriely, McVean et al. 2005). Oldridge et al. reported one patient with a triple consecutive 
nucleotide substitutions in the linker region (c.755_757delCGCinsTCT) changing Ser252 and 
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Pro253into Phe and to Ser respectively. Despite the presence of Phe at position 252, the mutation 
resulted in Pfeiffer syndrome, a less severe form of acrosyndactyly (Oldridge, Lunt et al. 1997). 
Substitution of multiple nucleotides may in fact reflect trans-located single nucleotide mutations. 
Maternal family members were not available for testing, but transmission of all 3 nucleotide variants 
from mother to son together with absence of polymorphism essentially proves that all three are in cis. 
The mechanism leading to the substitution of multiple adjacent nucleotides is still under discussion. 
First, the substitution of multiple consecutive nucleotides also termed Tandem Base Substitution (TBS) 
may have occurred in one single event (Averof, Rokas et al. 2000; Kondrashov 2003; Bazykin, 
Kondrashov et al. 2004; Chen, Ferec et al. 2013). Depending on the size of the TBS, mechanisms may 
include transient hypermutability, chromothripsis, gene conversion, in situ inversion or Alu insertions 
(Whelan and Goldman 2004; Bochukova, Roscioli et al. 2009; Chen, Ferec et al. 2013). Second, the 
mutations may have arisen as a number of independent consecutive events, each affecting one 
nucleotide at once (Averof, Rokas et al. 2000; Whelan and Goldman 2004). Such a pattern was 
previously observed in a patient with FGFR2, 755_756CG>TC substitutions whose mother was normal 
and father was heterozygous carrier of a 755C>T substitution only. (Goriely, McVean et al. 2005).  
When applied to our case, three putative first events could be proposed: c.756G>C (p.Ser252Ser, a 
synonymous mutation), c.757C>T (p.Pro253Ser) or c.758C>T (p.Pro253Leu). Of the three possibilities, 
the first appears to be the most likely first event, since it may remain silent and allow adjunction of 
further more pathogenic hits as in the report from Goriely et al. 2005. This unique mutation is the first 
mutation ever described in an Apert patient from Central Africa. Therefore, we hypothesized that our 
patients could harbour two true mutations in association to an adjacent population specific variant, 
c.756G>C synonymous SNP. In order to verify this assumption, we reviewed existing databases. The 
c.756G>C was not reported in any of them; however, a c.756G>A (C>T on the positive strand) 
synonymous variant was reported in one African-American chromosome out of 13005 total 
chromosomes in the ESP cohort population (rs138769323 in dbSNP builds 134-137), allowing us to 
calculate a prevalence of 0.00015. Although this region was not known as polymorphic in available 
databases, and given that sequence data from Congolese population are not available in existing 
databases, we undertook to exclude a putative Congolese specific polymorphism. We sequenced the 
FGFR2 exon IIIa in 105 controls DNA samples (210 chromosomes) from the Congolese population. 
These samples came from clinically normal parents of patients with Intellectual 
Disability/Developmental Delay (ID/DD) recruited in Kinshasa, DR Congo in the framework of a study 
on the genetics of ID/DD. None of the controls carried a nucleotide variation at nucleotide positions 
756_758. 
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In conclusion, we report on a novel and unique mutation involving three adjacent nucleotides. The 
present report underscores the usefulness of reaching a molecular diagnosis, even in cases with a well-
known genetic condition and where the spectrum of mutations is known. Only by this way rare and 
novel mutations can be discovered, leading to further insight into their pathogenesis. Moreover, it is 
tempting to speculate that the present observation is linked to the patients’ Central African origin, a 
population which is poorly accessible for genetic studies thus far.  
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GENERAL DISCUSSION. 
The main aim of this study was to contribute to the understanding of the genetic aetiology of ID in 
Central Africa. For the first time, we present data on a comprehensive and integrated clinical and 
(molecular) genetic study on the aetiology of ID in a central African country, the DR Congo.  
1.21 Understanding the genetic aetiology of ID in Kinshasa 
Overall, in the cohort we investigated, we find likely genetic causes in 34/127 patients (26.8 %). This 
yield is very similar to studies performed in other countries (Battaglia, Bianchini et al. 1999; Rauch, 
Hoyer et al. 2006; Bernardini, Alesi et al. 2010). Likewise, as in other studies before the introduction of 
NGS, chromosomal aberrations are the most common cause of ID, with Down syndrome being the 
most frequent  (Battaglia, Bianchini et al. 1999; Devriendt, Holvoet et al. 2003; Rauch, Hoyer et al. 
2006; Ropers 2008). In 10 out of 86 (11.62 %) patients with ID of clinically unknown aetiology we have 
found a submicroscopic chromosomal imbalance, and of interest, 4 of the 11 CNV’s were recurrent 
CNV’s, caused by a flanking low copy repeats. We did not identify a single fragile X patients. However, 
in this study we have confirmed an X-linked recessive disorder in two brothers, i.e. Partington 
syndrome and in one boy, a possible X-linked disorder caused by a variant in the TAF1-gene was 
identified. By means of exome analysis, we identified 1 possible autosomal recessive metabolic 
disorder. The majority of cases (65 %) remains without diagnosis, which compares well to other studies 
in the Caucasian population, where, using a similar approach, a diagnosis is rarely reached in more 
than 50% of patients (Battaglia, Bianchini et al. 1999; Devriendt, Holvoet et al. 2003; Rauch, Hoyer et 
al. 2006).  
The recent introduction of exome studies, which allow an unbiased genome-wide screening for SNV’s 
causing ID, has shown that the aetiology if ID is highly diverse. Nevertheless, mutations in certain genes 
are more prevalent. For instance, mutations in ARID1B, SATB2, SYNGAP1, ANKRD11, SCN1A, DYRK1A, 
STXBP1, MED13L were observed in 0.5 to 1% of cases (Deciphering Developmental Disorders Study. 
2015) (DDD 2015). It will be of interest to study a larger cohort of “unknown” Congolese cases with ID 
by means of exome analysis, to confirm our hypothesis that, similar to the CNV’s,  the same monogenic 
disorders are also frequent in Central Africa. 
The results of this study show for the first time that genetic factors are a major cause of ID in the DR 
Congo, as observed in other countries. Moreover, the same disorders were diagnosed as elsewhere. 
For the majority of the conditions diagnosed, such as Partington and Smith-Magenis syndrome and the 
various chromosomal imbalances, these represent the first cases ever reported in this part of the 
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world. Whereas the scientific value of reporting “the first case” of a specific syndrome appears to be 
limited from a Western point of view, this has significant impact on the local community. This is 
important evidence to fight false believes concerning the cause of ID and congenital malformations. 
To date, most persons still hold the opinion that ID has a supernatural cause (Abasiubong, Obembe et 
al. 2008; Kromberg, Zwane et al. 2008; Njenga 2008). In teaching health care workers and educating 
the public at large on ID, the fact that genetics have an important role can now be illustrated by data 
from our own country.   
1.22 Limitations of the study 
The diagnostic process was limited due to local circumstances.  
First, no imaging studies could be performed. For instance, in children with developmental delay or ID 
with macrocephaly or microcephaly, brain imaging is standard practice (Battaglia, Bianchini et al. 1999; 
Balci, Sawyer et al. 2015). Obviously, more diagnoses could have been made if this was available. 
Likewise, the suspected diagnoses of acquired brain injury could have been substantiated.  
Also, the genetic studies were not complete in all patients. One obvious reason is that exome analysis 
is still very expensive and could therefore only be performed in a subset of well-selected cases. 
Likewise, for financial reasons, microarray-CGH was done using recycled slides. Our protocol to strip 
the slides did perform well for 60k slides but not for 180k slides, resulting in a less than optimal 
resolution for our microarray-CGH analyses. Also, some DNA samples were missing. One reason is that 
access to parents was difficult. Parents were met during the recruitment process and sometimes a 
second time when results were communicated during one of the follow-up visits to Kinshasa. Often, 
only one of the parents was available, mainly the mother. Also, since genetic analyses were done in 
Leuven, biological samples had to be transported from Kinshasa to Leuven. The quality of certain 
samples suffered from this, and as a result, we did not obtain genetic data on the complete cohort.  
The present results are not necessarily representative of all children with ID in Kinshasa. There is a 
clear bias in the recruitment of the patients, who were ascertained in institutions and schools for 
children with ID. In the absence of a public schooling or social security system, parents  face a high cost 
to send their children to school. Therefore, the families we encountered during our study are mostly 
privileged ones. Also, very few children presented cerebral palsy, despite the fact that from other 
sources we know that this is common in developing countries (Durkin 2002; Bergen 2008; Van Rie, 
Mupuala et al. 2008; Adnams 2010). From our contacts with a parents’ association for children with 
ID, we learned that the majority of them suffered from cerebral palsy. Likely, these children often do 
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not attend the schools we included in our study. Also, only very few children present with a major 
malformation. It is likely that this is associated with a high mortality, but also a reduced likelihood of 
receiving school education.  
We did not diagnose a single case of Fragile-X syndrome in our cohort. It is unlikely that Fragile-X 
syndrome is absent in this country. Most likely, this is due to the small size of the study (including only 
94 boys), but may also be explained by a combination of factors causing a recruitment bias. The 
distribution of FMR1 CGG alleles is similar to other African groups and African-American (Crawford, 
Zhang et al. 2000; Peprah, Allen et al. 2010; Essop and Krause 2013). We have identified 2 carriers of 
intermediate alleles, which is an indirect clue that fragile X patients could be identified in a bigger 
cohort. In order to get more insights in the incidence and presentation of Fragile-X syndrome, we plan 
to focus on a cohort of familial ID, i.e. families with affected brothers or with pedigrees compatible 
with an X-linked inheritance. Also, screening of a cohort of new-borns to determine the incidence of 
the FMR1 premutation will yield more information. 
1.23 Clinical parameters and the chance of reaching an etiological diagnosis  
We also wished to define clinical parameters associated with a higher chance of reaching an etiological 
diagnosis. Especially in a country where access to expensive genetic testing is almost absent, a clinical 
approach will remain the cornerstone of reaching an etiological diagnosis. In this study, we have 
reached a clinical diagnostic in 24 out of the 127 patients (19 %). The clinical diagnosis of syndromes is 
challenging and requires an expertise that can only be gained by training under supervision by 
experienced experts. We therefore explored how certain clinical data could predict the likelihood of 
reaching a specific diagnosis or aid in the selection for further genetic testing.  
Previously, it has been shown that the presence of dysmorphism and/or major malformations 
increases the likelihood of detecting a chromosomal imbalance (Breckpot, Thienpont et al. 2010; 
Battaglia, Doccini et al. 2013; Shoukier, Klein et al. 2013). Our study is consistent with this, though the 
number of cases with a major malformation or with a chromosomal imbalance was too small to allow 
a proper statistical evaluation. Eight out the 10 individuals with a chromosomal imbalances found by 
microarray-CGH were dysmorphic, with the exception of the patient with a del15q11.2 and the carrier 
of the del2q24.3.  
Another way to reach a syndrome diagnosis is to replace the “human eye” by an expert syndrome 
recognition system starting from digitalized facial pictures. Syndrome databases such as POSSUM or 
London Dysmorphology Database allow the selection of syndromes matching the description of 
132 
 
features in a case. However, limiting factors include variability in expression of most syndromes, the 
difficulty to accurately and objectively describe dysmorphic features and often, the lack of specific 
features. Computer analysis of digitalized 2D or 3D pictures has been applied as a research tool, and 
more recently, user-friendly tools have been made available to support the clinical diagnosis of 
children with unknown syndromes. The most advanced of these systems if Face2Gene 
(http://www.fdna.com/face2gene/). The potential of such a system is huge, especially in an 
environment where access to expertise is lacking. Imagine the situation of a child born in a small village 
in Central DR Congo, with a syndromic aspect and a suspected diagnosis of Down syndrome or trisomy 
18. Uploading a picture of the child onto the online tool may support or refute this diagnosis. The 
logistics needed for this are accessible to any physician, since mobile telephones are an established 
means of communication in the country. However, performance depends on a high specificity and 
sensitivity of the tool. In its turn, this depends on training the system by a large number of clinical 
pictures of existing patients. Therefore, on can expect that such systems will probably only perform 
ideal for the more common syndromes. In addition, and more importantly for developing countries, 
we have shown that training with Caucasian patients only is not sufficient (see also discussion below).  
Testing for fragile X is one of the routines testing for ID in Western countries. In limited resource 
setting, it is very important to preselect patients for further testing and avoid unnecessary and costly 
testing. For that reason, pre-screening tools such as clinical checklists may be invaluable in Africa. Many 
studies have designed, used or adapted checklists to screen potential fragile-X patients (Hagerman, 
Amiri et al. 1991; Giangreco, Steele et al. 1996; de Vries, Mohkamsing et al. 1999; Maes, Fryns et al. 
2000; Guruju, Lavanya et al. 2009). In this study, we explored the usefulness of 3 fragile-X screening 
lists. Since fragile-X is absent in our cohort, we cannot draw final conclusions about the checklists. 
However, one remarkable result with these checklists is the large number of false positives, mainly due 
to the high prevalence of behavioural characteristics such as hyperactivity. This may indicate that 
existing screening lists for other conditions will need to be adapted to the local situation. When 
Congolese fragile X patients will be identified, it will be interesting to pursue the assessment and 
improvement of the checklist for their use in the DR Congo. 
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1.24 Variability in expression of genetic syndromes 
Another aim of this study was to gain insight into the variability in clinical expression of specific genetic 
disorders in Central Africa.  
We diagnosed several conditions clinically, e.g. Down syndrome, Partington syndrome, Williams 
syndrome. Clearly, the features in these conditions are very similar to those observed in the West. 
However, there are differences in facial features.  
Differences in clinical presentation may result from differences in ethnic background. As previously 
stated, Face2Gene is a tool that compares in an objective way the digitalized facial features of a child 
with dysmorphic features with a library of known syndromes. When we analysed a cohort of Congolese 
individuals with Down syndrome we noted that they were less easily recognized as Down syndrome 
compared to Flemish Down syndrome cases. This shows that there are ethnic differences in the facial 
presentation of Down syndrome, corroborating previous reports that the facial phenotype has ethnic 
differences for certain syndromes (McDonald-McGinn, Minugh-Purvis et al. 2005; Talbert, Kau et al. 
2014; Tekendo-Ngongang, Dahoun et al. 2014).  
Also, there appears to be differences in behavioural aspects. From the Fragile-X screening lists, we 
noted that many children have high scores on behavioural items such as hyperactivity. Whether this is 
a true difference in behaviour or is due to over-scoring by the parents remains to be investigated. Of 
interest, we did not clinically recognize the child with Smith-Magenis syndrome. One reason is that the 
behavioural aspects, which typically are an important guide towards the diagnosis, did not stand out 
in this child. No sleeping difficulties were reported either. More research is needed into possible 
differences of behavioural phenotype for this and other syndromes. 
The variability in clinical expression may result from effects of environmental factors on the course of 
the disease. One of the main differences with studies in developed countries is the environment in 
which Congolese children grow up. Birth injury, infectious diseases, malnutrition, etc, have a major 
impact on the health of children (Durkin 2002; Bergen 2008; Van Rie, Mupuala et al. 2008; Adnams 
2010). Indeed, we also found that in our cohort of patients, infections (such as meningitis) were 
common. However, in only few of them, an acquired brain insult was thought to be the cause of their 
ID. On the other hand, infections may influence the clinical manifestations, and one risks to overlook 
a genetic diagnosis, masked by an intervening environmental insult. For instance, we describe a young 
boy with the classical somatic phenotype of Williams syndrome. Surprisingly, he has severe ID and 
absent speech. The genetic mutation was the recurrent 1.57 Mb deletion in 7q11.23 causing this 
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syndrome. However, at age 2 years, he suffered from meningitis and coma, and lowered intellectual 
capacities, most likely due to brain damage. The same is also illustrated by the family we diagnosed 
with congenital adrenal hypoplasia, an X-linked condition. The family presented with multiple boys 
dying at young age due to infections. A suspicion of a genetic cause was raised when the pedigree 
revealed an X-linked inheritance pattern. Additional signs were also present, including the darker skin 
pigmentation (melanodermia), due to an increased ACTH production. 
Last but not least, the difference may just be due to the subjective interpretation by the clinicians. It is 
well known that the description of the phenotype is a subjective process that is influenced by the level 
of training and the experience of the clinician. In this study, we have shown that the ethnic origin of 
the clinician also influences his perception of clinical phenotype. Only medium inter-ratter agreement 
was found between 5 African clinicians and 5 Europeans when we ask them to score the facial gestalt 
of 127 Congolese patients.   
1.25 Causes of and variability in genetic mutations observed in Congolese patients with a 
genetic disorder 
During our doctoral training, we came across with a Congolese family with a child and his mother 
presenting typical features of Apert syndrome. About 99 % of cases are explained by 2 amino acid 
changes. Interestingly, the mutation analysis revealed a new mutation involving 3 consecutives 
nucleotides in the hotspot for Apert syndrome. This new mutation expanded the Apert syndrome 
mutation spectrum. However, it is remarkable that the first patient with Apert syndrome ever to be 
studied genetically in Central Africa carries a highly unusual mutation, raising the possibility that the 
specific African genetic background could somehow be at the basis of this.   
Currently, very little is known about the causes of mutations. Advanced maternal age is the main  risk 
factor for aneuploidies. The advanced maternal age in the majority of Down syndrome cases in our 
cohort is in agreement with this. Advanced paternal age is a risk factor for de novo SNV’s. However, 
our study cannot address this question. One of the well-known mechanisms of copy number variations  
are unequal crossing-overs between low copy repeats (LCR). This results in recurrent, relatively 
common microdeletions or duplications, which share a same size (flanked by the LCR’s) and often a 
recognisable phenotype. Also in our study, of the 11 submicroscopic imbalances, 4 were recurrent 
ones. This indicates, not surprisingly, that the same mechanism also operates in the Central-African 
genome.    
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1.26 Future prospects 
This study, its results and limitations highlight challenges for the introduction of human and medical 
genetics in developing countries and illustrates also the opportunities for such an exciting discipline in 
Africa. The main challenge now is to translate these findings to provide a better care for patients and 
families.  
From a clinical point of view, it is clear that a genetic evaluation must be part of the workflow of any 
child with ID. However, this requires knowledge and expertise in this field. The work performed during 
this thesis has significantly contributed to this. Next, once an etiological diagnosis is reached, the 
existing guidelines for the follow-up and guidance of individuals with specific syndromes should be 
implemented. Given the variable environment, the existing protocols should be evaluated and 
probably be adapted. This will be mostly important for the more frequent syndromes. A future study 
we therefore envisage is a clinical study in children with Down syndrome, evaluating the different 
medical and developmental manifestations and their treatment, based on the existing international 
guidelines.   
Finally, the data should be communicated to the families in the genetic counselling process. This is 
challenging, since we must take into account the specificities of each population. A person's needs are 
influenced by social, cultural, religious and legal factors that vary in different regions around the world. 
Future research in these aspects in the local population is therefore needed, in order to implement 
successfully genetic diagnosis for ID in the DR Congo.  
Following the clinical evaluation, genetic testing is a second cornerstone of the diagnostic process. 
Karyotyping is being introduced in the laboratory of the genetics centre in Kinshasa, since it is essential 
in the diagnosis of recurrent miscarriages, infertility, and useful for certain clinically recognizable 
aneuploidies such as trisomy 13, 18 and 21 as well as Turner syndrome. Also, for Down syndrome, 
karyotyping is essential to exclude a Robertsonian translocation. However, for genetic testing in 
individuals with unexplained ID, chromosomal microarray is currently the method of choice, since it 
allows the detection of the frequently occurring smaller chromosomal imbalances, below the 
resolution of classical karyotyping. In our study, only 3 of the 10 cases diagnosed by microarray-CGH 
would have been detected by standard karyotyping: a 11.9 Mb deletion on chromosome 8p, 50 % 
mosaic deletion of 47.9 Mb on chromosome 13 and a 33 Mb chromosome 20 duplication.   
However, in the current situation, the introduction of microarray-technology in the laboratory in 
Kinshasa is problematic. There is the high investment cost for the equipment and difficulties in 
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obtaining specialized support for its installation and maintenance, and there is the absence of locally 
available consumables. Therefore, one needs to consider alternatives. Multiplex Ligation-Dependant 
Probe Amplification (MLPA) allows the detection of several tens of different targeted chromosomal 
imbalances in one single reaction, at a reasonable cost. Equipment for the quantitative analysis of the 
fragments is less sophisticated than that required for microarray-CGH. Commercial kits are available 
that target the most common microdeletion syndromes or the subtelomeric regions. In the present 
study, 3 of the 10 imbalances detected by microarray-CGH could be identified by the SALSA MLPA P245 
Microdeletion Syndromes-1 probemix: 2p16 deletion, Smith-Magenis syndrome, 22q13 deletion. 
Combining standard karyotyping and this MLPA kit, 6/10 cases would have been diagnosed. This figure 
is similar to the study of Jehee et al. (2011) (Jehee, Takamori et al. 2011): the combination of MLPA 
and karyotyping detected 76.45 % of imbalances that were found by karyotyping and chromosomal 
microarray. An approach whereby a first screening is done by means of karyotyping and/or MLPA 
therefore offers an attractive alternative in a resource poor setting.   
On the long term, it is likely that whole genome sequencing, once its price will drop will become the 
standard tool to screen the entire genome for all types of mutations (SNV’s, CNV’s, balanced structural 
anomalies). This will become the first tier test, both in diagnostics and research. Likely, DNA sequencing 
could be done in one centralized (commercial) unit followed by data analysis locally, incorporating the 
clinical data. This might, at least in part, solve the problem of the lack of well-equipped molecular 
genetic laboratories in the country. However, the tools for bio-informatics analysis need to be 
established. Currently, the lack of fast internet access and frequent cuts in electricity supply make this 
problematic.     
Nevertheless, we believe that the anticipated introduction of whole genome sequencing as a cheap 
research tool should guide us in our future research. One of the opportunities of genetic studies in 
Central Africa is the possibility to identify novel genes or mutations for conditions which are unique to 
this region. One should therefore establish clinically well-defined cohorts of patients with rare diseases 
and store DNA from cases and their parents. In the field of common, multifactorial diseases, the unique 
environment in Central Africa will offer the possibility to gain insight in complex gene-environment 
interactions. 
At the onset of this study, the only contribution in the field of genetics were the courses in medical 
genetics given by Prof. P. Lukusa at UNIKIN and casual teaching visits by the team from the Centre for 
Human Genetics in Leuven, Belgium. Now, 5 years later, the situation has changed completely. The 
Congolese Society for Human Genetics has been installed, offering a forum for the emerging human 
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and medical genetics society in the country. A genetics centre was installed in Kinshasa, offering 
regular genetic clinics and teaching in medical genetics. A genetics laboratory has been installed at the 
faculty of medicine at the University of Kinshasa and INRB, which supports genetics diagnosis and 
research, mainly through a DNA extraction facility.  These circumstances offer a more secure basis for 
future research into the genetics of ID. These are first but important steps toward providing patients 
with ID and their families the same level of care as in the rest of the world.  
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POPULAR SUMMARY 
Intellectual Disability (ID) is a frequent medical concern, which affects about 3 % of the world 
population. In addition, ID has a major social and economic impact on families in developing countries 
such as DR Congo. Moreover, the attitude of African communities toward ID is influenced by traditional 
and mystical beliefs. This mostly results in stigmatization and exclusion and increased burden of 
psychological and social consequences for the individual, parents and families. Therefore, reaching an 
etiological diagnosis in a person with intellectual disability has an invaluable significance in Africa. In 
addition, it provides the parents and caregivers with a more accurate prognosis, management plan, 
allows counseling on recurrence risks. 
Both environmental and genetic factors play roles in the etiology of ID, either separately or in 
combination. Genetic factors causing ID are heterogeneous, and therefore, research into the genetics 
of ID often associates multiple but complementary strategies. Since some genetic conditions with ID 
have recognizable clinical manifestations, the first approach is clinically oriented and applies targeted 
testing based on the clinical hypothesis. The second approach is a screening in patients without clinical 
clues for a specific diagnosis. With the exception of a few case reports, data on prevalence and types 
of genetic causes as well as clinical description of central African patients with ID of genetic origin are 
still missing. In this research, we aimed to contribute to the understanding of the genetic etiology of 
ID in Congolese patients in Kinshasa, and to investigate the variability of both the clinical presentation 
and genetic mutations observed. 
In the first part of this research, we recruited patients with ID from 6 institutions across Kinshasa and 
applied a variety of techniques to detect genetic defects that could causal the disability. We were able 
to identify genetic causes in about one fourth of patients. In many patients, the genetic diagnostic 
confirmed our clinical suspicion. We did not diagnose Fragile X syndrome in this cohort. 
In the second part, we assessed the usefulness of 3 clinical checklists for the selection of patients with 
a higher risk for Fragile X syndrome. It appeared that the 3 checklists had a high rate of false positive 
results. This implies that many items included in those checklists, mainly behavioral items, are probably 
common features among Congolese children with ID, rather than being predictive for Fragile x 
syndrome as in non-African populations.  
An important part of this study focused on the clinical presentation. To date, for the majority of genetic 
syndromes, the clinical description has been based almost exclusively on studies conducted in 
Caucasian patients. We wanted to explore whether the presentation of dysmorphic syndromes was 
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similar between African and Caucasian individuals, and whether clinicians from these 2 settings classify 
faces of Congolese patients in the same way, meaning either dysmorphic (afwijkend) or not 
dysmorphic. First, we asked 5 African and 5 European clinicians to score the facial gestalt of Congolese 
patients. We noticed that, on average, African clinicians considered more patients as dysmorphic (and 
thus abnormal) compared to European clinicians. It means that the 2 groups of clinicians do not 
evaluate dysmorphism in the same way. We thought that a more objective phenotyping might clear 
this difference. Therefore, we tested a recently introduced automated syndrome recognition tool, 
Face2Gene, in its ability to recognize African versus Caucasian (Flemish) patients with Down syndrome. 
We found that the application was more efficient in the recognition of Flemish Down syndrome 
patients than Congolese children with Down syndrome. This means that the variation in clinical 
presentation may be either a subjective perception by the clinician due to his own ethnic background 
or a real influence from patients’ ethnic background. In addition, reviewing some Congolese cases we 
diagnosed during our thesis research, we found that further variation in clinical presentation could 
result from infectious disease, as these are very frequent and may be severely debilitating in a limited 
resource setting. 
Finally, we used the report of a family with Apert syndrome to illustrate how genetic study in Central-
African countries may expand our knowledge on disease causing mutations. 
This is the first comprehensive study that integrates clinical and molecular genetics on the aetiology of 
ID in a central African country, the DR Congo. The results of this study show for the first time that 
genetic factors are a major cause of ID in the DR Congo, as observed in other countries. These results 
offer the opportunity to openly discuss false believes and feelings of guilt, and establish a firm basis 
for further research and teaching in the field of genetics of ID. 
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SAMENVATTING 
Verstandelijke beperking (V.B.) is een frequente aandoening die ongeveer 3% van de wereldbevolking 
treft. De impact van verstandelijke beperking op gezinnen in ontwikkelingslanden zoals de DR Congo 
is groot, zowel op sociaal als op economisch vlak. Bovendien wordt de houding van de Afrikaanse 
maatschappij ten opzichte van verstandelijke beperking mee beïnvloed door traditionele en mystieke 
overtuigingen. Dit resulteert vaak in stigmatisering en uitsluiting, met bijkomende psychologische en 
sociale gevolgen voor de betrokkene, ouders en families. Daarom heeft het stellen van een etiologische 
diagnose bij een persoon met een verstandelijke beperking in Afrika een belangrijke betekenis. 
Bovendien biedt het de ouders en begeleiders een meer nauwkeurige prognose, een  betere aanpak 
en opent het de mogelijkheid van adequate erfelijkheidsadvisering.  
Zowel omgevingsfactoren als genetische factoren spelen een rol in de etiologie van verstandelijke 
beperking, afzonderlijk of in combinatie. De genetische factoren zijn zéér heterogeen en daarom is het 
genetische etiologisch onderzoek ook gebaseerd op meerdere verschillende strategieën. Gezien 
sommige genetische aandoeningen klinisch herkenbaar zijn is de eerste benadering steeds klinisch, 
gevolgd door gerichte tests, gebaseerd op een klinische hypothese. In tweede instantie kan er bij 
personen zonder klinische aanwijzingen voor een specifieke diagnose genetische screening uitgevoerd 
worde.  
Met uitzondering van enkele case reports, zijn er nagenoeg geen gegevens uit Centraal-Afrika over de 
genetische oorzaken van verstandelijke beperking en hun prevalentie, maar ook over de klinische 
manifestaties. Het doel van dit onderzoek was inzicht te verwerven in de genetische oorzaken van 
verstandelijke beperking bij Congolese patiënten in Kinshasa, en de variabiliteit van zowel de klinische 
presentatie als genetische mutaties te onderzoeken. 
In het eerste deel van dit onderzoek onderzochten we patiënten met een verstandelijke beperking uit 
6 voorzieningen in Kinshasa, zowel klinisch als met verschillende genetische tests. Bij ongeveer 1 op 4 
van hen kon een oorzaak aangetoond worden, vaak was dit een klinische diagnose bevestigd door 
genetische testing. Het fragiele X-syndroom werd in deze patiëntengroep niet aangetroffen. 
In het tweede deel van ons onderzoek evalueerden we de bruikbaarheid van 3 klinische checklists voor 
de selectie van patiënten met een hoger risico op het fragiele X-syndroom. Deze 3 checklists hadden 
een hoog aantal valse positieve resultaten. Dit betekent dat veel kenmerken in deze checklists, en dan 
vooral items in verband met gedragsproblemen waarschijnlijk frequent voorkomen bij Congolese 
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kinderen met verstandelijke  beperking, en niet zozeer voorspellend te zijn voor het fragiele X-
syndroom zoals in niet-Afrikaanse landen. 
Een belangrijk deel van ons onderzoek was gericht op de klinische manifestaties. Tot op heden is de 
klinische beschrijving van de meeste genetische syndromen vrijwel uitsluitend gebaseerd op 
onderzoek uitgevoerd bij blanke patiënten. Daarom onderzochten we of de presentatie van dysmorfie 
syndromen vergelijkbaar was tussen de Afrikaanse en Kaukasische individuen, en of Afrikaanse en 
Europese artsen gezichten van Congolese patiënten op dezelfde manier evalueren aangaande 
dysmorfie. 5 Afrikaanse en 5 Europese artsen evalueerden onze Congolese patiënten waarbij we 
merkten dat de Afrikaanse artsen een kind gemiddeld vaker als afwijkend of dysmorf beschouwen in 
vergelijking met Europese clinici. Dit betekent dat deze 2 groepen artsen dysmorfie niet op eenzelfde 
manier evalueren.  Dit wijst erop dat een meer objectieve fenotypering nodig is. Daarom testten wij 
een recent geïntroduceerde applicatie voor een geautomatiseerde herkenning van syndromen,  
Face2Gene. We vonden dat deze applicatie efficiënter was in het correct identificeren van Vlaamse 
patiënten met het syndroom van Down dan Congolese. Dit betekent dat de variatie in klinische 
presentatie zowel het gevolg kan zijn van verschillen in subjectieve perceptie door de clinicus als van 
reële verschillen in presentatie afhankelijk van de etnische achtergrond.  
Daarnaast stelden we ook vast dat nadelige omgevingsfactoren zoals infectieziektes een verklaring 
kunnen zijn van variatie in klinische presentatie, zeker in Centraal Afrika, waar infectieziekten frequent 
zijn, en gezien de beperkte middelen kunnen leiden tot ernstige verwikkelingen.  
Ten slotte illustreren we aan de hand van onze bevindingen in een familie met Apert syndroom, bij wie 
we een unieke mutatie aantroffen, hoe genetische studies in Centraal-Afrikaanse landen kunnen 
bijdragen tot onze kennis aangaande genetische mutaties. 
Dit is de eerste uitgebreide studie die een klinische evaluatie en (moleculaire) genetische studies 
combineert om de etiologie van verstandelijke beperking te bestuderen in de DR Congo, een centraal 
Afrikaanse land. De resultaten tonen voor het eerst dat genetische factoren een belangrijke oorzaak 
zijn van verstandelijke beperking in de DR Congo, zoals in andere landen. Deze resultaten bieden de 
mogelijkheid om openlijk verkeerde veronderstellingen en schuldgevoelens te bespreken, en vormen 
de basis voor toekomstige verder onderzoek en onderwijs in het domein van de verstandelijke 
beperking. 
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SCIENTIFIC SUMMARY 
Intellectual disability (ID) is a common impairment that affects about 3 % of the world population. Both 
environmental and genetic causative factors are incriminated. There is an enormous amount of 
literature on genetics of ID in Western countries. This contrasts with paucity of data from Africa in 
general and from Central Africa in particular. The prevalence of genetic defects or even the clinical 
presentation of African patients with a recognized syndromic cause of ID have not been systematically 
investigated thus far.  
This study aimed to contribute to the understanding of the genetic aetiology of ID in Central Africa, to 
gain insight into the variability in clinical expression of specific genetic disorders in Central Africa, and 
to gain insight into causes of and variability in genetic mutations observed in Congolese patients with 
a genetic disorder. 
This study was conducted in Kinshasa, the capital of the Democratic Republic of Congo. We 
collaborated with 6 institutions and recruited 127 patients including 33 (26 %) girls and 94 (74 %) boys 
with mean age 10.32 ± 4.68 years (range 1.24 - 24.65). After a systematic clinical examination, patients 
with a suspected diagnosis underwent further specific testing for that disorder. Conversely, patients 
without a clinical diagnosis were further studied by a genetic screening including microarray-CHG and 
fragile X syndrome. X-Chromosome Inactivation (XCI) pattern was studied in all available mothers of 
boys with ID and in all girls, thus selecting patients with a high chance of having an X-linked disorder 
for Whole Exome Sequencing (WES). WES was also performed in 2 affected sisters, with a suspected 
autosomal recessive condition. 
Overall, we detected a likely genetic cause in 34/127 patients (26.8 %). Down syndrome was the most 
frequent cause with 19 cases (14.8 %). In 10 out of 86 (11.62 %) patients with ID of clinically unknown 
aetiology a submicroscopic chromosomal imbalance was detected. We did not identify a single fragile 
X patient. Of the 41 mothers of boys with ID tested, 3 (7.32 %) (CI: 1.89 % to 18.63%) had a highly 
skewed X-inactivation (i.e. ≥90/10 %) and among the 27 female index patients with ID, 3 (11.11 %) had 
also a highly skewed X-inactivation. In one boy, a possible X-linked disorder caused by a variant in the 
TAF1-gene was identified after exome sequencing. In another child, we identified, by means of exome 
analysis, a possible autosomal recessive metabolic disorder. The majority of cases (65 %) remain 
without diagnosis. 
Several patients were clinically diagnosed with well-known conditions associated with ID, e.g. Down 
syndrome, Partington syndrome and Williams syndrome. The features in these conditions were very 
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similar to those observed in the West. However, we found only a fair agreement between African and 
European clinicians when evaluating the facial dysmorphism in 127 Congolese patients. Likewise, when 
we used a recently introduced computed phenotyping program, Face2Gene for the detection of Down 
syndrome patients, it performed better in Caucasian (80 %) compared to Congolese patients (35 %). 
Therefore, ethnic background of the patient and of the physician needs to be taken into account during 
the evaluation of dysmorphism. 
The variability in clinical expression may result from environmental factors influencing the course of 
the disorder. One of the main differences with studies in developed countries is the environment in 
which Congolese children grow up. Indeed, we also found that in our cohort of patients, infections 
(such as meningitis) were common. However, in only few of them, an acquired brain insult was 
convincingly thought to be the cause of their ID. On the other hand, infections may influence the 
clinical manifestations, therefore one risks to overlook a genetic diagnosis, masked by an intervening 
environmental insult. For instance, we describe a young boy with the classical facial phenotype of 
Williams syndrome, caused by the recurrent 1.57 Mb deletion in chromosome 7q11.23. Surprisingly, 
he had severe ID and absent speech, which is most likely explained by brain damage, secondary to. 
meningitis and coma at age 2 years. Similarly, we diagnosed a family with X-linked congenital adrenal 
hypoplasia, where multiple boys died at young age due to infections. The suspicion of a genetic cause 
was raised when the pedigree revealed an X-linked inheritance pattern.  
Currently, very little is known about the causes of mutations. Advanced maternal age is the main risk 
factor for aneuploidies, and the advanced maternal age observed in the majority of Down syndrome 
cases in our cohort is in agreement with this. Advanced paternal age is a risk factor for de novo SNV’s. 
However, our study cannot address this question. One of the well-known mechanisms of copy number 
variations are unequal crossing-overs between low copy repeats (LCR). This results in recurrent, 
relatively common microdeletions or duplications, which share a same size (flanked by the LCR’s) and 
often a recognisable phenotype. Also in our study, of the 11 submicroscopic imbalances, 4 were 
recurrent ones. This indicates, not surprisingly, that the same mechanism also operates in the Central-
African genome. Also, we report a family with Apert syndrome where a novel mutation was detected, 
to illustrate that genetic research in Africa can expand our knowledge on the type of mutations in well-
characterized genetic disorders. 
The results of this study show for the first time that genetic factors are a major cause of ID in the DR 
Congo. Our study provides local data and insights, which will be useful for teaching and counselling. 
Obviously, these first results indicate the need for further expansion of similar studies.
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WETENSCHAPPELIJKE SAMENVATTING 
Verstandelijke beperking is een veel voorkomende aandoening die ongeveer 3% van de wereld 
bevolking treft. De oorzaak is divers, met zowel omgevingsfactoren als genetische factoren. De grote 
hoeveelheid literatuur over de genetica van verstandelijke beperking in westerse landen contrasteert 
sterk met gebrek aan gegevens uit Afrika in het algemeen en vooral van Centraal-Afrika in het 
bijzonder. De prevalentie van genetische afwijkingen en zelfs de klinische presentatie van Afrikaanse 
patiënten met klassieke genetische syndromen geassocieerd met verstandelijke beperking is tot nu 
toe niet systematisch onderzocht. 
Deze studie had als doel een bijdrage te leveren aan het begrip van de genetische etiologie van 
verstandelijke beperking in Centraal-Afrika, om inzicht te krijgen in de variabiliteit in de klinische 
expressie van specifieke genetische aandoeningen en om inzicht te krijgen in de oorzaken van en de 
variabiliteit in genetische mutaties waargenomen in Congolese patiënten met een genetische 
aandoening. 
Deze studie werd uitgevoerd in Kinshasa, de hoofdstad van de Democratische Republiek Congo. We 
werkten samen met 6 instellingen en onderzochten 127 patiënten, waaronder 33 (26%) meisjes en 94 
(74%) jongens. De gemiddelde leeftijd was 10,32 ± 4,68 jaar (variërend van 1,24-24,65 jaar). Na een 
systematisch klinisch onderzoek, werden bij patiënten met een vermoedelijke diagnose verdere 
gerichte  tests voor die aandoening uitgevoerd. Patiënten zonder een klinische diagnose werden 
verder onderzocht door een genetische screening inclusief microarray-CHG en testing voor het fragiele 
X syndroom. Het X-chromosoom inactivatie (XCI) patroon werd onderzocht bij alle beschikbare 
moeders van jongens met verstandelijke beperking en bij alle meisjes, met als doel om patiënten te 
selecteren met een hoge kans op een X-gebonden aandoening en verdere testing door middel van 
exoom sequenering (WES). WES werd ook uitgevoerd in 2 zussen met een vermoedelijke autosomaal 
recessieve aandoening met verstandelijke  beperking. 
Samengevat werd een waarschijnlijke genetische oorzaak voor de verstandelijke beperking vastgesteld 
bij 34/127 patiënten (26,8%). Het syndroom van Down is de meest voorkomende oorzaak, vastgesteld 
bij 19 patiënten (14,8%). Bij 10 van de 86 (11,62%) patiënten met een verstandelijke beperking zonder 
klinische verklaring werd een submicroscopische chromosomale afwijking vastgesteld. Geen enkele 
fragiele X patiënt werd geïdentificeerd. Van de 41 moeders van jongens met verstandelijke beperking 
hadden er 3 (7,32%) een zeer afwijkend X-inactivatie patroon (dwz ≥90 / 10%). Ook bij 3 van de 27 
(11.11%) vrouwelijke index patiënten met verstandelijke beperking hadden een zeer afwijkend X-
inactivatie patroon. Na exxom sequenering werd bij één jongen, een mogelijke X-gebonden 
158 
 
aandoening geïdentificeerd, veroorzaakt door een variant van de TAF1-gen. Bij een andere patiënt 
identificeerden we na exoom sequenering een mogelijke autosomaal recessieve stofwisselingsziekte. 
Bij de meeste patiënten  (65%) kon geen oorzaak aangetoond worden.  
Bij verscheidene patiënten werden klinisch gediagnosticeerd met een bekende aandoening 
geassocieerd met verstandelijke beperking, bijvoorbeeld het syndroom van Down, Partington 
syndroom en het syndroom van Williams. De manifestaties bij deze aandoeningen waren vergelijkbaar 
met deze waargenomen in het Westen. Nochtans vonden we slechts een matige overeenkomst tussen 
Afrikaanse en Europese clinici bij het evalueren van faciale dysmorfie bij 127 Congolese patiënten. Ook 
wanneer we gebruik maakten van Face2Gene, een recent geïntroduceerde applicatie om syndromen 
te herkennen, bleek dat dit beter geschikt was om Kaukasische syndroom te patiënten correct te 
herkennen (namelijk 80%) in vergelijking met Congo patiënten (slechts 35%). Deze resultaten tonen 
aan dat men bij studies aangaande dysmorfie rekening moet houden met de etnische achtergrond van 
de patiënt maar ook met deze van de arts.  
De variatie in klinische expressie kan het gevolg zijn van omgevingsfactoren die het verloop van de 
aandoening beïnvloeden. Een van de belangrijkste verschillen met de studies in de ontwikkelde landen 
is de omgeving waarin Congolese kinderen opgroeien. Ook in ons cohort patiënten vonden we dat 
infecties (bijvoorbeeld meningitis) vaak voorkwamen.  Slechts in een paar van hen hadden we 
voldoende argumenten om een verworven hersenbeschadiging als oorzaak van hun verstandelijke 
beperking te weerhouden. Anderzijds kunnen infecties ook de klinische manifestaties beïnvloeden, 
waardoor we het risico lopen om een genetische diagnose te miskennen, omdat deze gemaskeerd 
wordt door omgevingsfactoren. Zo beschrijven we een jongen met het klassieke lichamelijke fenotype 
van Williams syndroom, veroorzaakt door de klassieke 1.57 Mb deletie in chromosoom 7q11.23. 
Verrassend genoeg had hij een ernstige verstandelijke beperking en afwezige spraak, die waarschijnlijk 
wordt verklaard door een bijkomende hersenbeschadiging, secundair aan meningitis en coma op de 
leeftijd van 2 jaar. Ook beschrijven we een familie met X-gebonden congenitale bijnier hypoplasie, met 
meerdere jongens die op jonge leeftijd overleden als gevolg van infecties. Een genetische oorzaak werd 
gesuggereerd door de stamboom die een X-gebonden overervingspatroon suggereerde. 
Momenteel is weinig bekend over de oorzaken van mutaties. Gevorderde leeftijd van de moeder is de 
belangrijkste risicofactor voor aneuploïdieën, en de gevorderde leeftijd van de moeders in de 
meerderheid van de Down-syndroom patiënten in onze cohort is hiermee in overeenstemming. 
Geavanceerde vaderlijke leeftijd is een risicofactor voor de novo SNV's, maar onze studie heeft hier 
geen gegevens over. Eén van de bekende mechanismes die variaties in het aantal kopijen van bepaalde 
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chromosoomfragmenten (CNV’s) veroorzaken zijn ongelijke crossing-overs tussen low copy 
herhalingen (LCR’s). Dit resulteert in recurrente en dus relatief frequente microdeleties of duplicaties, 
die meestal eenzelfde grootte hebben en geflankeerd zijn door LCR’s, en vaak een herkenbaar 
fenotype hebben. Ook in onze studie waren 4 van de 11 submicroscopische chromosomale afwijkingen 
dergelijke recurrente afwijkingen. Niet onverwachte geeft dit aan dat hetzelfde mechanismes ook 
optreden in het Centraal-Afrikaanse genoom. Ook rapporteren we een familie met Apert syndroom bij 
wie we een nieuwe mutatie gedetecteerd, hetgeen illustreert dat genetisch onderzoek in Afrika onze 
kennis kan uitbreiden aangaande type mutaties in goed gekarakteriseerde genetische aandoeningen. 
De resultaten van deze studie tonen voor het eerst dat genetische factoren een belangrijke oorzaak 
van verstandelijke beperking in de DR Congo. Onze studie geeft ons voor het eerst lokale data en 
inzichten, die nuttig zijn voor het onderwijs en begeleiding. Deze eerste resultaten wijzen op de 
noodzaak voor verdere, meer uitgebreide en vergelijkbare studies. 
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